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ABSTRACT
Cachexia is characterised by a chronic wasting syndrome, involving loss of skeletal muscle
tissue with or without adipose tissue, which is resistant to conventional nutritional support.
The typical patient with advanced cachexia demonstrates loss of appetite, early satiety,
severe weight loss, weakness, anaemia and fluid retention. Affected individuals are also
likely to report/experience decreased quality of life, decreased levels of physical
performance, increased levels of fatigue, increased risks of treatment failure (be it
chemotherapy, radiotherapy or surgery), increased risks of treatment side effects, and an
increased mortality rate. Cachexia is therefore an extremely important, yet often
underappreciated, cause of cancer patient morbidity and mortality which requires urgent
attention. However, due to the epidemic of obesity in Western Society, a substantial
proportion of oncology patients at the start of palliative therapy now have a BMI in the
overweight range and this can confound conventional measures used for risk stratification.
Cachexia in its advanced phase (where patients may have lost 20-30% of their body weight)
is easily identified. However, at this stage, the primary initiating events are frequently
compounded by secondary factors (e.g. prolonged patient bed rest), and it is often
impossible to attempt any realistic form of intervention, either practical or (given the patient's
almost imminent demise) ethically advisable. Thus, any systematic approach to the
treatment of cachexia requires early identification of patients at risk of cachexia and the
institution of prophylactic measures to attenuate its progression.
The main aims of this thesis are: 1) To assess if measures of body composition, specifically
skeletal muscle, have any prognostic value, and to chart time course changes in regional
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body fat and lean tissue compartments using pancreatic cancer as a model for cancer
cachexia. 2) To identify genetic variants that may be associated with susceptibility of
developing cancer cachexia by means of a candidate gene association study.
Using a novel method of assessing body composition using computed tomography (CT)
scans, 56% of pancreatic patients (n = 111) were found to be sarcopenic at the time of
diagnosis. A much greater rate of fat loss was observed as compared with muscle loss in the
course of the cancer journey. The combination of sarcopenia and overweight/obesity was
found to be a poor prognostic indicator (HR 2.07, 95%CI 1.23 - 3.50, p=0.006). Despite a
substantial proportion of cancer patients at diagnosis now having a BMI in the overweight
range, the previously noted tendency to muscle wasting continues with the majority of
patients' sarcopenic at diagnosis. The combination of sarcopenia and overweight/obesity
has been highlighted as a poor prognostic factor in cancer patients and should be
considered in the stratification of cancer patients' entering clinical trials, systemic therapy or
support care programs.
The candidate gene association study was carried out based on data from two preliminary
studies identifying genes involved in the pathogenesis of cancer cachexia. A systematic
literature review identified 184 polymorphisms in 92 genes that have potential as
susceptibility biomarkers for cancer cachexia. A gene expression array (Affymetrix)
examining muscle of cachetic versus non-cachetic patients revealed an 83 gene signature
correlating with weight loss.
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A total of 191 SNPs in 99 genes were selected for the candidate gene association analysis.
The study was carried out in a cohort of 775 patients and significant results were validated in
a separate cohort of 101 patients.
21 SNPs had significant associations with cachexia. However, only the C allele (minor allele
frequency 10.7%) of the rs6136 (SELP) SNP was found to be associated with cachexia
(weight loss >10%) both in the main study (OR 0.52, 95%C.I 0.29 - 0.93, p=0.026) and the
validation study (OR 0.09, 95%C.I 0.01 - 0.98, p=0.035). Gene-group analysis was
performed based on functional similarity according to gene ontology in the main study
patients. Gene groups regulating appetite, glucocorticoid signalling, and mitogen activated
protein kinases (MAPK) activity were associated with cachexia (weight loss >15% and CRP
>10mg/l) (p=0.0008, p=0.018, and p=0.026 respectively).
Patients who possess the C-allele of the P-selectin (SELP) rs6136 polymorphism appear to
be at reduced risk of developing cancer cachexia. The rs6136 polymorphism may prove to
be a useful susceptibility biomarker. Grouping of candidate genes according to gene
ontology revealed three groupings that were associated with the development of cachexia.
Genes regulating appetite, glucocorticoid signalling and MAPK activity appear to be





. . .the shoulders, clavicles, chest and thighs melt away. This illness is fatal. . .
(Hippocrates 460-370 BC)
The origin of the term 'cachexia' is from the Greek words kakos (bad) and hexis (condition or
appearance) and throughout medical history has been associated with the gravely ill patient.
Cachexia typically manifests in chronic diseases such as cancer, chronic obstructive
pulmonary disease (COPD), chronic heart failure (CHF), and chronic kidney disease (CKD).
The cachectic state is particularly problematic, typified by poor prognosis and often
associated with a lower response to therapy. Cachexia also impairs quality of life (QoL) and
is a significant cause of morbidity and mortality (Morley et al, 2006).
1.2 Definition of cachexia
While cachexia has long been recognized as a syndrome associated with many illnesses,
there is currently no universally agreed definition. Traditionally, the definition of cachexia is
limited to an assessment of involuntary weight loss. Although this has face-validity as an
approach to screening, it is not clear that this minimal approach is adequate to guide clinical
care decisions (Giordano & Jatoi, 2005). It is also not clear to what extent weight loss alone
is associated with adverse functional status. Poor physical function may relate to many
factors, including reduced substrate supply (food intake), and loss of lean body mass; all of
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which have been considered in the definition of cachexia (Fearon et al, 2006; Roubenoff et
al, 1997).
Weight loss
Weight loss has been shown to be an independent variable that predicts mortality in patients
with chronic diseases and weight loss cut-offs of between 4% and 10 %, and BMI thresholds
of between 18.5 and 23.0kg/m2 have been used in cancer, COPD and CHF to define
cachexia (Anker et al, 2003; Fearon & Moses, 2002; Schols, 2002).
Nutritional factors
A reduced nutritional intake secondary to anorexia is frequently a feature of cachexia.
Anorexia is common in cancer patients and a study of 66 cancer patients nearing the end of
life showed that 61% had anorexia despite the fact that they were not receiving
chemotherapy (Tranmer et al, 2003). Reduced calorie intake and anorexia has also been
correlated with weight loss in patients with chronic disease (Wallace & Schwartz, 2002). It
has been suggested that a reduced nutritional intake and/or anorexia should be a
component in the definition of cachexia (Evans et al, 2008; Fearon et al, 2006).
Skeletal muscle and strength
Muscle wasting is important in the pathophysiology of cachexia and a major cause of fatigue
in patients (Evans & Lambert, 2007). Grip strength was found to be lower in cancer patients
with a weight loss of >10% versus weight loss of 5% - 10% (Fearon et al, 2006). In 1997,
Roubenoff et al. suggested that cachexia be defined on the basis of lean body mass alone.
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This did not gain wide acceptance in the scientific community as patients with age-related
muscle loss could be labeled as cachetic without losing weight.
Systemic inflammation
Many of the factors in cachexia such as weight loss, muscle wasting, and anorexia have
been related, at least in part, to the effects of systemic inflammation (Laviano et al, 2003;
Stone, 2002). C-reactive protein (CRP), a widely used marker of pro-inflammatory activity,
has been shown to distinguish groups with weight loss versus weight stable patients with
cancer (Martin et al, 1999; Scott et al, 2002), although in a recent study there was no
significant difference in CRP levels between cachetic and non-cachectic male cancer
patients (Stephens et al, 2012). CRP has also been shown to be an independent variable of
adverse prognosis in patients with cancer (Crumley et al, 2006a; Deans & Wigmore, 2005).
Markers of systemic inflammation such as CRP have been included in a proposed
composite definition of cachexia (Fearon et al, 2006).
A study of patients with advanced pancreatic cancer, showed that weight loss alone does
not identify the full effect of cachexia and is not a prognostic variable (Fearon et al, 2006).
However, by utilising a multi-profile definition of cachexia, they were able to define a
population that had both a lower subjective and objective functional ability. The study
proposed that cachexia is defined by a combination of 3 factors (i.e. weight loss >10%, CRP
>10 mg/l, and food intake <1500 kcal per day).
Recently, in December 2006, a committee of scientists and clinicians met in Washington,
DC, to reach a consensus on the definition of the constellation of abnormalities that have
been grouped under the name cachexia and approved the following definition: "Cachexia is
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a complex metabolic syndrome associated with underlying illness and characterised by loss
of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is
weight loss in adults and growth failure in children. Anorexia, inflammation, insulin resistance
and increased muscle breakdown are frequently associated with cachexia. Cachexia is
distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption
and primary hyperthyroidism and is associated with increased morbidity" (Evans et al, 2008).
1.2.1 Classifying cancer cachexia
Cancer cachexia falls into a spectrum. Patients may first notice simple weight loss and then
progress through degrees of severity to the point where they are depleted of energy
reserves (fat), have gross muscle wasting, are immunocompromised, and will die primarily
as a result of these issues (Figure 1.1).
Figure 1.1 The cachexia journey
Not all patients progress along the entire pathway
Normal Mild Moderate Severe Death
cachexia cachexia cachexia
loss ideal body wasting
weight obvious
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The recent consensus article on the definition of cachexia has suggested classifying the
degree of cachexia as mild, moderate or severe, depending on whether the observed weight
loss is >5%, >10% or >15%, respectively (Evans et al, 2008).
1.3 The changing demographics of cancer patients
There is no doubt that cancer patients are becoming increasingly obese. For example,
despite a predicted prevalence of weight loss affecting «50% (Teunissen et al, 2007),
patients newly diagnosed to have incurable cancer commonly have a mean BMI greater than
25 (Irigaray et al, 2007). In obesity, however, a small degree of weight loss can mask a
proportionately higher loss of skeletal muscle mass (Roubenoff, 2004). Indeed, a recent
article has demonstrated that in advanced cancer patients with a mean BMI of 25.5, the
prevalence of sarcopenia approaches 80% (Prado et al, 2008).
1.4 Cachexia in cancer
Approximately one quarter of all deaths in Western Society are due to cancer. Half of all
patients with cancer lose some body weight; one third lose more than 5% of their original
body weight and up to 20% of all cancer deaths are caused directly by cachexia (through
immobility, cardiac/respiratory failure) (Skipworth et al, 2007). The incidence of weight loss
upon diagnosis varies greatly according to the tumour site (Figure 1.2). The greatest
incidence of weight loss is seen among patients with solid tumours, for example, gastric,
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pancreatic, lung, colorectal, and head and neck (Dewys et al, 1980). 80% of the patients with
pancreatic cancer have at least 10% weight loss at diagnosis and the cachexia syndrome is
present in 25% (Fearon et al, 2006). The overall prevalence of weight loss in cancer patients
may rise as high as 86% in the last 1-2 weeks of life (Teunissen et al, 2007).
Figure 1.2 Frequency and severity of weight loss in patients with advanced cancer




































1.4.1 Impact of cancer cachexia
Survival
Based on the three-factor profile (weight loss, reduced food intake, and systemic
inflammation) of cancer cachexia syndrome, pancreatic cancer patients who met at least two
of the components had a significantly worse prognosis (Fearon et al, 2006). Alternatively, in
a study of patients with oesophageal cancer, weight loss of more than 2.75% per month was
found to be an independent prognostic indicator of decreased survival (Deans et at, 2007b).
Quality of life
Cachexia has a detrimental effect on a patient's QoL. Patients with cancer cachexia report
altered body image, which impacts their emotions, spirituality, relationships, and social
functioning. Lives are restricted and isolated, which is compounded by emotional distancing
by carers and healthcare professionals (Hinsley & Hughes, 2007). These patients also
experience anorexia and increased fatigue (Fearon et at, 2006; Teunissen et al, 2007)
(Figure 1.3). Overall, this results in decreased performance status and QoL indices
(Fouladiun et al, 2007).
The devastating effect of cachexia is further characterized by considering the free-living
physical activity of patients. In a study examining patients using an electrical activity monitor
worn over a period of 1 week, patients with cancer cachexia demonstrate a 40% reduction in
the level of physical activity (Dahele et al, 2007).
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Figure 1.3 Symptom prevalence in patients with incurable cancer. (Derived from




















Cachexia has a significant impact on cancer treatment. Dewys et al. (1980) defined weight
loss of more than 5% prior to the onset of chemotherapy as the defining point for risk of poor
response to therapy and shortened survival. A separate study in patients with lung cancer
showed that patients with weight loss more frequently failed to complete at least three cycles
of chemotherapy and had decreased survival duration (Ross et al, 2004).
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Costs to Society
The economic costs of cachexia extend much further than the costs of therapeutic diets,
nutritional supplements, medications, laboratory tests, and supplies. Staff salaries, service
costs, and other indirect medical costs related to the provision of medical care must also be
included. Unfortunately, it is difficult to assess accurately the financial costs of cancer
cachexia due to paucity of data. The extent of the problem can, however, be highlighted by
examining the overall costs of cancer treatment (around $190 billion in the United States in
2007).
Less apparent are the costs associated with managing the consequences of involuntary
weight loss. Involuntary weight loss is associated with anaemia, postural hypotension,
cognitive dysfunction (i.e., confusion and impaired cognition), falls, and hip fractures
(Knudtson et al, 2005). Pressure ulcers are another frequent complication seen in patients
near the end of the 'cachexia journey' (Collins, 2003). Currently, billions of dollars are spent
each year to treat these complications. For example, the total direct cost of falls is
approximately $20 billion and the estimated cost of pressure ulcer management is currently
about $7 billion annually (Kumar et al, 2004; Stevens et al, 2006).
1.4.2 Mechanisms of cancer cachexia
Cachexia is brought about by a synergistic combination of a dramatic decrease in appetite
and an increase in metabolism of fat and lean body mass. Although the specific molecular
mechanisms leading to the development of cachexia are not fully understood, systemic
inflammation appears to play a central role (Morley et al, 2006) (Figure 1.4). Inflammation
results in a number of metabolic changes that are often characterized by negative energy
balance, increased thermogenesis and anorexia. These responses are mediated by
cytokines (Argiles et al, 2009; Dantzer & Kelley, 2007).
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Cytokines produced during inflammation can affect the brain by several pathways: i) they
can act on peripheral tissues producing hormones such as leptin which influence the activity
of the brain; ii) they can act on peripheral neurons which project to the brain through the
vagus nerve; iii) they can also directly enter the brain and act locally (Guyon et al, 2008).
Many cytokines are known to have an effect on appetite, including interleukin (IL)-1 a, IL-1(5,
and IL-6 as well as tumour necrosis factor- a (TNF-a) (Plata-Salaman et al, 1988). IL-1, in
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particular, has been clearly associated with the induction of anorexia (Plata-Salaman, 2000),
by blocking neuropeptide Y (NPY)-induced feeding. The levels of this molecule (a feeding-
stimulating peptide) are reduced in anorectic tumour-bearing rats and a correlation between
food intake and brain IL-1 has been found in anorectic rats with cancer (Chance et al, 1994).
Increased energy expenditure
Resting energy expenditure (REE) is significantly higher in those with an elevated acute
phase response (APR) (Falconer et al, 1994). The APR is a series of changes in liver protein
synthesis, which shifts from production of albumin to acute phase proteins (APP), such as C-
reactive protein (CRP), fibrinogen, serum amyloid A, and a-1 antitrypsin, in response to an
insult such as inflammation.
There is a known association between the development of an APR and the rate of loss of
body mass in lung and gastrointestinal cancers (McMillan et al, 1998), and in patients with
non- small cell lung cancer (NSCLC), serum levels of IL-6 were found to correlate with
concentrations of circulating CRP (McKeown et al, 2004).
Altered carbohydrate metabolism
Tumour growth results in energetic consequences which locally changes from aerobic to
anaerobic dissimilation and causes metabolic adaptation in the liver. Tumours demonstrate
changed metabolic profiles with hypoxia in the growing tumour (Harris, 2002) and increases
in glucose uptake (Jerusalem et al, 2002), glycolysis and lactic acid production.
From the moment tumour cells start the anaerobic dissimilation the increasing glucose
demand can only be met by accelerated hepatic gluconeogenesis, characterised by
increased activity of the Cori cycle (Holroyde et al, 1984). This cycle consists of the
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fermentation of glucose to lactic acid in the tissues, and the conversion of lactic acid to
glucose in the liver (Roh et al, 1984).
The increased hepatic glucose production is also partially due to a lack of inhibition of
gluconeogenesis by insulin (Yoshikawa et al, 1999). Resistance to insulin occurs in patients
with cancer and is negatively correlated with the APR, suggesting the involvement of
inflammatory reactions (Yoshikawa et al, 2001).
Altered lipid metabolism
The multifunctional cytokine, TNF-a exerts a series of biological actions in different cells,
tissues, organs, and species and has been demonstrated to regulate and interfere with
energy metabolism, especially lipid homeostasis. A large body of research suggest that the
effects of TNF-a on lipid metabolism mainly include five aspects: i) suppression of free fatty
acid (FFA) uptake and promotion of lipogenesis; ii) induction of lipolysis; iii) inhibition of lipid-
metabolism-related enzyme activity; iv) regulation of cholesterol metabolism; v) regulation of
other adipocyte-derived adipokines (Chen et al, 2009).
While TNF-a is the first cytokine reported to have catabolic effects on fat cells, subsequent
studies have shown that multiple cytokines acting through multiple receptors have similar
activities. TNF-(3, interferon-a, interferon-y, IL-1, and IL-6 decrease lipoprotein lipase activity
and increase lipolysis in cultured fat cells (Doerrler et al, 1994). TNF-(3 and both interferons
also decrease de novo fatty acid synthesis in cultured fat cells (Doerrler et al, 1994). The
catabolic effects of cytokines on adipose tissue triglyceride metabolism is also a possible
contributor to the development of cachexia (Tisdale, 2009).
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Impaired protein synthesis
Inflammatory-mediated signalling may limit muscle protein synthesis by several
mechanisms. Inflammatory cytokines such as TNF-a and IL-6 are likely to play an important
role. TNF-a can activate the transcription factor NF-kB, which inhibits the synthesis of the
muscle specific transcription factor MyoD, thereby inhibiting differentiation (Acharyya &
Guttridge, 2007). In addition, a recent study found that skeletal muscle protein synthesis was
dramatically reduced by relatively low-dose IL-6 infusion in humans (van Hall et al, 2008).
Preliminary reports have described marked elevations in myostatin (a negative regulator of
muscle mass that inhibits myogenic proliferation and differentiation) in cachectic cancer
patients. Animal models suggest that the inflammatory cytokine TNF-a is at least partially
responsible for this increase (Costelli et al, 2008). TNF-a is also known to negatively
influence the anabolic mTOR signaling pathway, which is a major mediator of anabolic
responses in skeletal muscle (Lang et al, 2007).
IL-15 is a cytokine which is highly expressed in skeletal muscle (Grabstein et al, 1994). IL-15
is anabolic in nature and acts by activation of protein synthesis and concomitant inhibition of
protein degradation in cultured skeletal muscle cells (Quinn et al, 1995). IL-15
administration in an in vivo rodent model of cancer cachexia has been shown to inhibit
skeletal muscle wasting (Carbo et al, 2000). Muscle and serum IL-15 levels are thought to
be reduced in cachexia (Pajak et al, 2008).
Increased protein degradation
Inflammatory stimulation activates pathways associated with muscle protein breakdown
(Burckart et al, 2010). In cancer cachexia, the ubiquitin proteasome pathway is greatly
influenced (Lecker et al, 1999). Many of these effects are thought to occur through activation
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of NF-kB by upstream factors such as TNF-a (Ladner et al, 2003). NF-kB stimulates
transcription of the ubiquitin E3 ligase muscle ring finger (MuRF)-1, which is known to
positively regulate activity of the ubiquitin proteasome pathway (Cai et al, 2004).
1.5 Biomarkers of cancer cachexia
Cachexia in its advanced phase (where patients may have lost 20-30% of their body weight)
is easily identified. However, at this stage, the primary initiating events are frequently
compounded by secondary factors (e.g. prolonged patient bed rest), and it is often
impossible to attempt any realistic form of intervention, either practical or (given the patient's
almost imminent demise) ethically advisable. One systematic approach to the treatment of
cachexia requires early identification of patients at risk of cachexia and the institution of
prophylactic measures to attenuate its progression. The development of predictive or early
biomarkers of cachexia is thus essential to aid in the selection of patients for early
management.
The search for potential biomarkers of cachexia has encompassed several different body
compartments including plasma, urine, tumour and skeletal muscle. More recently, the
search has focused on the patients' genome.
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1.6 Rationale of genetic involvement in cancer cachexia
Based on current knowledge of demographic and clinical factors, it is not possible to predict,
for any given cohort of patients, who will develop cancer cachexia and who will not. It is also
not possible to predict accurately who will develop cachexia quickly versus those who may
develop the syndrome at a slower pace. Such variation may, in part, be due to the patient's
genotype. The case to support a genetic predisposition to cachexia is strengthened from the
known genetic contribution to the activity of a variety of key mechanisms that underlie the
cachexia syndrome (e.g. systemic inflammation). However, it must be said that, unlike other
common diseases where twin studies have suggested a clear heritable component to the
disease (e.g. Crohn's disease, etc), there have been no such studies to support a heritable
component to cachexia so far.
1.7 Genetic approaches to study cancer cachexia
One of the most common approaches to find genes involved in complex traits are genetic
association studies. The rationale of genetic association studies is to detect association
between one or more genetic polymorphism(s) and a trait or disease. Association studies
identify polymorphisms in which an allele occurring in the general population occurs at a
different frequency in the disease group. In these instances, the disease associated allele
does not cause the disease in the same way that a Mendelian mutation does but increases
susceptibility to the disease as a genetic risk factor, most likely in conjunction with other
genetic and/or environmental risk factors. Association studies can either be direct or indirect.
In direct association studies, target polymorphisms which are themselves putative functional
variants (for example a SNP variant in a gene at a codon that changes an amino acid) are
16
genotyped in both the general (control) and also trait (disease) population. A statistically
different frequency of the alleles and/or genotypes in the control population versus the
disease group would suggest that the polymorphism in question has a direct effect on
disease pathogenesis. However, it is likely that many causal variants contributing to complex
disorders will be non-coding. These variants could include those that affect gene regulation,
expression or alternative splicing and such functional variants are difficult to predict. For this
reason, most association studies are indirect; where the polymorphisms genotyped in the
control populations and trait populations are surrogates for the unknown causal locus.
Identifying susceptibility genes for complex disorders by the indirect method depends on the
existence of an association between the causal variants and surrounding polymorphisms
nearby. This association is termed linkage disequilibrium (LD) and is defined as the non-
random association of alleles at two or more loci and describes a situation in which
correlation between nearby variants such that the alleles at neighbouring markers (observed
on the same chromosome) are associated within a population more than if they were
expected by chance.
1.7.1 Candidate gene association analysis in cachexia
The finding that only a proportion of patients with chronic disease develop cachexia has
prompted studies looking for genetic polymorphisms that may underlie differential
susceptibility (Tan et al, 2008). The most frequent targets for these studies have been genes
encoding pro-inflammatory cytokines, such as TNF-a and some of the interleukins. This is
based on the hypothesis that continued systemic inflammation plays a central role to the
pathogenesis of cachexia (see above).
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One of the earliest genetic susceptibility studies by Broekhuizen et at. (2005) found that a -
511 polymorphism in the IL1B gene (rs16944) correlated strongly with cachexia in patients
with COPD. The C/C genotype at this position in the gene was associated with frequent
cachexia, while the T/T genotype was not associated with cachexia.
While this finding has not been confirmed in subsequent studies, Zhang et at. (2007) have
found that a separate polymorphism within the IL1B gene is associated with cachexia.
Gastric cancer patients in China with cachexia showed a significantly higher prevalence of
the (rs1143634) IL1B +3954 T allele than those without, and the IL1B +3954 C/T genotype
was associated with an 2.5 times increased risk of developing cachexia. Unfortunately, the
reverse association was found in another study involving patients with gastric and gastro-
oesophageal junction cancer (Jatoi et at, 2007). Patients with the IL1B +3954 C/T and T/T
genotypes showed greater improvements in their weight and in survival over time than did
patients with the C/C genotype.
A recent article has recently investigated the relationship between five cytokine
polymorphisms and markers of nutritional status among patients with gastro-oesophageal
cancer (Deans et at, 2009a). Possession of the (rs1800896) IL10 -1082 G allele was found
to be associated with increased weight loss and the G/G genotype was associated with a 2.3
times increased risk of developing cachexia. A separate study involving patients with gastric
cancer in China confirmed that the G allele was more prevalent in patients with cachexia
(Sun et at, 2010). The study also found that individuals with the (rs1800871) IL10 -819 C/C
genotype were at increased risk of developing cachexia.
A further two cytokine polymorphisms have been associated with cachexia. The (rs1800796)
IL6 -634 G allele has been shown to be significantly more prevalent in Chinese pancreatic
cancer patients with cachexia compared with those without cachexia (Zhang et at, 2008)
(Table 1). In patients with gastric cancer in China, the frequency of (rs2227306) IL8 +781 T
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allele was noted to be significantly increased in patients with cachexia and the +781 T/T
genotype was observed to be associated with a significantly increased risk of cachexia
(Song et al, 2009).
While much attention has been placed on cytokine polymorphisms and their association with
cachexia, it is of note that mechanisms surrounding the pathogenesis of cachexia is complex
and is likely to involve gene products which act both upstream and downstream of cytokines.
Pathways not affected by cytokines may also play a role in the development of cachexia. It is
therefore highly likely that genetic variations in non-cytokine genes may also contribute to
the susceptibility of developing cachexia. For example, a study by Vigano et al. (2009) have
shown that the Angiotensin converting enzyme gene (ACE) insertion/deletion polymorphism
(rs4646994) is associated with lower total fat mass and lean body mass in patients with
gastro-intestinal cancer and non-small cell lung cancer.
1.8 Hypothesis
1. Altered body composition in advanced cancer patients carries prognostic significance
2. Sarcopenic obesity is an identifiable entity that relates to shortened survival
3. Genetic variation contributes to the prevalence of cancer cachexia
4. Genetic variance in non-cytokine genes may also contribute to the susceptibility of
developing cancer cachexia
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1.9 Aims of thesis
1. To evaluate body composition in advanced cancer patients using image analysis of CT
scans and relate changes to outcomes
2. To evaluate specifically the presence of sarcopenic obesity in advanced cancer patients
and relate it to outcomes
3. To undertake a systematic review to explore genetic polymorphisms in potential
candidate genes involved in the development of cancer cachexia
4. To identify other possible candidate genes of cachexia by utilising mRNA microarray
technology to analyse the differential expression of genes in skeletal muscle in patients
with and without cachexia.
5. To undertake genetic association studies assessing for susceptibility to cachexia as
informed by the results of the systematic review and microarray study.
1.10 Plan of thesis
The prominent clinical feature of cachexia has traditionally been understood to be weight
loss and the relationship between changes in total body weight over time and cancer
outcomes has a long history.
It is widely accepted that changes in body weight may involve any of its major tissue
compartments (lean tissues, adipose tissues, and bone) and that within these
compartments; there may be specific changes of organs, tissues, and regions.
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A feature of body composition changes such as differential accumulation of lipids in different
compartments and tissues is that these changes are invisible. Skeletal muscle wasting is
another phenomenon, which can be hidden within the bulk of body weight and body weight
change, and there is a new recognition of sarcopenia (severe muscle wasting) as a clinically
important phenomenon. Sarcopenia is a term denoting a reduced quantity of skeletal muscle
more than 2 SDs below that typical of healthy adults (Baumgartner et al, 1998).
The aging process is often paralleled by decreases in muscle and increases in fat mass,
which may culminate in sarcopenic obesity (Roubenoff, 2000; Zamboni et al, 2008); this
condition combines the health risks and functional losses of both conditions and is
increasingly prevalent in Westernized countries (Bouchard et al, 2009; Rolland et al, 2009).
It is important to note that a unit of human body weight, or of body weight change, does not
have a constant composition and the recently published consensus definition of cancer
cachexia (Evans et al, 2008) notably makes a distinction between the behaviour of skeletal
muscle and adipose tissue: 'cachexia, is a complex metabolic syndrome associated with
underlying illness and characterized by loss of muscle with or without loss of fat mass. This
acknowledgement of a distinction between the behaviour of muscles and adipose tissues,
bring the need for specific body composition measures clearly into view.
Pancreatic cancer has been noted previously to be a useful model for the study of cancer
cachexia (Fearon et al, 1999). By utilising a novel method of analysis enabling routine
derivation of body composition data from computed tomography scans, Chapter 3 assesses
if measures of body composition, specifically skeletal muscle, have any prognostic value in
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patients with pancreatic cancer. Time course changes in regional body fat and lean tissue
compartments in pancreatic cancer patients were also studied.
In the current chapter, the rationale and background behind the genetic association to
cancer cachexia was reviewed. At the onset of this work, support for a heritable component
to the susceptibility of developing cachexia has been highlighted in a few studies mainly
focussed on variants in inflammatory cytokine genes. However, there is a distinct lack of
association studies on genes regulating other key mechanisms that underlie the cachexia
syndrome such as muscle and adipose tissue metabolism.
A systematic literature review is presented in Chapter 4 which explores genetic
polymorphisms with known functional or clinical significance in potential candidate genes
involved in the development of cancer cachexia. It also identifies the polymorphisms with the
most likely potential as susceptibility markers for cancer cachexia.
Chapter 5 explores further possible candidate genes involved in the development of
cachexia by examining the differential expression of genes in muscle of cachetic versus non-
cachetic patients using mRNA microarray technology.
A large scale candidate gene association study is presented in Chapter 6. Utilising data from
the systemic literature review and the microarray study, 129 SNPs across 80 genes were
analysed in 775 cancer patients assessing their contribution to cachexia susceptibility. A
further validation association study was also performed on an independently recruited cohort
(n=101) of cancer patients
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In chapter 7, the implications of the data presented throughout the thesis are discussed. The
results are placed in the context of current work performed during and after the completion of





2.1.1 Body composition study (Chapter 3)
This was a retrospective cohort study. All patients referred to the regional cancer centre in
Edmonton, Alberta, Canada between January 2004 and October 2008 were considered for
the study. Patients with a primary diagnosis of pancreatic cancer entering a palliative
programme who had an abdominal CT scan within 60 days of initial assessment were
selected for the study. Patients with ampullary carcinoma, cholangiocarcinoma or neuro¬
endocrine tumours were excluded. Coding of the primary cancer by its site and morphology,
clinical information, and demographic information were obtained from the Alberta Cancer
Registry for every patient in the cohort. The Alberta Cancer Registry is a computerised
database of all cancer cases in the region (population 1.8 million).
2.1.2 Microarray muscle gene expression study (Chapter 5)
Patients were recruited to this study between August 2007 and October 2008. All patients
were above 18 years of age had a diagnosis of upper gastro-intestinal cancer (oesophageal,
gastric, pancreatic) and were undergoing surgery with the intent of resection of the primary
tumour. All patients were enrolled before any treatment was initiated and within 1-2 weeks of
diagnosis. Newly diagnosed patients were identified principally from the regional oesophago-
gastric and hepatobiliary cancer multidisciplinary team (MDT) meetings at the Royal
Infirmary of Edinburgh, UK. The oesophago-gastric and hepatobiliary MDTs provides
regional referral services for patients with oesophageal, gastric and pancreatic cancer from
the Lothian and Borders regions. Patients with newly diagnosed upper gastro-intestinal
cancer within these regions are referred to the MDTs which meet on a weekly basis to
discuss all new referrals and to decide on individual patient management strategies.
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Participants were recruited at their surgical clinic appointments at the Royal Infirmary of
Edinburgh.
Control patients (i.e. with benign conditions necessitating abdominal surgery e.g. incisional
hernias) were recruited at outpatient surgical clinics prior to their surgery.
2.1.3 Candidate gene association study (Chapter 6)
Patients were recruited from three centres for this study with a separate independent
validation cohort of patients recruited from a fourth centre. Exclusion criteria were as follows:
i) under 18 years of age; ii) learning disability, and mental health problems; iii) inability to
give written, informed consent.
The main study cohort was recruited from this study between January 2004 and November
2008 from the following three institutions:
1) NHS Lothian, Edinburgh, UK
2) Cross Cancer Institute, Edmonton, Canada
3) McGill Cancer Center, Montreal, Canada
NHS Lothian
All patients recruited had either a confirmed diagnosis of gastro-oesophageal or pancreatic
malignancy. Approximately 300 retrospective patients recruited for previous studies with
blood stored in a tissue bank with relevant weight loss data were entered into the study.
Another 150 patients were recruited prospectively. These patients were identified principally
from the regional oesophago-gastric and hepatobiliary cancer multidisciplinary team (MDT)
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meetings at the Royal Infirmary of Edinburgh, UK. Patients were recruited at first
presentation to surgical or oncological clinic at Royal Infirmary of Edinburgh or Western
General Hospital, Edinburgh, UK.
Cross Cancer Institute
Approximately 190 patients were entered into the study. All patients had been previously
recruited for clinical research studies with relevant weight loss data and had blood stored in
a tissue bank. All patients had a confirmed diagnosis of non-small cell lung cancer (NSCLC).
McGill Cancer Center
All patients recruited had confirmed diagnosis of colorectal, pancreatic or non-small cell lung
cancers. Patients had previously participated in clinical research studies with relevant weight
loss data and had blood stored in a tissue back. Approximately 130 patients were entered
into the study.
Validation cohort
Patients for the validation cohort were recruited from Oncology & Palliative Medicine,
Cantonal Hospital, St. Gallen, Switzerland from January 2007 to December 2008. Patients
with all proven malignancies were considered and 101 patients were prospectively recruited.
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2.2 Clinical and pathological data collection
Demographic data was recorded and included age and sex for each patient across all
centres. The date of diagnosis was also recorded in all instances.
Histological confirmation of disease was obtained where possible and patients were staged
according to the American Joint Committee on Cancer stage groupings (AJCC). Tumours of
the gastro-oesophageal junction were classified according to Siewert and Stein and those
classified as type I and II were staged as oesophageal tumours and type III as gastric
cancers.
2.3 Nutritional assessment
All patients underwent measurements of height and weight at the time of recruitment. Pre¬
morbid weight was recalled by the patient and verified where possible from the medical
notes. There is evidence to support the reliability of self-reported weight and weight history
(Perry et al, 1995; Stunkard & Albaum, 1981). Individual weight loss was calculated and
expressed as percentage of pre-morbid body weight lost. Height and weight data were
subsequently used to compute a common anthropometric descriptor, body mass index (BMI)
(kg/m2).
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2.4 Collection of biological samples
2.4.1 Blood collection
Patients recruited for the gene microarray and candidate gene studies had up to 10ml of
blood collected into EDTA tubes and tubes with gel separator and clot activator. The blood
was usually collected when the patients were having blood taken as part of their on-going
clinical care as requested by their supervising clinician and not merely for participation in the
research study.
2.4.2 Skeletal muscle biopsies
For patients recruited for the gene microarray study, biopsies were taken at the start of open
abdominal surgery. The edge of the rectus abdominis was exposed and a 1cm3 biopsy was
removed with sharp dissection. Excess blood was removed and the biopsy was snap frozen
immediately in liquid nitrogen and stored at -80 degrees until further analysis.
2.5 Ethical approval
All studies contained in this thesis received full ethical permission from their respective host
institutions. Ethical approval for research carried out in Edinburgh was granted by the
Lothian Research Ethics Committee (reference 08/S1103/19).
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2.6 Blood assays
2.6.1 Measurement of C-reactive protein (CRP)
Serum CRP concentration was measured using an automated immuno-turbidimetric assay.
Using this assay, a concentration of 10mg/l represents the upper limit of normal range with
most healthy individuals having a serum concentration <2mg/l.
2.7 Body composition analysis
2.7.1 Estimation of total body skeletal and adipose tissue using computed
tomography (CT) scans
CT scans used for analysis were performed solely for routine cancer care. Two consecutive
transverse CT images extending from the third lumbar vertebrae (L3) in the inferior direction
were assessed for each scan date and then averaged; the foremost image being the one in
which both transverse processes were first clearly visible. Images were analyzed with
SliceOmatic V4.3 software (Tomovision, Montreal, Canada) which enables specific tissue
demarcation using Hounsfield unit (HU) thresholds. Skeletal muscle was identified and
quantified by HU thresholds of -29 to +150 (Mitsiopoulos et al, 1998). The muscles in the L3
region contain psoas, erector spinae, quadratus lumborum, transversus abdominus, external
and internal obliques, and rectus abdominus. The following HU thresholds were used for
adipose tissues: -190 to -30 for subcutaneous and intramuscular adipose (Kvist et al, 1986),
and -150 to -50 for visceral adipose (Vehmas et al, 1996). Tissue boundaries were manually
corrected as needed (Figure 2.1).
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Figure 2.1 Cross sectional CT images at L3 showing demarcation of skeletal muscle and
adipose tissue using Slice-o-matic software
Cross-sectional areas (cm2) were computed automatically by summing tissue pixels and
multiplying by pixel surface area. All CT images were analysed by a single trained observer.
Cross-sectional area for muscle and adipose tissue was normalised for stature (cm2/m2) and
reported.
Routine diagnostic CT scans usually only evaluate the chest, abdomen and pelvis and
therefore only partial images are available to determine skeletal muscle mass. Estimates of
whole body stores were generated from the raw data (cm2) using the following regression
equations by Mourtzakis et at. (2008) which show a close correlation between muscle and
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fat areas in CT images at the 3rd lumbar vertebrae and whole body compartments of fat-free
mass and fat mass respectively.
Total body fat-free mass (FFM) (kg) = 0.3 x [skeletal muscle at L3 (cm2)] + 6.06, (r =
0.94)
- Total body fat mass (FM) (kg) = 0.042 x [total adipose tissue at L3 (cm2)] + 11.2, (r =
0.88)
2.8 Cellularmethods
2.8.1 Nuclear protein extraction and RNA isolation from muscle
Approximately 20 mg of muscle was re-suspended in 180 pi of low salt lysis buffer (10 mM
HEPES, 10 mM KCI, 1.5 mM MgCI2, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM
PMSF, protease inhibitors (Roche Diagnostics; 1 tablet per 10 ml)) and ground using a
handheld homogenizer. Samples were incubated on ice for 5 minutes before two cycles of
freeze-thaw lysis. After a brief vortex, samples were centrifuged at 4,000 rpm for 3 minutes.
The supernatant was removed and the pellet (containing the nuclei) re-suspended in 40 pi
high salt extraction buffer (20 mM HEPES, 420 mM NaCI, 1 mM EDTA, 1 mM EGTA, 25%
glycerol, 1 mM DTT, protease inhibitors (Roche Diagnostics; 1 tablet per 10 ml)). Samples
were incubated on ice for 30 minutes with gentle mixing of the tubes every 5 to 10 minutes.
Samples were centrifuged at 4,000 rpm for 5 minutes at 4°C. The supernatant which now
contained the nuclear proteins was aliquoted into tubes and stored at -80°C.
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Total RNA was extracted from the supernatant using TRIzol (Invitrogen, Paisley, UK)
reagent. 800 pi of TRIzol reagent was added to each sample. Samples were incubated for 5
minutes at 15 to 30°C to permit the complete dissociation of nucleoprotein complexes. 160
pi of chloroform was then added. Tubes were shaken vigorously by hand for 15 seconds and
incubated at 15 to 30°C for 2 to 3 minutes. Samples were centrifuged at 12,000g for 15
minutes at 4°C. Following centrifugation, the mixture separates into a lower red, phenol-
chloroform phase, an interphase, and a colourless upper aqueous phase. RNA remains
exclusively in the aqueous phase. The aqueous phase was transferred to a fresh tube and
RNA was precipitated by mixing with 400 pi of isopropyl alcohol. Samples were incubated at
15 to 30°C for 10 minutes and centrifuged at 12,000g for 10 minutes at 4°C. The
supernatant was then removed and the RNA pellet washed with 800 pi 75% ethanol. The
sample was mixed by vortexing and then centrifuged at 7,500g for 5 minutes at 4°C. The
RNA pellet was then air dried for 5 to 10 minutes and then re-suspended in DEPC treated
water.
2.8.2 DNA extraction from blood
Genomic DNA was extracted from samples of blood taken in EDTA tubes. The Wizard
Genomic DNA purification kit (Promega, Southampton, U.K) was used. Whole blood was
centrifuged at 1,500g for 5 minutes at 4°C. 300 pi of the cellular layer was added to 900 pi of
cell lysis solution in a 1.5 ml micro centrifuge tube and mixed thoroughly by inverting the
tubes several times. The mixture was incubated for 10 minutes at room temperature followed
by centrifugation at 15,000g for 20 seconds also at room temperature. The supernatant was
discarded and the process of adding cell lysis solution, incubation and centrifugation was
repeated once more. 300 pi of nuclei lysis solution was added to the pellet and the tube was
vortexed to resuspend the white cells. The solution was pipetted gently several times to lyse
the white cells. 1.5 pi of RNase solution (Promega) was added to each tube, mixed and
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incubated at 37°C for 15 minutes. After allowing the tubes to cool to room temperature, 100
pi of protein precipitation solution was added and mixed by vortex for 15 seconds. Samples
were then centrifuged at 15,000g for 3 minutes at room temperature. The supernatants were
then transferred to a clean 1.5 ml micro centrifuge tube and mixed with 300 pi of pure
isopropanol. Gentle mixing reveals the appearance of the DNA as white thread-like strands.
Further centrifugation at 15,000g for 1 minute at room temperature allows the DNA to be
collected as a pellet at the bottom of the tube. The supernatant was then decanted and 300
pi of ethanol 70% is added to wash the pellet. The samples were then centrifuged again for
a further minute at 15,000g and the ethanol carefully aspirated away. 100 pi of DNA
rehydration solution (10 mM Tris-HCI and 1 mM EDTA) was added to each tube and
samples were incubated at 65°C for 1 hour. DNA samples were then stored at 4°C.
2.8.3 Quantification of RNA and DNA
DNA and RNA concentrations were measured using a Nanodrop ND-1000
spectrophotometer. Absorbance at 260nm were used for quantification of nucleic acids,
optical density of 1 corresponding to 50ng/pl DNA and 40ng/pl RNA. Absorbance ratios (260
nm/280 nm) of approximately 1.8 for DNA and 2.0 for RNA indicated that the nucleic acid
preparations were sufficiently free from protein contamination for downstream experiments.
2.9 Gene expression analysis
The Affymetrix GeneChip short-oligonucleotide arrays (Affymetrix, High Wycombe, U.K) was
utilised for muscle gene expression analysis. These arrays are small wafers of which the
area is divided into thousands of very small pieces (spots). Probes are chosen to fit to a
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unique part of the target RNA of which the quantity has to be measured. They are
complementary to this sequence since the RNA will then automatically bind (hybridize) to the
probe. The target RNA is labelled with a fluorescent label. Finally, the RNA molecules that
did not bind to any probe are washed away from the array and the amount of fluorescence
for each probe is measured in a scanner. This amount represents the amount of RNA that
was present for each gene. The Affymetrix technology uses multiple probes per gene, the
probe-set, to measure RNA abundances, with up to 1.3 million probe-sets on a single array.
The outline of the Affymetrix Genechip analysis protocol is illustrated in figure 2.2. The
genechips were scanned using the GeneChip scanner 3000 (Affymetrix, High Wycombe,
U.K).
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Figure 2.2 Outline of Affymetrix Genechip analysis protocol
1. Total mature RNA is isolated from tissue/cell being studied.
2. RNA is reverse transcribed into cDNA for storage purposes
3. Prior to running the array, cDNA is transcribed back to cRNA and labeled with Biotin.
4. Labeled cRNA is randomly fragmented to between 30 to 400 base pairs in length
5. Fragmented, Biotin-labeled cRNA is added to the Genechip array
6. cRNA is hybridized to complimentary probes in the array.
7. cRNA is tagged with florescent label and array is washed to remove any non-hybridized RNA
8. Lastly, the array is scanned for quantitative analysis of RNA present for each gene.
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2.10 Single nucleotide polymorphism (SNP) genotyping
The SNPlex Genotyping System (Applied Biosystems, California, USA) was utilised for SNP
genotyping. The SNPlex Genotyping System utilises a suite of pre-optimized universal assay
reagents kits and a set of SNP-specific ligation probes to perform genotyping up to a 48-plex
level (i.e., 48 SNPs genotyped in a single reaction). The SNPlex Genotyping System is
based on the oligonucleotide ligation/PCR assay (OLA/PCR) with a universal ZipChute™
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probe detection for high throughput SNP genotyping. Fluorescently labelled ZipChute probes
are hybridized to complementary ZipCode™ sequences that are part of genotype specific
amplicons. These ZipChute probes are eluted and detected by electrophoretic separation on
a 3730 DNA Genetic Analyzer (Applied Biosystems, California, USA). The assay workflow
for the SNPlex Genotyping System is illustrated in figure 2.3
Figure 2.3 Workflow for SNPlex Genotyping System
1. Allele-specific oligonucleotide ligation (OLA) reaction; during which allele-specific
oligonucleotide (ASO) probes and locus-specific oligonucleotide (LSO) probes hybridize to
the genomic target sequence. A unique ZipCode sequence is attached at the 5' end of the
genomic equivalent sequence within each ASO.
2. Purification of OLA reaction by exonucleolytic digestion of excess probes and linkers.
3. Universal PCR reaction to amplify ligation products, and biotinvlation.
4. Capturing of biotin-labelled PCR products in streptavidin coated microtiter plates.
5. Binding of fluorescently labelled ZipChute probes to single-strand PCR products; Each
ZipChute probe contains a sequence complementary to the unique ZipCode sequence within
each ASO.
6. Elution of hybridized ZipChute probes; and
7. Detection by Capillary Electrophoresis
Step 1: Activation & Ligation
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The Applied Biosystems' GeneMapper® Software (version 4.0) was used to perform
automated allele calls and genotype clustering of each individual sample. Any SNPs with
less than 90% of the sample auto-called by the software were either rescored manually or
discarded if clustering confidence was low.
2.11 Statistics
2.11.1 General statistics
General statistical analyses were performed using SPSS® Version 15.0 (SPSS, Chicago,
Illinois, USA). Data are presented as mean ± standard deviation unless otherwise stated.
Univariate and multivariate survival analysis and calculation of hazard ratios in Chapter 3
were performed using a Cox regression model. Comparisons between groups of patients
were assessed using one way ANOVA or Pearson's chi-square test. Survival curves were
constructed using the Kaplain-Meier technique. Log-rank test was used to compare survival
between groups of patients. Comparison of data at different time points for body composition
analysis in Chapter 3 was performed using the paired t-test. P values <0.05 were regarded
as statistically significant.
2.11.2 Microarray statistical analysis
Microarray data were analysed using the Microarray Suite software (MAS) version 5.0
(Affymetrix). Genes called absent on every array by the MAS5 software were filtered from
the data and remaining genes analysed using the significance analysis of microarrays
(SAM) and Limma packages in the Bioconductor suite. Genes covarying with weight loss
were identified by a false discovery rate (FDR) of <10%.
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2.11.3 SNP genotyping statistical analysis
Statistical analyses were performed using PLINK (version 1.06). Unconditional logistic
regression was employed to calculate odds ratios (OR) and their 95% confidence intervals
(95% CI) for the minor allele of individual SNPs and its association with each proposed
cachexia phenotype. To account for multiple testing, permutation testing was performed by
running the adaptive permutation test in PLINK within each proposed phenotype.
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CHAPTER 3




Using pancreatic cancer as a model for cancer cachexia, the aim of this chapter is to
evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic
computed tomography (CT) scans, is of prognostic value. The nature and extent of tissue
loss over subsequent months was also evaluated.
Methods
111 pancreatic cancer patients entering a palliative therapy programme, who had CT images
and undergone nutritional screening, were studied. In patients where follow-up scans were
available (n=44), longitudinal changes in body composition were studied at a mean of 230 ±
62 and 95 ± 60 days prior to demise.
Results
62 patients (55.9%) were sarcopenic, 44 (39.6%) were overweight/obese, and 18 (16.2%)
were both. Age >59 years (HR 1.71, 95%CI 1.10 - 2.66, p=0.018), and overweight/obese
sarcopenia (HR 2.07, 95%CI 1.23 - 3.50, p=0.006) were identified as independent
predictors of survival on multivariate analysis. Longitudinal analysis revealed that total fat-
free mass (FFM) index decreased from 15.5 ± 2.5kg/m2 to 14.5 ± 2.0kg/m2 (p=0.002), and




Sarcopenia in overweight/obese patients with advanced pancreatic cancer is an occult
condition but can be identified using CT scans. This condition is an independent adverse
prognostic indicator. Longitudinal analysis of body composition in pancreatic cancer patients
revealed a loss of both skeletal muscle and adipose tissue in the course of the cancer
journey but, adipose tissue was lost more rapidly than muscle.
3.2 Introduction
One of the most distressing features of pancreatic cancer is marked and progressive weight
loss. Cachexia occurs in up to 80% of deaths in patients with advanced pancreatic cancer
(Dewys et al, 1980). Pancreatic cancer has been shown previously to be a good model for
the study for cancer cachexia (Fearon et al, 1999).
Due to the epidemic of obesity in Western Society, a substantial proportion of oncology
patients at the start of palliative therapy now have a BMI in the overweight range (Irigaray et
al, 2007) and this can confound conventional measures used for risk stratification. Indeed
recent studies have reported that obesity (i.e. BMI >30 kg/m2) in the presence of sarcopenia
is predictive of morbidity and mortality in both malignant and non-malignant disease.(Honda
et al, 2007; Prado et al, 2008) The development of novel methods of image analysis
enabling routine derivation of body composition data from diagnostic CT scans (and in
particular the estimation of skeletal muscle mass) provides an opportunity to assess if
measures of body composition has any prognostic value in patients with pancreatic cancer.
The present study focused on sarcopenia specifically, both in the presence or absence of an
elevated BMI.
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When considering the significance of sarcopenia in a given population, it is important to
know the likely longitudinal pattern of wasting and how this may be altered by concomitant
systemic oncological therapy. The nutritional and metabolic status of patients who respond
to chemotherapy may improve spontaneously and a substantial proportion of patients now
receive anti-neoplastic therapy even in the last weeks of life. Another aim of the present
study was to assess time course changes in regional body fat and lean tissue compartments
by analysing computed tomography (CT) images in a subset of pancreatic cancer patients
being managed within a regional palliative therapy programme.
3.3 Methods
Patients
All patients referred to the regional cancer centre in Edmonton, Alberta, Canada between
January 2004 and October 2008 were considered for the study. Patients with a primary
diagnosis of pancreatic cancer entering a palliative programme who had an abdominal CT
scan within 60 days of initial assessment were selected for the study (n=111). Patients with
ampullary carcinoma, cholangiocarcinoma or neuro-endocrine tumours were excluded.
Coding of the primary cancer by its site and morphology, clinical information, and
demographic information were obtained from the Alberta Cancer Registry for every patient in
the cohort. The Alberta Cancer Registry is a computerised database of all cancer cases in
the region (population 1.8 million). Patient-reported height, weight, and weight history were
collected during this visit by use of the Patient-Generated Subjective Global Assessment
(PG-SGA).(Bauer et at, 2002) Height and weight data were subsequently used to compute a
common anthropometric descriptor, body mass index (BMI) (kg/m2). Height and weight
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recorded by hospital staff on the same date were used for verification where available, and
classification of patients' BMI with the use of patient-reporting was found to be accurate.
Patient-reported height, weight, and weight history have been shown to be reliable.(Perry et
al, 1995) Stage of disease was based on the American Joint Committee on Cancer stage
groupings I, II, III and IV.
From the initial cohort of 111 patients, 44 patients were further identified who: a) had had at
least one further follow-up CT scan, and b) had a documented duration of survival for
inclusion into the study of longitudinal changes of body composition.
CT image analysis
CT scans used for analysis were performed solely for routine cancer care. The technique for
CT image analysis has been described in detail in chapter 2.
CT dates were expressed in terms of the number of days to death. Any change in tissue
area was expressed as either an absolute change (cm2) or as a percentage change per 100
days. This provided a standardised unit and allowed for comparison across different
intervals.
Cut-offs for sarcopenia was based on a CT-based sarcopenic obesity study of cancer
patients by Prado et al. (2008) (i.e. L3 skeletal muscle index: <38.5 cm2/m2 for women and
252.4 cm2/m2 for men).
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Statistical analysis
Data are presented as mean ± standard deviation unless otherwise stated. Survival was
determined from the time initial assessment until death or until the censor date of 05 January
2009.
Univariate and multivariate survival analysis and calculation of hazard ratios were performed
using a Cox regression model. Owing to the large number of covariates examined, only
those that were significant on univariate analysis were included in multivariate analysis.
Receiver-operator characteristic (ROC) curves were used to select cut-off values for
continuous variables. Values with the best combination of sensitivity and specificity were
chosen. A backward stepwise procedure was performed to derive a final model of the
variables that had a significant relationship with survival. To remove a variable from the
model, the corresponding p-value had to be greater than 0.05.
Comparisons between groups of patients were assessed using one way ANOVA or
Pearson's chi-square test. Survival curves were constructed using the Kaplain-Meier
technique. Log-rank test was used to compare survival between groups of patients.
Comparison of data at different time points for body composition analysis was performed
using the paired t-test. P values <0.05 were regarded as statistically significant. Statistical
analysis was performed using SPSS 15.0 statistical package (SPSS Inc., Chicago, IL, USA).
3.4 Results
Details of the 111 pancreatic cancer patients identified at the time of referral to the cancer
centre are shown (Table 3.1). About two-thirds of the patients had tumours in the head of
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the pancreas. Approximately 75% of patients had biopsy proven adenocarcinoma. At the
time of censoring, 101 patients (91.0%) had died. Overall median survival was 130
(interquartile (IQ) range 71 - 302) days. Percentage weight loss in the preceding six months
was 12 ± 6% with 89 patients (80.2%) losing more than 5% of their normal body weight. BMI
at the time of assessment was 23.9 ± 4.9 kg/m2 and 44 patients (39.6%) were overweight or
frankly obese (BMI S25 kg/m2). Body composition parameters of patients are also reported in
Table 1. 62 patients (55.9%) were sarcopenic at this point. 18 patients were
overweight/obese (BMI >25 kg/m2) and sarcopenic. The prevalence of sarcopenia within the
various BMI categories is presented in Figure 3.1.
Patients were then divided into 4 groups: neither sarcopenic or overweight/obese,
overweight/obese, sarcopenic, and both sarcopenic and overweight/obese (Table 3.2).
There were no significant differences in age, sex, tumour site, histology, stage of disease,
and weight loss between the groups.
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Figure 3.1 Venn diagram ofBMI classes and sarcopenic patients
Body composition was determined by CT image analysis in patients (n = 111) with advanced
pancreatic cancer. Sarcopenia was defined as L3 skeletal muscle index: ^38.5 cm2/m2 for women and













Table 3.1 Overall pancreatic patient (n = 111) demographics, nutritional variables and
body composition at the time of entry to palliative care programme
No. of patients
(n=111)





57 (61.3)"Head of pancreas
Body of pancreas 18
I ail of pancreas 4
Pancreatic duct 1












Body mass index (kg/m2)+ 23.9 ±4.9
Underweight (BMI <18.5 ky/rri7) 11 (9.9)
Normal (BMI 18.5 - 24.9 kg/m2) 56 (50.5)
Overweight/Obese (BMI >25 kg/m2) 44 (39.6)
Percentage weight loss (in preceding 6 months)f 12.14 ±6.35
Lumbar total muscle cross sectional area (cm2)f 126.0 ±30.7
Lumbar total adipose tissue cross sectional area (cm2)f 243.7 ± 162.3
Lumbar skeletal muscle index (cm2/m2)+ 43.8 ±7.9
Lumbar adipose tissue index (cm2/m2)f 86.1 ±57.4
Estimated total fat-free mass (kg)f 43.9 ± 9.2
Estimated total fat mass (kg)f 21.2 ±6.9
Sarcopenic 62 (55.9)




Values are number of patients with percentages in parentheses unless indicated otherwise; Values
are mean ± SD; unknown tumour site was excluded from calculation of overall percentage.
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On univariate analysis, age and overweight/obese sarcopenia were associated with outcome
for the patient group. Neither overweight/obese (BMI >25 kg/m2) nor sarcopenia in the non-
overweight/obese group failed to reach statistical significance (Table 3.3). In contrast,
median survival for patients who were both overweight/obese and sarcopenic was 55 (IQ
range 43 - 207) days compared with 148 (IQ range 80 - 369) days for the rest of the patient
cohort without overweight/obese sarcopenia (log-rank test, p=0.003) (Figure 3.2). Using
ROC curves, cut-off values with the best discriminatory value for age was greater or equal
than 59 years.
On multivariate analysis, age £59 years (HR 1.71, 95% CI 1.10 - 2.66, p=0.018), and
overweight/obese sarcopenia (HR 2.07, 95% CI 1.23 - 3.50, p=0.006) retained independent
prognostic value (Table 3.3).
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Figure 3.2 Survival curves of patients who were neither overweight nor sarcopenic,







Longitudinal analysis of body composition
A subset of 44 patients underwent repeated CT scans as part of their medical management
and was therefore available for study of longitudinal changes in body composition. This
cohort of patients had a significantly longer survival compared with the entire group (median
survival 189 days vs. 130 days, p=0.019 (log-rank test)). 71% of patients with follow-up CT
scans received active treatment compared with just 28% of patients who had no follow-up
CT scans (p <0.0001, chi-square test). Patients had their 1st CT scan at a mean of 230 ± 62
days before death. The 2nd CT scan was performed at a mean of 95 ± 60 days before death.
The changes in cross sectional area of skeletal muscle and adipose tissue between the two
scans are presented in table 4. Patients displayed a significant loss of both skeletal muscle
and adipose tissue. Overall, 32 patients (72.7%) lost skeletal muscle and all but one patient
(97.6%) lost adipose tissue. The measurements for cross-sectional area were used to
estimate whole body fat-free mass (FFM) and whole body fat mass (FM) using regression
equations and then normalised for height (kg/m2) (Table 3.4).
20 patients (45.5%) were sarcopenic at the time of the 1st CT with an estimated FFM index
of 15.5 ± 2.5 kg/m2. By the time of the 2nd CT 27 patients (61.4%) were sarcopenic and FFM
had decreased to 14.5 ± 2.0kg/m2. Estimated FM index decreased from 7.5 ± 2.0 kg/m2 (1st
CT) to 6.0 ± 1.5 kg/m2 (2nd CT).
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Table 3.4 Change in body composition over time in pancreatic cancer patients (n=44).




Time to death (days) 230 + 62 95 ± 60 135 ±57
Skeletal muscle (cm2) 126.5 ±31.1 119.6 ±28.6 -7.0 ± 13.6 0.002
Adipose tissue (cm2)
Visceral adipose tissue 91.2 ±69.9 45.4 ±47.0 -45.8 ± 47.5 <0.0001
Intramuscular and
subculai ieuus adipose tissue
148.5 ± 85 8 87 0 + 66.4 -61.5 ±53.9 <0.0001
Total 236.6 ± 145.5 128.6 ± 102.6 -108.0 ±89.1 <0.0001
Estimated whole body fat-free
mass (FFM) (kg)
44.0 ±9.3 41.9 ±8.6 2.1 ±4.1 0.002
Estimated whole body adipose
tissue (FM) (kg)
21.1 ±6.1 16.6 ±4.3 -4.5 ±3.7 <0.0001
Estimated FFM index (kg/m2) 15.5 ±2.5 14.5 ±2.0 -1.0 ±1.5 0.002
Estimated FM index (kg/m2) /.h + 20 6.0 ± 1.5 -1.5 ± 1.5 <0 0001
Values are mean ± SD. 'Paired t-test
A distinct distribution for muscle and adipose tissue changes over time is more clearly
revealed by analysis of population tertiles (Figure 3.3). The overall change of skeletal muscle
was -3.1 ± 12.0%/100 days. However, the 1st tertile gained a small amount of muscle tissue
(7.9 ± 14.4%/100 days) while the 3rd tertile lost muscle at a rate of-12.7 ± 5.2% /100 days. In
comparison, adipose tissue was lost across all 3 tertiles and the overall change of adipose
tissue was -40.4 ± 25.4%/100 days (p<0.0001, paired t-test). The proportion of patients
receiving chemotherapy was not significantly different across all 3 tertiles of muscle
(p=0.372, chi-square test) or adipose tissue loss (p=0.804, chi-square test). Moreover, the
changes in muscle (p=0.113, Student's t-test) and fat mass (p=0.862, Student's t-test) were
not significantly different between those who did or did not receive chemotherapy. There was
also no significant difference in survival across all 3 tertiles for both muscle loss (p=0.142,
log-rank test) and adipose tissue loss (p=0.542, log-rank test).
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Figure3.3Intensityofcha gesibodc mpositionpresentedyte til a)Skeletalmuscle b)Adiposetissu Tertiles
3.5 Discussion
Patients with pancreatic cancer have long been associated with the most severe forms of
cachexia. In a similar study undertaken more than 10 years ago, Wigmore et at. (1997a)
documented median BMI at diagnosis to be 20.7 and this fell to 17.7 near to the time of
death. Average weight loss over this time increased from 15% to 25%. Loss of muscle and
fat to levels consistent with significant undernutrition increased from 30% to 70% and from
65% to 90% respectively. This was consistent with the conventional view of cancer cachexia
(i.e. marked weight loss, severe muscle wasting and gross loss of subcutaneous fat (Fearon
& Preston, 1990)). In the present chapter, patients had a mean BMI of 23.9 with 40% of
individuals being in the overweight/obese range. Thus, the average physiognomy appears to
have changed with patients demonstrating large energy reserves (fat) at the time of
presentation with advanced disease. However, underneath this mantle of adipose tissue the
previously noted tendency to muscle wasting continues. The use of CT images in the
present study identified that 56% of patients had sarcopenia at the time of presentation
(Table 3.1) and the tendency to muscle loss continued in at least a proportion of patients
(Figure 3.3).
A BMI <18.5kg/m2 is considered by many authorities to represent an individual at serious
risk of undernutrition (Shetty, 2003). In the present chapter, only 10% of individuals at
baseline fulfilled this criterion. Given the prevalence of overweight/obesity (40%) it would
seem unlikely that even in the presence of ongoing weight loss, the majority would reach this
boundary at or near the time of death. However, BMI has clear limitations and more detailed
evaluation of body composition clearly revealed wasting of the lean tissues, with a majority
of patients below or well below benchmark levels of muscularity known to be associated with
mortality and functional disability (Janssen et at, 2002). The estimated lean body mass of
patients classified as sarcopenic was within the range described for a variety of
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wasted/emaciated patient populations with and without malignant disease (Baumgartner et
al, 1998; Prado et at, 2008). In the current literature it is becoming increasingly evident that
concurrent sarcopenia and high fat mass is a worst case scenario (Bigaard et al, 2004;
Heitmann et al, 2000; Honda et al, 2007; Prado et al, 2008), and this is clearly apparent in
the study group (albeit small), where sarcopenic overweight/obese patients had the worst
prognosis overall, even compared with patients who were sarcopenic and had a lower body
weight.
Sarcopenia alone had no discernable effect on mortality yet being overweight/obese and
sarcopenic was associated with decreased survival duration. However, a variable can only
serve a predictive function where it varies in the relevant population. It should be noted that
all patients with a BMI <18.5 were sarcopenic and the majority were sarcopenic in the BMI
range 18-5 - 24.9. Thus, one explanation for the finding that sarcopenia was not predictive
for the overall population, but was predictive for those with obesity would lie in the differential
frequency distribution of sarcopenia in the different BMI categories. Evaluation of this
question in a much larger patient population would help resolve this issue.
In the present chapter, patients entering the palliative phase of their pancreatic cancer
management had a remarkably high prevalence of sarcopenia compared with reports in the
literature for healthy elderly in a similar age bracket (Baumgartner et al, 1998); thereby
suggesting that substantial muscle wasting had occurred prior to initial evaluation of these
patients. The pre-existing nature of this muscle loss makes it difficult to comment as to its
mechanisms, except perhaps to suggest that it may be driven by the primary malignancy, by
weight loss, and/or by co-morbid conditions which include obesity, insulin resistance, various
types of organ failure, and low levels of physical activity. The muscle loss that occurred
thereafter, which was characterized during the 135 days scan-scan interval may be driven by
disease progression, increased metabolism and inflammation (Falconer et al, 1994; Falconer
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et al, 1995), and by negative energy balance which might be inferred from the loss of fat
mass (i.e. 4.54 kg x -9000 kcal/kg = 40,840 kcal) in 135 days.
The mechanism that links sarcopenic overweight/obesity with accelerated demise is not
known. Muscle wasting is a known complication associated with insulin resistance found
commonly in obesity (Wang et al, 2006). Adipose tissue synthesises and secretes circulating
hormones and 'adipokines' which act as systemic inflammatory mediators and signals of
nutritional status (Shoelson et al, 2007). These adipocyte factors, such as tumour necrosis
factor-alpha (TNFa) and interleukin- 6 (IL-6) are thought to play a major role in the induction
of insulin resistance in skeletal muscle leading to an increase in muscle protein loss. The
main mediators thought to be involved in this process are inhibitor kB Kinase (IKK) and its
downstream effector nuclear factor kB (NF-kB) (Dietze et al, 2004). However, not all patients
who are overweight/obese have sarcopenia. It may be that cancer-related factors stimulate
the initial loss of muscle and being overweight/obese perpetuates and/or enhances muscle
loss/loss of muscle function leading to poorer survival. The observation that
overweight/obesity may be associated with better survival in patients with weight-losing
cardiac failure (Oreopoulos et al, 2008) may seem to contradict the present observations in
cancer patients. However, the studies in patients with cardiac failure have not been stratified
for body composition (specifically sarcopenia) and may represent a disease-specific
phenomenon.
Current published results on body composition changes in cancer are varied. Some studies
confirm a decline in lean body mass (Maturo et al, 2003; Segal et al, 2003), while others
emphasise a loss of body fat (Fouladiun et al, 2005; Lundholm et al, 1994). There are also
reports that suggest a proportional loss of lean tissue and fat leading to an unchanged body
composition (Heymsfield & McManus, 1985; Moley et al, 1987). In the present study, roughly
half of the patients were found to be already sarcopenic at the time of assessment.
Subsequently, a much greater rate of fat loss was noted as compared with muscle loss (see
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longitudinal study). In fact, some patients were able to maintain or even gain muscle mass.
The patients that gained muscle could have been positive responders to chemotherapy.
However, in patients with pancreatic cancer, the use of CT scans to determine response to
chemotherapy is complicated by factors such as peritumoural inflammation, therefore
duration of survival was regarded as a more robust measure (accepting the small numbers
involved in this study). In the present study the survival of patients was not significantly
different across all 3 tertiles of loss of muscle mass, thus response to chemotherapy as the
main reason for patients to gain muscle mass cannot be confirmed. An alternative
hypothesis would be that a proportion of patients were able to activate compensatory
mechanisms aimed at conserving muscle. There is increasing evidence that gene
polymorphisms are related to cancer cachexia susceptibility (Deans et al, 2009a; Vigano et
al, 2009).
Systemic inflammation is known to be a key mediator in cachexia (Stephens et al, 2008),
and has been associated with poor prognosis in previous studies on pancreatic cancer
(Fearon et al, 2006; Glen et al, 2006). A limitation of the present study is the lack of
measures of systemic inflammation such as C-reactive protein (CRP) which may be
significant when assessing factors influencing survival in pancreatic cancer.
Nevertheless, this study has shown that sarcopenia in overweight/obese advanced
pancreatic cancer patients may be an occult condition but can be identified using diagnostic
CT scans and is an independent adverse prognostic indicator. Longitudinal analysis of body
composition in pancreatic cancer patients revealed a loss of both skeletal muscle and




IDENTIFICATION OF POSSIBLE GENETIC VARIANTS




The aims of this chapter are to explore genetic polymorphisms with known functional or
clinical significance in potential candidate genes involved in the development of cancer
cachexia by means of a systematic literature review, and to identify the polymorphisms with
the most likely potential as susceptibility markers for cancer cachexia.
Methods
A systematic search of the Medline and EmBase databases, covering 1986 - 2008 was
performed for potential candidate genes/genetic polymorphisms relating to cancer cachexia.
Related genes were then identified using pathway functional analysis software. All candidate
genes were reviewed for functional polymorphisms or clinically significant polymorphisms
associated with cachexia using the OMIM and GeneRIF databases.
Results
A total of 184 polymorphisms with functional or clinical relevance to cancer cachexia were
identified in 92 candidate genes. Of these, 42 polymorphisms (in 33 genes) were replicated
in more than one study with 13 polymorphisms found to influence two or more hallmarks of
cachexia (i.e. inflammation, loss of fat mass and/or lean mass, reduced survival).
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Conclusions
Selection of candidate genes and polymorphisms is a key element of multigene study
design. The present chapter provides an initial framework in which to select
genes/polymorphisms for further study in cancer cachexia (see chapter 6).
4.2 Introduction
Certain tumour types are more commonly associated with cachexia, but even with the same
tumour type there are variations in the extent to which patients exhibit cachexia. Such
variation may, in part, be due to the patient's genotype rather. It is therefore likely there may
be a cachexia prone genotype as well as a cachexia protective genotype.
The cachexia syndrome is thought to result from a complex interplay of mechanisms
involving the initiation of a host inflammatory response mediated by tumour-derived
proinflammatory cytokines; the reprioritisation of protein metabolism with induction of the
acute phase response and mobilisation of fat reserves; and activation of neuroendocrine
pathways which may lead to hypermetabolism and increased catabolism (Tan et al, 2008).
The wealth of known genetic variation in genes regulating the above mechanisms suggests
their exploitable potential as biomarkers of inter-individual predictability of developing
cachexia.
Single nucleotide polymorphisms (SNPs) are the most common type of stable genetic
variation in the population (Brookes, 1999). SNPs occur in approximately one in every
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thousand bases. There are several ways that SNPs can lead to an aberrant gene product.
Promoter polymorphisms that alter DNA binding of transcription factors have the potential of
decreasing or increasing gene expression; Sequence variation in the 5' untranslated region
(UTR) could disrupt mRNA translation, and mutations in the 3' UTR could affect mRNA
cleavage, stability, and export; Finally, non-synonymous SNPs in exons could alter protein
function or activity. It has been estimated that 10% of all SNPs in the genome are functional,
thereby having the potential of altering some biological process (Wjst, 2004).
Over the past 10 years, considerable information has emerged on mechanisms of cancer
cachexia of which inflammation is postulated to play a significant role. These mechanisms
can be broadly grouped into five domains of interest: systemic inflammation, central energy
balance, control of muscle metabolism/function, control of adipose tissue
metabolism/function, and regulation of appetite.
This chapter aims to explore genetic polymorphisms with known functional or clinical
significance in potential candidate genes involved in the development of cancer cachexia
within the above-mentioned domains by means of a systematic literature review. It also aims




The scientific literature published between 1986 and 2008 was searched in Medline and
EmBase databases. In order to maximise the potential of identifying potential candidate
genes, search terms were utilised that took into the account the effects of cachexia. E.g.
'survival' as a surrogate for accelerated death which may be due to cachexia. The term
'body composition' was used to identify potential genes of interest that may predispose
individuals to higher/lower body mass which may influence the propensity to the
development of cancer cachexia. 'Inflammation' was used as a main search term due to its
postulated central role in the development of cancer cachexia.
Overall, the following search terms were used to identify potential candidate
genes/polymorphisms of interest:
• ((genes/genetics) OR polymorphism(s)) AND (inflammation OR cancer OR cachexia OR
weight loss OR body composition OR survival)
The search was limited to English language and humans.
Following the initial retrieval of possible candidate genes, the genes were entered into a
pathway functional analysis software (Ingenuity Pathways Analysis (IPA), Ingenuity
Systems, California) to further identify related genes.
All identified candidate genes were then reviewed for functional polymorphisms or clinically
significant polymorphisms in terms of cachexia using OMIM and GeneRIF databases.
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related to cachexia identified
Possible genes related to
cachexia identified
Genes entered into IPA program
to further identify related genes
Genes entered into
OMIM/GeneRIF databases
Candidate gene variants were grouped into categories according to genes that regulate or
code for the following:
• Inflammation
o Innate immune receptors and mediators of the immune response
o Cytokines
o Cytokine receptors and related binding proteins
o Acute phase protein reactants
• Central homeostasis
o Energy production
o Insulin like growth factors and related proteins
o Corticosteroid signalling proteins
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• Muscle




o Lipid turnover and transport
o Adipokines and adipokine receptors
• Appetite
• Others
Summary tables of polymorphisms are also presented according to each category with 'easy
to see' boxes that denote whether a polymorphism has any effect on inflammation,
weight/body composition (i.e. lean mass/fat mass) and cancer survival. The summary tables
also denoted if a functional or clinical association with a polymorphism was replicated in
more than one study. In addition polymorphism reference numbers (rs numbers) were also
recorded if known, as well as the minor allele frequency of the polymorphism based on a
population with European ancestry derived from the HapMap or dbSNP databases
4.4 Results
A total of 184 polymorphisms with functional and/or clinical significance in terms of cachexia
were identified in 92 genes.
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Inflammation
Inflammation has long been associated with cancer cachexia. Systemic inflammation could
result from tumour cell or host cell mediated production (Stewart et al, 2006). In experimental
models, pro-inflammatory cytokines such as interleukin 1-beta (IL-1|3), interleukin 6 (IL-6),
tumour necrosis factor alpha (TNFa), and interferon gamma (IFNy) may lead to an acute
phase response and trigger tissue catabolism (Argiles et al, 2003).
Innate immune receptors and mediators of the immune response
Table 4.1 explores the possible genetic determinants in the generation or suppression of the
inflammatory response and how they may relate to cancer cachexia. These include variants
in genes coding for the Toll-like receptor (TLR) family, and associated genes, which play an
instructive role in innate immune responses as well as the subsequent induction of adaptive
immune responses. TLRs are involved in triggering intracellular signals, culminating in the
activation of nuclear factor (NF)-kB, where it participates in enhancing expression of other
immuneregulatory substances (Kawai & Akira, 2006). NF-kB is a transcriptional regulator
that plays a central part in responses to inflammatory signalling. Polymorphisms in genes
encoding for NF-kB and genes involved in the activation or inhibition of NF-kB are also
shown in table 4.1.
Also of interest are variants in genes coding for cell adhesion molecules (CAMs) which are
proteins located on the cell surface involved with the binding with other cells or with the
extracellular matrix. CAMs are known to mediate migration of cells to sites of inflammation.
Functional polymorphisms in the heat shock proteins genes HSPA1L and HSPA1B have
been noted in relation to inflammation and these are also displayed in table 4.1.
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Cytokines and cytokine receptors
Cytokines are secreted proteins that play a role in the induction and effector phases of all
immune and inflammatory responses. They serve diverse functions including induction of
cell proliferation, mediating intercellular communication, chemotaxis and cell killing. Genetic
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Cytokines exert their effects via matching cell-surface receptors. Subsequent cascades of
intracellular signalling then alter cell functions. This may include the upregulation and/or
downregulation of several genes and their transcription factors, resulting in the production of
other cytokines, an increase in the number of surface receptors for other molecules, or the
suppression of their own effect by feedback inhibition (Ihle, 1995). Table 4.3 summarizes the
variations in genes encoding cytokine receptors and related binding proteins.
77







































•Variable86 prepeat polymorphismIntr n2 Allele2(240bp)
















•ElevatedLITAFmRNAexpressionin extramammaryPaget'sdis asetumour sample(Matsu uraetl,2004)
*InhibitionofLITAFmRNAexpressi niTHP-1 cellsresultedinareductionofTNF-atranscrip s (Myokaietal,1999)
T
fIncrease;J.Decr ;Increaseorde e(evid ncconflicting);sPres n efr p tstudies
78
Acute phase protein reactants
Acute-phase protein reactants (APPR) are proteins whose plasma concentrations increase
(positive acute-phase proteins) or decrease (negative acute-phase proteins) in response to
inflammation (Stephens et at, 2008), and are also predictors of adverse outcomes in cancer
patients. Some APPR also have roles in modulating the immune response such as C-
reactive protein (CRP). Variants in genes coding for APPR are shown in table 4.4.
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Central homeostasis
Body mass is controlled by the balance of energy intake and expenditure, like all
thermodynamic systems. In certain forms of cancer, patients with cachexia have been
observed to have much higher resting energy expenditure (REE) (Fredrix et al, 1991). Gene
polymorphisms in the regulatory pathways controlling energy intake and expenditure are
discussed below. The following section also explores genes involved in growth and
development, and metabolic pathways common to both muscle and adipose tissue.
Energy production
Uncoupling proteins (UCPs) are transporters, present in the mitochondrial inner membrane,
that mediate a regulated discharge of the proton gradient that is generated by the respiratory
chain. This energy-dissipatory mechanism can serve functions such as thermogenesis,
maintenance of the redox balance, or reduction in the production of reactive oxygen species
(Ledesma et al, 2002). There are a total of five UCP homologs in humans. There are known
significant polymorphisms within three UCP genes that may have a role in the development
of cachexia and these are presented in table 4.5.
A polymorphism in the gene coding for Those phosphate isomerase (TPI) which plays an
important role in glycolysis and is essential for efficient energy production is also shown in
table 4.5. TPI deficiency leads to a metabolic block of the glycolytic pathway and hence a
generalized impairment of cellular energy supply causing generalised skeletal muscle
deficiency.
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Insulin like growth factors and related proteins
The insulin-like growth factors (IGFs) are polypeptides with high sequence similarity to
insulin. IGFs are part of a complex system that cells use to communicate with their
physiologic environment. This complex system (often referred to as the IGF "axis") consists
of two ligands (IGF-1 and IGF-2), two cell-surface receptors (IGF1R and IGF2R), and a
family of six high-affinity IGF binding proteins (IGFBP 1-6) (Jones & Clemmons, 1995). This
system regulates normal cellular metabolism, proliferation, differentiation and protecting
against apoptotic signals (Jerome et at, 2003). High levels of IGF-1 and IGFBP3 have been
implicated with poorer prognosis in certain types of cancers. Polymorphisms in genes coding
for components of the IGF axis have been shown to affect serum levels of their respective
proteins as well as body composition (Table 4.6).
Also shown in table 4.6 are polymorphisms in the iodothyronine deiodinase, type 1 gene
(DI01) which activates thyroid hormone by converting the prohormone thyroxine (T4) by
outer ring deiodination to bioactive triiodothyronine (T3). Thyroid hormone is known to
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Corticosteroid signalling proteins
Corticosteroids are essential steroid hormones that are secreted by the adrenal cortex and
affect multiple organ systems. Corticosteroids are involved in a wide range of physiologic
systems such as stress response, immune response and regulation of inflammation,
carbohydrate metabolism and protein catabolism. The genetic variants of the components in
the mechanism of corticosteroid signalling are examined in table 4.7.
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Muscle atrophy is known to occur in cancer cachexia. This results from a depression of
muscle protein synthesis, an increase in muscle protein degradation, or a combination of
both (Eley & Tisdale, 2007). Experimental studies have also showed a shift in the myosin
isoform content of skeletal muscle in cancer cachexia from type I to type II (Diffee et al,
2002). The following section examines the genetic variations that affect the structure and
function of muscle as well as those that regulate muscle proteolysis.
Muscle structure and function
Genes involved in regulating muscle structure and function include ACTN3 (Alpha-actinin 3),
which bind to actin at the Z-line within muscle fibres and act to anchor actin filaments, and
IL15 (interleukin-15). IL-15 signals through IL-15 receptor alpha (IL-15RA) and is found in
abundance in skeletal muscle. IL-15 has been shown to be anabolic, marked by an increase
in myosin heavy chain accumulation (Quinn et al, 2002). Polymorphisms in ACTN3, IL15 and
IL15RA are shown in table 4.8.
Steroid androgens play an important role in determining lean body mass and muscle
strength. Variants in the gene coding for the androgen receptor (AR), which is activated by
binding of either of the androgenic hormones testosterone or dihydrotestosterone and has
been known to be capable of activating myogenic genes (Vlahopoulos et al, 2005), are also
displayed in table 4.8.
Polymorphisms associated with alterations fat free mass in the gene encoding the vitamin D
receptor (VDR) are also included in table 4.8.
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Muscle proteolysis
Angiotensin converting enzyme (ACE) plays a critical role in the renin-angiotensin system by
catalyzing the conversion of the inactive angiotensin I to angiotensin II, which is the
physiologically active form of the hormone. Acute and chronic exposure to angiotensin II in
animal models has been associated with weight loss and enhanced protein breakdown in
skeletal muscle (Brink et at, 2001; Brink et at, 1996).
In atrophying muscles, the ubiquitin ligase, atrogin-1, is induced and this response is
necessary for rapid atrophy. Foxo3 is known to act on the atrogin-1 promoter to cause
atrogin-1 transcription and this leads to dramatic atrophy of myotubes and muscle fibres
(Sandri et al, 2004). Polymorphisms in the ACE and FOX03A gene are presented in table
4.9.
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Adipose tissue
Body-fat depletion is a major component of weight loss in cancer cachexia. Increased
lipolysis appears to be a key factor underlying fat loss, though decreases in lipid deposition
and adipocyte development may also contribute (Legaspi et al, 1987). The following section
examines polymorphisms in genes regulating adipose tissue metabolism.
Adipogenesis
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor
proteins that function as transcription factors regulating the expression of genes. There are
three subtypes of the receptor (PPARa, PPAR(3 and PPARy). PPARa is most commonly
expressed in organs and tissues in which fatty acid oxidation is active. PPARa is known to
participate in the regulation of key proteins involved in extracellular lipid metabolism, fatty
acid oxidation, and inflammation (Torra et al, 2001). PPARy is an important regulator of fat
cell function by orchestrating differentiation of new adipocytes and by inducing expression of
genes promoting uptake of fatty acids, triglyceride synthesis and insulin sensitivity (Lehrke &
Lazar, 2005). Polymophisms in the PPARA and PPARG gene are shown in table 4.10.
Also of interest are the lipin proteins (lipin-1, lipin-2, and lipin-3) which are thought to be
required for glycerolipid biosynthesis. They also act as transcriptional coactivators that
regulate expression of lipid metabolism genes (Reue, 2009). Variants of genes coding of
lipin-1 (LPIN1) and lipin-2 (LPIN2) are also presented in table 4.10.
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Lipid turnover and transport
During lipolysis, trigylcerides are broken down in a stepwise fashion to free fatty acids
(FFAs). This process is partly modulated by the sympathetic nervous system induced
secretion of cathecholamines which act though (31, (32 and (33 adrenergic receptors ((3-ARs)
(Large et al, 2004). The signals between (3-adrenergic receptors and effector proteins are
integrated by G proteins which are of composed an alpha, a beta, and a gamma subunit.
Polymorphisms of genes coding for (3-ARs and the beta subunit of the G proteins (GNB3)
are shown in table 4.11.
Lipoprotein lipase (LPL) is an enzyme that hydrolyses lipids in lipoproteins and plays a
central role in the overall lipid metabolism and transport (Mead et al, 2002). Fatty acid
binding proteins (FABPs) are a family of carrier proteins for fatty acids and other lipophilic
substances. These proteins are thought to facilitate the transfer of fatty acids between extra
and intracellular membranes (Chmurzynska, 2006). Polymorphisms in the LPL and FABP
genes are also shown in table 4.11.
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Adiopkines and adipokine receptors
Adipose tissue is also recognized as a major endocrine organ because the tissue
synthesizes and secretes an array of protein hormones and signals (Fantuzzi, 2005). These
adipokines act locally in an autocrine/paracrine manner and/or as endocrine signals to
regulate appetite, energy expenditure and a range of physiological processes including
insulin sensitivity and the inflammatory response which may have an important role in the
pathogenesis of cancer cachexia (Kerem et al, 2008).
Resistin is an adipocyte-derived pro-inflammatory cytokine. Resistin also appears to have
effects on substrate metabolism through impairment of insulin action and insulin independent
pathways (McTernan et al, 2006). There are three polymorphisms within the RETN gene
which codes for resistin that may influence the development of cachexia. These are shown
in table 4.12.
Adiponectin is a protein hormone that is exclusively secreted from adipose tissue and
modulates a number of metabolic processes, including glucose regulation and fatty acid
catabolism (Diez & Iglesias, 2003). Adiponectin binds to a number of receptors including
adiponectin receptor 1 and 2. An increase in adiponectin concentration has been assoicated
with cachexia in patients with heart failure (McEntegart et al, 2007). Leptin is a protein
hormone secreted by adipose tissue that plays a key role in regulating energy intake and
energy expenditure, including appetite and metabolism. Leptin acts through the leptin
receptor. Polymorphisms in genes coding for adiponectin, leptin and their respective
receptors are also presented in table 4.12.
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Anerexia, defined as the less ef the desire te eat, is cemmen in patients with cancer
cachexia. In additicn to any effects cf the tumour on the gastrointestinal tract and
psychological depression, patients with cancer frequently have a decreased taste and smell
of food (DeWys & Walters, 1975). Cancer anorexia may be a result of an imbalance between
orexigenic signals and anorexigenic signals. The following section explores the variants in
the genes encoding these signals.
Ghrelin is synthesized principally in the stomach and is released in response to acute and
chronic changes in nutritional state. In addition to having a powerful effect on the secretion of
growth hormone, ghrelin stimulates food intake and transduces signals to hypothalamic
regulatory nuclei that control energy homeostasis (Hosoda et al, 2002). The melanocortin 4
receptor, a G-protein coupled receptor, binds a-melanocyte stimulating hormone (a-MSH).
Melanocortin 4 receptors have been found to be involved in feeding behaviour and the
regulation of metabolism (Fan et al, 1997). Endocannabinoids, acting at brain cannabinoid
type 1 receptors, play a role in stimulating appetite and ingestive behaviours, partly through
interactions with more established orexigenic and anorexigenic signals (Kirkham, 2005).
Ciliary neurotrophic factor (CNTF) has been shown to activate hypothalamic leptin-like
pathways which suppress food intake without triggering hunger signals or associated stress
responses that are otherwise associated with food deprivation (Lambert et al, 2001). CNTF
acts via CNTF receptors (CNTFRs) which are located in hypothalamic nuclei involved in
feeding. Polymorphisms of interest in the genes encoding ghrelin (GHRL), melanocortin 4
receptor (MC4R), cannabinoid type 1 receptor (CNR1) and the CNTFR are shown in table
4.13.
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Others
Metallothionein (MT) is a family of cysteine-rich, low molecular weight proteins. MTs are
encoded by a family of genes consisting of 10 functional MT isoforms, and the encoded
proteins are conventionally subdivided into 4 groups: MT-1, MT-2, MT-3, and MT-4 proteins.
The physiological roles of MTs are not well understood but they are thought to play a role in
the control of oxidative stress and protection against inflammation (Simpkins, 2000).
The P2Y-receptors belong to the superfamily of G-protein-coupled receptors and mediate
the actions of extracellular nucleotides in cell-to-cell signalling. The P2Y11 receptor is highly
expressed in immunocytes and may play a role in the differentiation of these cells (von
Kugelgen, 2006).
Glutamine:fructose-6-phosphate aminotransferase (GFAT) is the rate-limiting enzyme of the
hexosamine biosynthetic pathway (HBP), which catalyzes the conversion of fructose-6-
phosphate to glucosamine-6-phosphate. The flux through the HBP has been shown to be
linked to the regulation of energy intake and energy expenditure (Obici et al, 2002).
Fat mass and obesity associated (FTO) is thought to play a role in energy homeostasis but
its exact function is unknown.
Genetic variants encoding the proteins discussed above may play a role in the development
of cachexia and are listed in table 4.14.
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Analysis of results
Out of the 184 polymorphisms that have been identified, the functional or clinical significance
of only 42 polymorphisms have been verified in more than one study.
Of these 42 polymorphisms, 13 polymorphisms have been shown to have more than one
effect on clinical features associated with cancer cachexia (i.e. inflammation, changes in
lean and/or fat mass, and overall survival). These 13 polymorphisms represent the most
promising candidates in terms of susceptibility biomarkers of cancer cachexia (Table 4.15)
and are explored in more detail below.
The C allele of the A37674C SELP polymorphism (rs6136) is associated with decreased
serum P-selectin levels (Miller et al, 2004; Volcik et al, 2006). P-selectin is required for
efficient recruitment of neutrophils in acute inflammation and of macrophages in later stages
of the inflammatory response and serum levels of P-selectin have been found to be
significant prognostic factors in survival in patients with gastric and colorectal malignancies
(Alexiou et al, 2001; Alexiou et al, 2003)
TNF-a is a cytokine involved in systemic inflammation and is a member of a group of
cytokines that stimulate the acute phase reaction. Within the TNF gene , the -308A allele
(rs1800629) has been associated with an increased TNF-a production as well as a 6-fold
increase in transcription of the TNF gene (Sallakci et al, 2005; Wilson et al, 1997).
Interestingly, the A/A genotype has been linked to increased fat accumulation in women
(Hoffstedt et al, 2000). The -863A allele (rs1800630) associated with decreased
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transcriptional activity and reduced serum TNF-a levels (Day et al, 1998; Kaluza et al, 2000;
Sharma et al, 2006; Skoog et al, 1999). Of note, obese individuals express 2.5-fold more
TNF mRNA in fat tissue (Hotamisligil et al, 1995).
LTA, a member of the tumour necrosis factor family, is a cytokine produced by lymphocytes,
and mediates a large variety of inflammatory and immunostimulatory, responses. The G
allele of the 252 A>G polymorphism (rs909253) has been associated with increased serum
TNF-a levels (McArthur et al, 2002; Stuber et al, 1996), and patients who are A/A
homozygotes have been linked with better prognosis in lung cancer and gastric cancer
(Shimura et al, 1994; Shimura et al, 1995).
IL-ip is a cytokine protein which is encoded by the IL1B gene and is an important mediator
of the inflammatory response. The -31 C>T (rs1143627) and -511 C>T (rs16944)
polymorphisms in the promoter region of the IL1B gene have been linked with increased
transcriptional activity of the IL1B gene and subsequently increased IL-ip production (Wen
et al, 2006). The -31C and -511T alleles are linked with poorer progression-free survival and
overall survival in advanced gastric cancer (Graziano et al, 2005).Increased IL-1 p levels
have been linked to a synonymous C to T polymorphism at nucleotide position 3953
(rs1143634) (Hernandez-Guerrero et al, 2003). The T/T genotype has also been associated
with lower plasma levels of IL-1 receptor antagonist (IL-1RA) (Tolusso et al, 2006). In
addition the T allele has been found to be a major risk factor for cachexia in gastric cancer
(Zhang et al, 2007), as well as being linked to lower total fat mass(Strandberg et al, 2006).
The T/T genotype was found to be associated with shorter survival in pancreatic cancer
(Barber et al, 2000).
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IL-6 is a cytokine involved in a wide variety of biological functions. It is critical for B-cell
differentiation and maturation, immunoglobulin secretion, cytotoxic T-cell differentiation and
acute-phase protein production (Kishimoto, 2005). The -174 G>C promoter polymorphism
(rs1800795) in the IL6 gene has been associated with lower serum levels of IL-6 (Fishman et
al, 1998). The G allele has been linked to higher fasting insulin and lower adiponectin levels
which may have a role in the regulation of adiposity (Yang et al, 2005). In addition the C/C
genotype has been associated with lower fat free mass and increased waist circumference
(Berthier et al, 2003; Roth et al, 2003).
IGF-1 plays an important role in childhood growth and continues to have anabolic effects in
adults. IGF-1 is one of the most potent natural activators of the Akt signalling pathway, a
stimulator of cell growth and multiplication. IGF-1 also mediates many of the growth-
promoting effects of growth hormone (GH) (Jones & Clemmons, 1995). A CA repeat
polymorphism is found within the promoter region of the IGF1 gene. The 19CA repeat allele
is associated with both lower serum IGF-I levels and IGFBP-3 levels (Morimoto et al, 2005;
Rosen et al, 1998). The 19CA repeat allele is also associated with reduced risk of weight
gain (Landmann et al, 2006; Voorhoeve et al, 2006). Of note, increasing IGF-1 levels have
been associated with poorer prognosis in oesophageal cancer patients (Sohda et al, 2004).
Angiotensin converting enzyme (ACE) plays a critical role in the renin-angiotensin system by
catalyzing the conversion of the inactive angiotensin I to angiotensin II, which is the
physiologically active form of the hormone. Acute and chronic exposure to angiotensin II in
animal models has been associated with weight loss and enhanced protein breakdown in
skeletal muscle (Brink et al, 2001; Brink et al, 1996). A common insertion/deletion (l/D)
polymorphism (rs4646994) is present in intron 16 of the ACE gene. The I allele has been
associated with lower circulating ACE levels (Tiret et al, 1992). The D allele has been
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associated with increased strength gains thorough isometric training (Folland et al, 2000)
and has also been associated with obesity (El-Hazmi & Warsy, 2003; Riera-Fortuny et al,
2005). The D/D genotype has been linked with increased survival in women with colorectal
cancer (Rocken et al, 2007).
Lipoprotein lipase (LPL) is an enzyme that hydrolyses lipids in lipoproteins and plays a
central role in the overall lipid metabolism and transport (Mead et al, 2002). The rs328
polymorphism in the LPL gene results in a premature stop codon at amino acid 447.The stop
codon results in lower LPL activity (Groenemeijer et al, 1997; Kozaki et al, 1993), and is
associated with lower levels of IL-8 (Ak et al, 2007). Individuals not in possession of the stop
codon are associated with central obesity (Huang et al, 2006).
Resistin is an adipocyte-derived pro-inflammatory cytokine. Resistin also appears to have
effects on substrate metabolism through impairment of insulin action and insulin independent
pathways (McTernan et al, 2006). The -420 C>G polymorphism (rs1862513) has been
shown to be linked to increased plasma resistin (Cho et al, 2004; Osawa et al, 2007), and
individuals with the G/G genotype have been associated with an increased prevalence of
obesity (Norata et al, 2007). Overall, increased plasma resistin has been shown to correlate
with increased CRP and insulin resistance (Degawa-Yamauchi et al, 2003; Kusminski et al,
2007; Nagaev et al, 2006; Osawa et al, 2007; Silswal et al, 2005).
Adiponectin is a protein hormone that is exclusively secreted from adipose tissue and
modulates a number of metabolic processes, including glucose regulation and fatty acid
catabolism (Diez & Iglesias, 2003). An increase in adiponectin concentration has been
associated with cachexia in patients with heart failure (McEntegart et al, 2007). The ADIPOQ
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gene, which codes for adiponectin, has a 45 T>G polymorphism (rs2241766) that is
associated with increased plasma adiponectin (Berthier et al, 2005; Mackevics et al, 2006).
Individuals with the G/G genotype have been observed to be leaner with less abdominal fat
(Loos et al, 2007b).
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Like many complex conditions and diseases, the risk of developing cancer cachexia is
probably determined by multiple genetic factors and environmental factors are likely to add
to the heterogeneity of the condition. Although the number of reports on polymorphic gene
variants associated with multi-factorial diseases and conditions are dramatically growing,
very few studies provide firm and reliable evidence of causative relationships between these
polymorphisms and risk or pathogenesis. Indeed, in a recent review of allelic association
with common disease phenotypes, only six of 166 associations subjected to multiple
evaluations were confirmed consistently (Hirschhorn et al, 2002). Possible causes of false-
positive association studies include population stratification, variable linkage disequilibrium
and genotype misclassification. In addition, in many of these studies the possible effects of
single gene variants were assessed in situations when combined impacts of multiple factors
could be expected (Loktionov, 2003). In this chapter, 42 out of 184 polymorphisms have
been identified with a potential role in the development of cachexia and have been
independently verified in at least one repeat study.
It can be assumed that analysis of combinations of gene variants encoding interacting
factors within a biological chain or cascade, rather than isolated investigation of its single
components, may have more chances to reveal real causative connections between gene
polymorphisms and phenotypes. In this chapter, functional polymorphisms in genes with a
possible role in cachexia have been recorded as well as polymorphisms with clinical
consequences related to cachexia such as inflammation, weight/body composition changes
and cancer survival.
Of the 42 polymorphisms with a potential role in the development of cachexia that have been
independently verified in at least one repeat study, 13 polymorphisms have been shown to
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have more than one effect on clinical features associated with cancer cachexia. These 13
polymorphisms are likely to be the most promising candidates in terms of susceptibility
biomarkers of cancer cachexia and should be further investigated.
In multigene studies, judicious selection of candidate genes and polymorphisms within them
is a key element of study design. It is always important to choose genes, products of which
interact within regulatory or metabolic pathways. In most cases it is not realistic to analyze all
possible gene variants and combinations, hence existing polymorphisms should be initially
prioritized on the basis of their likelihood to affect function of the encoded product (Tabor et
al, 2002).
In conclusion, the present chapter has provided an initial framework in which to select and
study the possible genetic variance associated with developing cancer cachexia by
identifying polymorphisms with putative functional and/or clinical significance in relation to
the development of cachexia. The identification of genetic variants that have undergone
repeat studies allows the selection of robust and reliable candidates. Furthermore,
prioritisation of the most likely genetic variants that are likely to influence the development of
cachexia have been derived by selecting polymorphisms that influence two or more
hallmarks of cachexia (i.e. systemic inflammation, loss of fat mass, loss of lean mass,
reduced survival). Polymorphisms identified in this chapter will be studied in further detail for
association with cancer cachexia in chapter 6.
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CHAPTER 5
IDENTIFICATION OF NOVEL BIOMARKERS OF SKELETAL





The aim of this chapter is to carry out global molecular profiling in the skeletal muscle of
cancer patients and relate findings to percentage weight loss.
Methods
Rectus abdominis muscle biopsies were obtained from 18 upper gastrointestinal (UGI)
cancer patients and 3 normal controls during surgery and RNA profiling was performed using
the Affymetrix U133+2 platform.
Results
Quantitative significance analysis of microarrays produced an 83-gene signature that
correlated with percentage weight loss. The most significant positive correlation was
CaMK2B with weight loss. Previously postulated candidates genes involved in skeletal
muscle wasting, the ubiquitin E3 ligases, were not related to weight loss in this human
clinical study.
Conclusion
This chapter has potentially discovered new molecular biomarkers of human cancer
cachexia. The CaMK2B gene correlated positively to weight-loss and excessive CaMKlip
activation maybe a potential mechanism for reduced muscle protein synthesis in cachexia.
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Polymorphisms in genes identified in this chapter may account for the inter-individual
variation in developing cancer cachexia and will be further explored in Chapter 6.
5.2 Introduction
Cachectic patients suffer loss of both muscle mass and adipose tissue (with comparative
sparing of visceral protein) and this tissue loss appears resistant to nutritional support (Nixon
& Lawson, 1983). There is a need for more primary investigations to shed light on the
detailed mechanisms that produce the syndrome in patients.
Muscle mass is maintained by physical activity, reflecting a balance between protein
synthesis and degradation. Many of the molecular signalling pathways that are postulated to
contribute to muscle atrophy in preclinical models mediate their effects through activation of
the ubiquitin proteasome pathway (UPP) (Jagoe & Goldberg, 2001). Identification of two
muscle-specific E3 ubiquitin ligases, MuRF-1 and MAFbx/atrogin-1, in a large number of
animal models of atrophy (Bodine et al, 2001; Gomes et at, 2001) has been used to provide
an argument for a major contribution of the UPP in muscle wasting, such that these genes
are now measured as surrogate indicators of UPP activation .However, there is also
evidence that the UPP is first activated with increasing weight loss then declines as the
disease severity progresses (Khal et al, 2005). This suggests that UPP is a marker of protein
turn-over rather than wasting per se (with turn-over increasing as the muscle weakens, but
only while the patient continues to be ambulatory) or that UPP proteins are not reliable
biomarkers. Furthermore, recent data indicates a dissociation between protein dynamics in
vivo and activation or expression of the UPP-related signalling molecules in human skeletal
muscle (Greenhaff et al, 2008). Overall, it is not clear what regulates muscle mass in vivo
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nor is it clear to what extent protein degradation contributes over inhibition of protein
synthesis (Emery et al, 1984; Greenhaff et al, 2008). Given the paucity of data derived from
cancer cachexia patients, including study of the UPP system, this chapter sought to carry out
global molecular profiling in the skeletal muscle of cancer patients and relate findings to
clinical status (i.e. percentage weight loss).
5.3 Methods
Patients
Patients were recruited from surgical clinics from Royal Infirmary of Edinburgh as described
in Chapter 2. Participating patients had a diagnosis of upper gastrointestinal cancer
(oesophageal, gastric or pancreatic) and were undergoing surgery with the intent of
resection of the primary tumour. A small number of weight stable patients undergoing
surgery for benign, non-inflammatory conditions (n = 3) were also recruited for the study.
Patient-reported height, weight, and weight history were collected. Height and weight data
were subsequently used to compute a common anthropometric descriptor, body mass index
(BMI) (kg/m2). A weight loss >5% was used to identify weight-losing (WL) cancer patients as
opposed to weight stable (WS) individuals.
Skeletal muscle biopsy
All biopsies were taken at the start of open abdominal surgery. The edge of rectus
abdominis was exposed and a 1cm3 specimen removed using sharp dissection. The biopsy
was snap frozen in liquid nitrogen and stored at -80°C until further analysis.
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Nuclear protein extraction and RNA isolation
Nuclear proteins were extracted from approximately 20mg of skeletal from which ribonucleic
acid (RNA) was obtained from using commercially available kits. The methods are described
in detail in Chapter 2.
Microarray target preparation and hybridisation
Total RNA (3.5 pg) was reverse transcribed and processed according to the protocol
provided by Affymetrix Inc. for the GeneChip Expression 3' Amplification One-Cycle Target
Labelling and Control Reagents kit (Affymetrix, High Wycombe, UK). Reverse transcription
and second strand cDNA synthesis were followed by in vitro transcription and biotinylation.
Biotinylated cRNA products were cleaned up using columns (Affymetrix). The quality of the
biotinylated cRNA was assessed by Nanodrop (LabTech International, UK) and BioAnalyzer
(Agilent Technologies) instruments and the cRNA was then fragmented according to
Affymetrix protocols. Samples were hybridized to the HGU-133plus2 GeneChip array
(covering approximately 54,000 sequences). The raw data files can be accessed at the
Gene Expression Omnibus using the ID [GEO:GSE18832],
Microarray statistical analysis
Microarray data were analyzed using the Microarray Suite software (MAS) version 5.0
(Affymetrix). To improve the accuracy of the gene to probe relationship, a custom chip
definition file (CDF) (Sandberg & Larsson, 2007) was used defining the Affymetrix probes by
Ensembl transcript ID. Data were normalized using MAS5 and robust multi-array average
(irizarry et al, 2003). Genes called absent on every array by the MAS5 software were filtered
from the data and remaining genes analysed using the quantitative function in significance
analysis of microarrays (SAM) (Tusher et al, 2001) implemented in the Bioconductor suite
(Gentleman et al, 2004). Percentage weight loss was used as the quantitative variable. To
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test the robustness of the approach, the Limma package in the Bioconductor suite was used
to identify genes covarying with weight loss. Both SAM and Limma generate a false
discovery rate (FDR) (Benjamini et al, 2001). All genes identified by both procedures with an
FDR <10% that covaried with weight loss were further examined.
5.4 Results
Twenty-one subjects were recruited (3 controls and 18 patients with upper gastrointestinal
cancer). Patient demographics are shown in Table 5.1. Average weight loss of the cancer
patients was 8.9% (range -0.5 to 43.8%). Compared with the control group, cancer patients
had significant weight loss (P < 0.01) and had a lower BMI (P = 0.08). The controls were
substantially younger (P < 0.01) and hence could not be used as a case control comparison
group for the molecular profiling. Instead, gene expression was related to body mass status.
Table 5.1 Demographics of control and cancer patients
Control (n = 3) Cancer (n = 18) p-value
Male / Female 2/1 12/6 N.A
Age (years) f 45 ±2 67 ±2 <0.01
% Weight Loss f 0 8.9 ± 1.6 <0.01
BMIf 28.5 ± 1.7 24.4 ±0.8 0.08
Values are number of patients unless indicated otherwise; Values are mean ± SE; BMI: body mass
index.
Genes that varied with percentage weight loss were identified using the quantitative SAM
methodology (Tusher et al, 2001). In this multiple comparison corrected correlation analysis,
the weight stable group contained both cancer patients and three non-cancer controls in
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order to identify bona fide cachexia associating genes. SAM identified 74 genes with a FDR
between 0 and 10% (most <5% FDR) that covaried positively with weight loss (Table 5.2),
and nine genes with a FDR between 0 and 10% (most <5% FDR) that covaried negatively
with weight loss (Table 5.3). Correlation coefficients (R) for these 83 genes were generated
using Pearson's product moment correlation. Positive coefficients ranged from 0.82 to 0.57
(P < 0.01), and for negatively correlating genes, R ranged from -0.74 to -0.65 (P < 0.01).
Most of the genes correlating with weight loss had not been associated previously with
cachexia in humans or animal models. Notably, the E3 ligases MURF1 and MAFbx were
absent from this list.
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Cancer cachexia is thought to arise due to an imbalance of the anabolic and catabolic
pathways with consequent loss of muscle mass (along with an accompanying loss of
adipose tissue). In the present study, the expression of 74 genes correlated positively with
weight loss in cancer cachexia subjects and that of 9 correlated negatively with it.
The most significantly positively correlated gene with weight loss, CAMK2B, encodes
calcium/calmodulin-dependent protein kinase II beta (CaMKlip), a serine/threonine protein
kinase that is activated by Ca27calmodulin, leading to autophosphorylation and maintenance
of CaMKII activity even after the Ca2+ signal has diminished (Chin, 2004). CaMKlip is
expressed in skeletal muscle. Levels of the protein as well as its phosphorylation status and
activity increase after exercise training (Rose et al, 2007). In addition, it has recently been
demonstrated that Ca(2+)-CaM-eEF2K signaling may be responsible for acute exercise-
induced inhibition of muscle protein synthesis (van Hoek et al, 2009) and it is thus
conceivable that chronic inappropriate activation of this 'endurance training'-related signaling
molecule (Timmons et al, 2005) subdues normal maintenance of skeletal muscle mass.
Additional factors that could modulate CaMKII activity include alterations in lipid metabolism
(Raney & Turcotte, 2008). Finally, CaMKII has also been implicated in muscle adaptation
through phosphorylation of HDAC5 leading to MyoD/MEF2-driven differentiation of muscle
cells (McKinsey et al, 2000). CAMK2B may thus have an important role in regulating skeletal
muscle function and metabolism.
Contrary to evidence from animal models (Bodine et al, 2001; Gomes et al, 2001;
Mammucari et al, 2007), there were no significant differences in expression of the E3 ligases
MURF1 and MAFbx. Given the robust increase in expression of the E3 ligases reported
previously in various animal models of cachexia (Bodine et al, 2001; Gomes et al, 2001;
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Lecker et al, 2004), it is somewhat surprising that the microarray did not detect any
regulation of MuRF1 and MAFbx.
Previous results of E3 ligase expression analysis from other human models of cachexia
have been contradictory. Studies including patients following bed rest, amputation for
vascular disease, limb immobilization, chronic obstructive pulmonary disease, amyotrophic
lateral sclerosis and ageing have demonstrated both increased and decreased expression of
MuRF1 and MAFBx (de Palma et al, 2008; Doucet et al, 2007; Edstrom et al, 2006; Leger et
al, 2006; Salanova et al, 2008). This seems to suggest that the ubiquitin E3 ligases do not
play the same role in human cancer cachexia as that previously demonstrated in animal and
cell studies. However, cancer cachexia encompasses a spectrum progressing from early
weight loss through to severe muscle wasting. The prominence of the individual proteolytic
pathways at different time points along this spectrum is yet to be determined and one must
keep in mind that during severe tissue wasting, both breakdown (and of course synthesis)
may well be reduced with the net balance between the two widened.
In an animal model of muscle atrophy the largest changes in E3 ligase expression were
seen early, when rates of muscle weight loss were the highest, then fell as the rate of
atrophy slowed. Nearly all the atrogene mRNAs returned to basal levels by 14 days while
some atrogenes maintained their differential expression for a longer period (Sacheck et al,
2007). It may be likely that the patients in this study were recruited at a time point in which
the expression of E3 ligases has returned to their baseline state.
A limitation of the current study is that the focus was on changes in total body mass which
does not reveal the relative contributions from lean body mass and adipose tissue. The
muscle gene expression results indicate, however, that there is a skeletal muscle molecular
signature that reflects changes in whole body mass and it is hard to conceive that this is not
somehow reflecting the changes in the muscle tissue.
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In conclusion, the present chapter has shown a variety of genes which are correlated with
weight loss in cancer. In particular, the up regulation of the CAMK2B gene appears to be a
promising new biomarker for cancer cachexia. Polymorphisms in the genes identified in this
chapter may play a role in the inter-individual variability of developing cachexia and will be
examined in Chapter 6.
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CHAPTER 6
A P-SELECTIN POLYMORPHISM IS ASSOCIATED WITH
THE DEVELOPMENT OF CANCER CACHEXIA: RESULTS




The aim of this chapter is to utilise a candidate gene approach to evaluate the association
between genetic polymorphisms and the risks of developing cachexia in patients recruited
across three centres with attempted validation using patients recruited from a fourth centre.
Methods
129 SNPs in 80 genes were analysed for association with cachexia based on degree of
weight loss (>5, >10, >15%) alone or with the presence of systemic inflammation (CRP
>10mg/l). 775 cancer patients from three centres were recruited at first presentation to a
surgical or oncology clinic. Percentage weight loss was calculated from weight measured at
recruitment and pre-morbid weight recalled. A validation association study was performed on
an independently recruited cohort (n=101) of cancer patients from one centre. Association
testing was adjusted for age, sex, tumour type, BMI and stage.
Results
21 SNPs had significant associations with cachexia phenotypes. However, only the C allele
(minor allele frequency 10.7%) of the rs6136 (SELP) SNP was found to be associated with
weight loss >10% both in the main study (OR 0.52, 95%C.I 0.29 - 0.93, p=0.026) and the
validation study (OR 0.09, 95%C.I 0.01 - 0.98, p=0.035). Gene-group analysis was
performed based on functional similarity according to gene ontology in the main study
patients. Gene groups regulating appetite, glucocorticoid signalling, and mitogen activated
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protein kinases (MAPK) activity were associated with both weight loss >15% and CRP
>10mg/l (p=0.0008, p=0.018, and p=0.026 respectively)
Conclusion
The C-allele of the rs6136 polymorphism is associated with reduced risk of developing
cachexia and this finding may prove useful in the risk stratification of pre-cachetic cancer
patients. Gene groups regulating appetite, glucocorticoid signalling, and mitogen activated
protein kinases (MAPK) activity may have central roles in the pathogenesis of cancer
cachexia.
6.2 Introduction
Cachexia is particularly problematic in cancer, typified by poor prognosis and often
associated with a lower response to chemotherapy and radiotherapy than might be expected
(Tisdale, 2002). Patients are also more likely to report decreased quality of life (QoL) scores
(Fearon et al, 2006). More than half of cancer patients suffer from cachexia, and it is
responsible for death in up to 20% of cases (Tisdale, 2002). Cachexia is therefore a
significant cause of morbidity and mortality in cancer patients.
Cachexia in its advanced phase (where patients may have lost 20-30% of their body weight)
is easily identified. However, at this stage, the primary initiating events are frequently
compounded by secondary factors (e.g. prolonged patient bed rest), and it is often
impossible to attempt any realistic form of intervention, either practical or (given the patient's
almost imminent demise) ethically advisable. Thus, one systematic approach to the
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treatment of cachexia requires early identification of patients at risk of cachexia and the
institution of prophylactic measures to attenuate its progression.
Based on our current knowledge of demographic and clinical factors, we are unable to
predict, for any given cohort of patients, who will develop cancer cachexia and who will not.
Such variation may, in part, be due to the patient's genotype. The cachexia syndrome is
thought to result from a complex interaction between host neuroendocrine and cytokine
systems and tumour-derived products (Skipworth et at, 2007). The wealth of known genetic
polymorphisms in genes controlling pro/anti-inflammatory pathways, neuronal melanocortin
signalling pathways, and muscle and adipose tissue metabolic pathways suggest their
exploitable potential as biomarkers of inter-individual predictability of developing cachexia.
This aims of this chapter is to utilise a candidate gene approach to evaluate the association
between genetic polymorphisms and the risks of developing cachexia in patients recruited
across three centres, with attempted validation using patients recruited from a fourth centre.
6.3 Methods
Main study population
Study subjects were recruited from three centres from 2004 - 2008: NHS Lothian, UK; Cross
Cancer Institute, Edmonton, Canada; and McGill University Health Centre, Montreal,
Canada.
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All patients with proven cancer diagnosis were considered and recruitment was conducted at
first presentation to surgical or oncology clinics at each institution. Recruitment was
performed sequentially with the following exclusion criteria: i) under 18 years of age; ii)
learning disability, and mental health problems; iii) inability to give written, informed consent.
Overall, 855 patients with confirmed diagnosis of cancer were recruited. More than 98% of
the study subjects were of European descent. Information collected on each patient included
date of birth, date of diagnosis, type and stage of cancer. All patients underwent
measurements of height and weight at the time of recruitment to the study. Pre-morbid
weight was recalled by the patient and verified where possible from the medical notes. There
is evidence to support the reliability of self-reported weight and weight history (Perry et al,
1995; Stunkard & Albaum, 1981). Individual weight loss was calculated and expressed as
percentage of pre-morbid body weight lost. Height and weight data were subsequently used
to compute a common anthropometric descriptor, body mass index (BMI) (kg/m2).
Where available, serum C-reactive protein (CRP) concentration was measured with an
automated immunoturbidimetric assay by each institution's clinical chemistry department
using blood collected from patients at the time of recruitment and before any therapeutic
intervention.
Stage of disease was based on the American Joint Committee on Cancer stage groupings I,
II, III and IV.
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All subjects recruited had participated in clinical or research studies at the host institutions
under ethically approved protocols. All patients provided written informed consent to allow
analysis of their DNA.
Phenotype definitions
There is currently no consensus on the definition of cachexia. Many studies have used
varying thresholds of weight loss to study cancer cachexia, the most common being >5%
weight loss (Fox et al, 2009; Knoll et al, 2008; Maltoni et at, 2001) and >10% weight loss
(Gordon et al, 2005; Skipworth et al] Zhang et al, 2007). A weight loss of >15% has been
liked to major complications in cancer patients undergoing surgery (Antoun et al, 2009). A
recent article by Evans et al. has suggested classifying the degree of cachexia as mild,
moderate or severe, depending on whether the observed weight loss is >5%, >10% or
>15%, respectively (Evans et al, 2008).
The presence of systemic inflammation (serum C-reactive protein (CRP) >10mg/l) has been
linked to decreased survival in cancer patients (Mahmoud & Rivera, 2002; McMillan et al,
2003), and has also been correlated positively with weight loss in human cancer patients
(Deans et al, 2009b; O'Gorman et al, 1999). CRP has also been incorporated into a three-
factor mathematical definition of cachexia for patients with pancreatic cancer (Fearon et al,
2006). The latter multi-profile definition was found to have more prognostic value compared
with weight loss alone.
To take into account the above, cachexia was classified based on degree of weight loss (>5,
>10>, >15%), as well as weight loss in the presence of systemic inflammation.
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Candidate gene and SNP selection
Candidate gene and SNP selection was based on a systematic literature review of SNPs
with either putative functional or clinical relevance in the development of cancer cachexia
described in Chapter 4. All 184 SNPs across 92 genes identified were considered for the
study with priority given to the 13 polymorphisms which have been shown to have more than
one effect on clinical features associated with cancer cachexia, and have been
independently verified in at least one repeat study. SNPs with unknown rs numbers were
excluded from the study.
In addition, all genes that were negatively correlated with weight loss and genes with a
positive correlation of r >0.65 with weight loss identified in the gene expression analysis
array study on muscle samples of cancer patients with cachexia described in Chapter 5 were
subject to further study. From these genes, SNPs were selected using the following criteria:,
i) within exons, ii) non-synomymous and, iii) with a MAF of >0.1 using the SNPbrowser
software. This approach was chosen as it was not realistic to analyse all possible gene
variants and combinations; SNPs selected in this manner were more likely to be functional
variants and hence have a greater possibility to be associated with cachexia.
SNPs were entered into the Applied Biosystems online SNPlex assay design submission
tool using their respective rs numbers. For SNPs that failed the SNPlex design pipeline,
replacement SNPs were selected based on linkage disequilibrium (r2 of at least 0.9) using
the SNPbrowser software.
Overall 191 SNPs in 99 genes were considered for the association study (see table 6.2).
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DNA extraction
Genomic DNA was extracted from whole blood using commercially available kits. The
methods are described in detail in Chapter 2.
Genotyping
The Applied Biosystems SNPlex™ Genotyping System (Applied Biosystems, California,
USA) was employed for SNP genotyping. All DNA samples were processed and assayed
without regard to phenotype. DNA samples were separated electrophoretically on a 3730
DNA Genetic Analyzer (Applied Biosystems, California, USA), and automated allele calls
and genotype clustering of each individual sample was performed by Applied Biosystems'
GeneMapper® Software (version 4.0). All automatic calls by the software were evaluated by
one researcher. Any SNPs with less than 90% of the sample auto-called by the software
were either rescored manually or discarded if clustering confidence was low. Reproducibility
was determined by rerunning entire plates of DNA samples and a reproducibility rate of
99.7% was achieved.
Individual samples were removed if more than 10% of SNPs failed genotyping, and
individual SNPs were removed if more than 10% of samples failed. As an additional
genotyping quality-control check, SNPs with significant deviation from Hardy-Weinberg
equilibrium (HWE) (p <0.01) were removed from the final analysis. SNPs with a MAF <0.03
were also removed from the final analysis.
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Power calculations
Power calculations were performed using Quanto. For the most prevalent cachexia
phenotype (i.e. >5% weight loss, 54% affected), the present study has between 43% to 97%
power to detect an odds ratio of 1.5 for SNPs with a MAF of 0.05 - 0.35.
For the least prevalent cachexia phenotype (i.e. >15% weight loss & CRP >10 mg/l, 14%
affected), the present study has between 12% to 40% power to detect an odds ratio of 1.5
for SNPs with a MAF of 0.05 - 0.35.
Statistical analysis
Statistical analyses were performed using PLINK (version 1.06) (Purcell et al, 2007).
Patients who met the criteria for each of the proposed cachexia phenotypes were compared
with patients who have lost <5% body weight as control. Unconditional logistic regression
was employed to calculate odds ratios (OR) and their 95% confidence intervals (95% CI) for
the minor allele of individual SNPs and its association with each proposed cachexia
phenotype. All analyses were adjusted for covariates that may affect weight loss, i.e. age at
diagnosis, sex, pre-morbid BMI, tumour type and stage.
To account for multiple testing, permutation testing was performed by running the adaptive
permutation test in PLINK within each proposed phenotype. Permutation tests are often
employed to adjust groups of correlated tests for multiple testing, since conventional
methods such as Bonferroni correction are overly conservative when tests are correlated
(Conneely & Boehnke, 2007). The adaptive permutation test in PLINK gives up permuting
SNPs that are clearly going to be non-significant. This greatly speeds up the permutation
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procedure, as SNPs that are not significant will drop out quite quickly, making it possible to
properly evaluate significance for the handful of SNPs that require millions of permutations.
SNPs with a permuted p value of <0.02 within the same chromosomal region (within
10,000kb) were then analysed for any possible haplotype associations. Only haplotypes that
had a frequency greater than 5% were considered for further analysis. Each identified
haplotype and significant SNPs were then tested for association with percentage weight loss
as a continuous variable.
Finally, candidate genes (and the SNPs in the corresponding gene regions) were grouped
based on known functional similarity according to gene ontology using AmiGO (Table 6.1).
The set-based test in PLINK was used to analyse association between grouped SNPs and
cachexia phenotypes. The set-based test selects the best set of SNPs whose mean of these
single SNP statistics is significant after permutation, which is particularly suited to large-
scale candidate gene studies (Ott & Hoh, 2003). The empirical p values of the set-based test
were obtained by a permutation of 10,000 times of phenotype labels.
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Table 6.1 Candidate genes groupings based on known functional similarity according to
gene ontology
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Subjects from the validation study were recruited from an independent centre, Oncology &
Palliative Medicine, Cantonal Hospital, St. Gallen, Switzerland from 2007 - 2008. Like the
main study, all patients with proven cancer diagnosis were considered. Patients were
recruited sequentially at first presentation to the oncology clinic. Exclusion criteria were
identical to the main study.
In total, 101 cancer patients were recruited, all of whom were of European descent. Like the
main study, all patients underwent measurements of height and weight at the time of
recruitment. Premorbid weight was recalled by the patient and verified where possible from
the medical notes. Individual weight loss was calculated and expressed as percentage of
pre-illness body weight lost. Height and weight data were subsequently used to compute a
common anthropometric descriptor, body mass index (BMI) (kg/m2). Serum C-reactive
protein (CRP) concentration was measured with an automated immunoturbidimetric assay at
the institution's clinical chemistry department using blood collected from patients at the time
of recruitment and before any therapeutic intervention.
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Patients were genotyped for SNPs found to have permuted p <0.05 in the main study and
quality control checks were carried out as described previously. As with the main study,
patients in each of the proposed cachexia phenotypes were compared with patients with
£5% weight loss as control, and association analyses were adjusted for age at diagnosis,
sex, pre-morbid BMI, tumour type and stage.
6.4 Results
Following the relevant quality control checks, 129 SNPs in 80 genes (Table 6.2) were
available for analysis in 775 patients. The overall completion rate of genotyping was 95.6%.
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Table 6.2 Details of SNPs analysed
CHR GENE SNP BP A1 A2 HWE MAF
CALL
RATE
1 TNFRSF1B rs496888 12155392 G A 0.7342 0.3152 0.95262
1 TNFRSF1B rs976881 12156340 A G 0.1276 0.3158 0.95903
1 TNFRSF1B rs1061622 12175541 G T 0.5976 0.2252 0.94366
1 TNFRSF1B rs3397 12189878 C T 0.9382 0.3777 0.96287
1 TNFRSF1B rs1061631 12191085 A G 0.5167 0.2133 0.97567
1 TAF12 rs3795845 28804211 C A 1 0.2744 0.8633
1 TAF12 rs1804642 28821087 G N.A 0 0.92958
1 DI01 rs11206244 54148288 T C 0.562 0.33 0.94878
1 DI01 rs11206246 54150613 C T 0.22 0.09921 0.96799
1 LEPR rs1137100 65809028 G A 0.414 0.2769 0.96415
1 LEPR rs1137101 65831100 G A 0.7712 0.4519 0.98464
1 LEPR rs1805134 65839696 C T 0.0651 0.1985 0.8322
1 LEPR rs8179183 65848539 C G 1 0.1706 0.97951
1 VCAM1 rs3176860 100959806 G A 0.6359 0.3748 0.93086
1 CRP rs2794520 157945439 T C 0.4986 0.3242 0.93214
1 CRP rs1130864 157949714 T C 0.1479 0.3143 0.75588
1 CRP rs1800947 157950061 C G 1 0.05867 0.96031
1 SELP rs6136 167830574 C A 0.3419 0.1073 0.96031
1 IL10 rs1800872 205013029 A C 0.2993 0.2338 0.9283
1 IL10 rs1800896 205013519 G A 0.4675 0.4704 0.97311
1 HSD11B1 rs12086634 207946881 G T 1 0.2036 0.95903
1 HSD11B1 rs2236903 207950102 T A 0.7536 0.2286 0.9411
1 TGFB2 rs947712 216631503 A G 0.002483 0.3503 0.9283
1 TGFB2 rs1890995 216671300 T C 0.7866 0.2868 0.93982
1 TGFB2 rs1418553 216676876 T C 0.7955 0.298 0.97951
1 TLR5 rs5744168 221351822 T C 1 0.06216 0.9475
2 LTBP1 rs817529 33350838 G A 0.5945 0.3921 0.97311
2 IL1R1 rs2228139 102148080 G C 0.7606 0.06425 0.8968
2 IL1A rs17561 113253693 T G 0.2042 0.2748 0.98079
2 IL1A rs1800587 113259430 T C 0.2043 0.2793 0.96287
2 IL1B rs1143634 113306860 T C 0.4445 0.2137 0.94366
2 IL1B rs1143627 113310857 C T 0.9356 0.3406 0.97183
2 IL1B rs16944 113311337 A G 0.5209 0.3618 0.7132
2 IRS1 rs1025333 227353768 A T 0.3098 0.08016 0.94238
2 IRS1 rs2234931 227370996 A G 0.3025 0.0748 0.97567
2 CXCR7 rs10183022 237146707 A G 0.2562 0.4379 0.5877
2 CXCR7 rs9287599 237153091 G A 0.05299 0.07486 0.93214
2 CXCR7 rs1045879 237154642 T C 0.07954 0.2925 0.97183
3 GHRL rs35681 10304376 A G 0.5556 0.4744 0.94878
3 GHRL rs42451 10305376 T C 0.9248 0.2661 0.93598
3 GHRL rs696217 10306456 T G 0.04991 0.07397 0.9347
3 GHRL rs34911341 10306518 T C 1 0.006711 0.95391
3 GHRL rs26802 10307364 G T 0.06909 0.3233 0.8912
3 PPARG rs1801282 12368124 G C 1 0.1265 0.95647
3 PPARG rs1800571 12397847 C N.A 0 0.95391
3 PPARG rs3856806 12450556 T c 0.5231 0.1341 0.93086
3 KBTBD5 rs6805421 42703147 A G 0.149 0.3686 0.92061
3 KBTBD5 rs123509 42708471 A G 0.09578 0.2496 0.8412
3 KBTBD5 rs3846062 42708670 T G 0.008731 0.4232 0.95903
3 APEH rs4855881 49690449 C T 0.5131 0.4494 0.9872
3 APEH rs2960548 49695396 G C 0.3798 0.4539 0.97183
3 ADIPOQ rs17300539 188042153 N.A N.A 0
3 ADIPOQ rs266729 188042167 G C 0.2185 0.229 0.97567
3 ADIPOQ rs2241766 188053585 G T 0.8719 0.1313 0.9411
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3 ADIPOQ rs1501299 188053816 A C 0.6378 0.2711 0.92574
3 TFRC rs2284890 197272543 A G 0.5831 0.3891 0.8881
3 TFRC rs41301381 197282716 C N.A 0 0.97183
3 TFRC rs3817672 197285207 G A 0.307 0.4578 0.97183
3 TFRC rs9877119 197286762 N.A N.A 0
4 ALB rs3775485 74494684 T A 0.05969 0.4369 0.93342
4 ALB rs962004 74504102 C T 0.1678 0.4476 0.8924
4 IL8 rs4073 74824887 A T 0.8194 0.4949 0.8822
4 NFKB1 rs3774932 103643222 A G 0.5549 0.4347 0.97055
4 NFKB1 rs1801 103720091 C G 0.5371 0.3892 0.9475
4 UCP1 rs12502572 141704583 A G 0.8652 0.3138 0.95903
4 UCP1 rs1800592 141713410 G A 0.4635 0.271 0.97567
4 TLR2 rs4696480 154826575 T A 0.1236 0.4786 0.95519
4 TLR2 rs3804099 154844105 C T 0.9336 0.4571 0.7465
4 TLR2 rs3804100 154844858 C T 0.6464 0.08824 0.95775
4 TLR2 rs5743708 154845766 A G 0.4117 0.02649 0.96671
5 IL13 rs1800925 132020707 T C 0.5467 0.1867 0.95006
5 IL4 rs2243248 132036542 G T 0.7719 0.0678 0.98207
5 IL4 rs2070874 132037608 T C 0.6698 0.1526 0.95262
5 CD14 rs2569190 139993099 A G 0.9423 0.4836 0.97695
5 GCCR rs6195 142759509 G A 0.5401 0.032 0.96031
5 NR3C1 rs11749561 142771869 T C 0.76 0.4768 0.8822
5 ADRB2 rs1042711 148186540 N.A N.A 0
5 ADRB2 rs1042713 148186632 A G 0.26 0.3641 0.92318
5 ADRB2 rs1042714 148186665 G C 0.7097 0.4326 0.95903
5 ADRB2 rs1042717 148186838 A G 0.08141 0.2163 0.5327
5 ADRB2 rs1800888 148187077 T C 1 0.004781 0.93726
5 ADRB2 rs1042719 148187639 C G 0.2349 0.3089 0.717
5 IL12B rs1368439 158674591 G T 0.8041 0.1771 0.97951
6 LTA rs909253 31648292 C T 0.3205 0.3796 0.98335
6 TNF rs1799964 31650287 C T 0.1053 0.2017 0.92702
6 TNF rs1800629 31651010 A G 0.4232 0.2021 0.9347
6 LY6G5B rs2142234 31747108 T C 0.3769 0.06755 0.96671
6 LY6G5B rs9267532 31747958 T C 0.5171 0.06166 0.95519
6 LY6G5B rs1266076 31748497 C A 0.816 0.3878 0.9411
6 HSPA1L rs2227956 31886251 N.A N.A 0
6 HSPA1B rs6457452 31903529 T C 0.2676 0.07258 0.95262
6 AGER rs2070600 32259421 A G 0.2616 0.07105 0.97311
6 CNR1 rs1049353 88910353 A G 1 0.2493 0.96799
6 F0X03 rs9486902 108984744 T C 0.7922 0.1643 0.98207
6 SGK1 rs1743966 134535639 C T 0.7239 0.1982 0.8479
6 IFNGR1 rs9389484 137571619 N.A N.A 0
6 IFNGR1 rs7749390 137582062 G A 0.5432 0.4199 0.9347
7 IL6 rs1800795 22733169 C G 0.009327 0.4203 0.97951
7 IL6 rs2069835 22734395 C T 0.4716 0.05556 0 8204
7 IL6 rs1554606 22735231 T G 0.07892 0.4463 0.97695
7 IL6 rs2069845 22736673 G A 0.1884 0.4566 0.97439
7 CAMK2B rs917791 44235309 c T 1 0.3681 0.92702
7 CAMK2B rs10441113 44255189 A G 0.4365 0.3724 0.96799
7 CAMK2B rs4526269 44262831 T G 0.8715 0.3745 0.8924
7 IGFBP3 rs2453839 45920097 C T 0.6509 0.2012 0.97055
7 IGFBP3 rs3110697 45921554 N.A N.A 0
7 LEP rs7799039 127666018 A G 0.8824 0.4522 0.95134
8 LPL rs1800590 19840950 G T 0.429 0.02726 0.96287
8 LPL rs326 19863718 G A 0.4711 0.2804 0.96799
8 LPL rs328 19864003 G C 0.2588 0.08921 0.96159
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8 ADRB3 rs4994 37942954 C T 0.3894 0.05857 0.5903
8 LY96 rs6472812 75079637 A G 0.05192 0.04408 0.8932
9 IFNA2 rs624704 21373897 C T 0.2513 0.2876 0.5787
9 IFNA2 rs632941 21378711 A G 0.576 0.2768 0 8366
9 DCTN3 rs3802427 34608640 A G 0.1939 0.1673 0.97951
9 TLR4 rs4986790 119515122 G A 0.7894 0.07238 0.96415
9 ZER1 rs13284665 130553190 N.A N.A 0
9 ZER1 rs8507 130555367 G T 0.2095 0.4543 0.8866
9 ZER1 rs4836625 130556658 T C 0.1756 0.4972 0.8953
10 MBL2 rs1800450 54201240 A G 0.000873 0.1731 0.7618
10 MBL2 rs5030737 54201247 T C 1.44 x 10" 0.08491 0.8822
10 MBL2 rs7096206 54201690 G C 1 0.2023 0.94622
10 TTC18 rs4294502 74705262 C T 0.4232 0.07464 0.7993
10 TTC18 rs3812621 74706864 G A 0.5045 0.05785 0.96287
10 ADRB1 rs1801253 115795045 G C 0.5678 0.2709 0.8853
11 IGF2 rs680 2110209 A G 0.6978 0.2534 0.95006
11 NUP160 rs11039426 47819694 A G 0.6922 0.361 0.8677
11 ACTN3 rs1815739 66084670 T C 0.2458 0.4545 0.98592
11 UCP2 rs660339 73366751 T C 0.7049 0.4025 0.96543
11 UCP2 rs659366 73372401 T C 0.1699 0.3591 0.92702
11 UCP3 rs1800849 73397812 T C 0.9202 0.2413 0.95262
11 IL18 rs360729 111522130 A T 0.7868 0.2846 0.94494
11 IL18 rs549908 111526125 G T 0.7811 0.2792 0.9219
11 IL18 rs5744256 111528057 C T 0.7784 0.2702 0.93598
11 IL18 rs2043055 111536833 G A 0.3444 0.3637 0.96287
11 IL18 rs187238 111540197 C G 1 0.2473 0.93982
11 IL18 rs1946519 111540716 A C 0.6978 0.392 0.93086
11 HYLS1 rs3088241 125268955 C G 0.1459 0.498 0.96927
11 HYLS1 rs549990 125271253 C A 0.4411 0.3029 0.7808
11 HYLS1 rs622756 125271382 A C 0.5832 0.1121 0.97055
11 HYLS1 rs547232 125278208 T C 0.3577 0.3854 0.97183
12 ADIPOR2 rs16928751 1760459 A G 0.6067 0.1226 0.92958
12 ADIPOR2 rs35854772 1763337 T G 0.6073 0.1241 0.9283
12 TNFRSF1A rs767455 6321205 C T 0.4898 0.4145 0.92061
12 TNFRSF1A rs4149570 6321850 T G 0.4151 0.4149 0.98592
12 GNB3 rs5443 6825135 T C 0.4493 0.3195 0.8578
12 VDR rs1544410 46526101 A G 0.9384 0.4076 0.8843
12 DCD rs2029851 53327703 G A 0.2179 0.3032 0.92702
12 IFNG rs2193049 66833188 C G 0.7903 0.2849 0.98207
12 IFNG rs2069727 66834489 G A 0.5075 0.4697 0.95134
12 IFNG rs2430561 66838786 A T 0.6637 0.4751 0.97695
12 IFNG rs2069709 66839969 G N.A 0 0.92958
12 IGF1 rs11111272 101351570 G C 0.09348 0.3019 0.92446
12 IGF1 rs10735380 101368365 G A 0.7759 0.2767 0.8886
13 F0X01 rs2701896 40025891 C G 0.7005 0.3836 0.96799
13 FOX01 rs17446593 40026084 G A 0.9043 0.1854 0.97055
13 FARP1 rs3848017 97828589 C T 0.709 0.2631 0.97823
13 FARP1 rs584800 97836087 A G 0.6988 0.1745 0.9283
14 NFKBIA rs696 34940843 A G 0.5173 0.3546 0.93342
14 AKT1 rs11555433 104312524 N.A N.A 0
16 TSC2 rs7187438 2060402 C T 0.9362 0.3461 0.96927
16 LITAF rs4280262 11554992 G A 0.3061 0.2322 0.95391
16 MT2A rs34326929 55199886 N.A N.A 0
16 MT2A rs10636 55200843 C G 0.2132 0.2533 0.97567
16 MT1B rs1875233 55244204 G A 0.2336 0.4814
0.92702
16 FOXC2 rs34221221 85157930 C T 0.03428 0.3867
0.92702
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17 CCL2 rs1024611 29603900 C T 0.1716 0.277 0.8591
17 CCL5 rs2107538 31231892 T C 1 0.1758 0.8848
17 ACE rs4295 58910029 G C 0.2541 0.3933 0.97183
17 ACE rs4329 58917189 G A 0.0635 0.4611 0.93726
17 ACE rs4341 58919721 C G 0.1141 0.4677 0.8104
17 ACE rs4362 58927492 C T 0.603 0.4719 0.93342
17 GPS1 rs4969484 77608149 N.A N.A 0
18 LPIN2 rs3745012 2910287 T C 0.5799 0.2743 0.95006
18 APCDD1 rs3748415 10461731 T C 0.8736 0.1304 0.97695
18 MC4R rs52820871 56189811 G T 0.1198 0.01326 0.96543
18 MC4R rs2229616 56190255 A G 0.08036 0.01105 0.92702
19 RETN rs34124816 7639675 C A 0.6334 0.04128 0.97695
19 RETN rs1862513 7639792 C G 0.2029 0.315 0.95519
19 P2RY11 rs12460842 10083194 A G 4.06 x 10" 0.4319 0.8553
19 EIF3G rs3826785 10088148 T C 0.8712 0.1304 0.9475
19 ICAM1 rs281432 10251657 G C 0.4254 0.4681 0.98335
19 ICAM1 rs5498 10256682 N.A N.A 0
19 GCDH rs11085824 12862546 G A 0.5807 0.3601 0.96543
19 GCDH rs9384 12871642 T G 0.5857 0.3735 0.96159
19 GDF15 rs1058587 18360421 C G 1 0.2449 0.94366
19 TGFB1 rs1800469 46552135 T C 0.8061 0.3218 0.1114
20 TH1L rs163781 56997159 G A 0.3757 0.4305 0.97695
20 CTSZ rs163792 57009741 A C 0.7675 0.4235 0.97951
22 MIF rs755622 22566391 G C 0.1556 0.1919 0.9475
22 PPARA rs1800206 44992937 G C 0.5225 0.06345 0.9283
CHR: Chromosome number; BP: SNP base-pair position; A1: Minor allele; A2: Major allele; HWE:
Hardy-Weinberg Equilibrium; MAF: minor allele frequency (from main study population)
Lines in red denote SNPs removed from final analysis.
The general characteristics of the study population are presented in Table 6.3. Average age
of the patient cohort at diagnosis was 65.5 ±11.8 years (mean ± S.D). The majority of
patients were diagnosed with stage III or IV cancers. Average weight loss was 6.9 ± 9.8%
with a mean BMI of 24.9 ± 4.9 at diagnosis. Of the patients in whom CRP levels were
assessed (n=569), 58.7% had a CRP concentration of >10 mg/l. There were no significant
differences in age, stage of disease, BMI and percentage weight loss between patients with
CRP measured and the entire cohort.
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Table 6.3 Patient demographics (main cohort)
Patients recruited from (2004 - 2008): NHS Lothian, UK; Cross Cancer Institute, Edmonton,
Canada; and McGill University Health Centre, Montreal, Canada.
No. of patients
(n=775)






Oesophageal or Gastric 389 (50.2)
Pancreatic 114 (14.7)










Body mass index (kg/m2)f 24.9 ± 4.9
Range (12.9-46.7)
Percentage weight loss ' 7.95 ±8.16
Range (0-43.8)
C-reactive Protein (mg/l)1 (n=569) 23.0 ± 35.9
CRP >10 mg/l 235 (41.3)
CRP 2 1U mg/l 334 (58.7)
Values are number of patients with percentages in parentheses unless indicated otherwise; Values
are mean ± SD. Characteristic s were measured at first presentation to a surgical or oncology clinic.
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Table 6.4 lists the detailed results for SNPs with permutated p values of <0.05 for each
cachexia phenotype. Eight SNPs have associations of p <0.02 with various cachexia
phenotypes. Three of these SNPs are found within chromosome 1 in the genes SELP,
LEPR and DI01; three within chromosome 3 in the genes APEH and GHRL, one within
chromosome 12 in the TNFRSF1A gene, and one within chromosome 19 in the ICAM1
gene. SNPs found on the same chromosomal region (within 10,000kb) were grouped
together to form haplotypes. The haplotypes formed by the rs4855881 and rs2960548 SNPs
in the APEH gene failed to show any significant association with weight loss.
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Analyses of candidate gene groups based on functional similarity revealed three groups that
were associated with at least one cachexia phenotype at the p<0.05 level (Table 6.5).
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Validation study
A total of 101 patients were recruited independently for the validation study. Patient
demographics of the validation cohort are presented in Table 6.6. Study subjects were
genotyped for SNPs with p<0.05 in the main study.
Table 6.6 Patient demographics (validation cohort)




Age (years) ' 62.0 ± 11.5





Oesophageal or Gastric 18 (17.8)
Pancreatic 6 (5.9)









Body mass index (kg/m2)f 23.7 ±4.3
Range (15.4-37.8)
Percentage weight lossf 5.54 ± 7.91
Range (0-43.1)
C-reactive Protein (mg/l)f (n=95) 75.5 ± 76.4
CRP > 10 mg/l 78 (77.2)
CRP< 10mg/l 17 (16.8)
Values are number of patients with percentages in parentheses unless indicated otherwise; Values
are mean ± SD. Characteristic s were measured at first presentation to a oncology clinic.
One replication of the main study was found. The C allele of the rs6136 SNP was inversely
associated with weight loss >10% in the main study (OR 0.52, 95% C.I 0.29 - 0.93, p =
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0.026) as well as in the validation study (OR 0.09, 95% C.I 0.01 - 0.98, p = 0.035). However,
there was no association with weight loss >15% (OR 0.31, 95% C.I 0.03 - 3.60, p = 0.53)
6.5 Discussion
This study has identified that individuals who carry the C-allele of the rs6136 polymorphism
are at reduced risk of developing cachexia as defined by weight loss >10%. The SELP gene
which encodes P-selectin is a candidate for the development of cachexia due to its role in
the recruitment of neutrophils and macrophages in the inflammatory response. The C allele
of the non-synonymous intronic variant, rs6136 has been previously associated with
decreased serum P-selectin levels (Miller et al, 2004; Volcik et al, 2006).
In cachexia, as with a study of with many potential polygenic traits, one of the main
obstacles is the lack of a uniform phenotype. However, a recent consensus document on the
definition of cachexia suggested a key component of cachexia to be at least a 5% loss of
oedema-free body weight during the previous 12 months or less (Evans et al, 2008). The
document also suggested classifying the degree of cachexia as mild, moderate or severe,
depending on whether the observed weight loss within the previous 12 months (or less) was
>5%, >10% or >15%, respectively. Hence in the present study we considered cachexia as a
spectrum using these cut-offs.
CRP has been studied in a wide variety of tumour types and has been linked to poorer
survival (Mahmoud & Rivera, 2002; McMillan et al, 2003). CRP has also been incorporated
into a three-factor mathematical definition of cachexia for patients with pancreatic cancer
(Fearon et al, 2006). The multi-profile definition was found to have more prognostic value
compared with weight loss alone. To reflect that cachexia represents a spectrum and that
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the presence of systemic inflammation with weight loss may represent a unique sub-
phenotype of cachexia which confers an increased mortality risk, we have chosen to study
cachexia across three different percentage weight loss categories alone and with the
presence of an increased CRP concentration in comparison with a weight-stable phenotype
(i.e. <5% weight loss). Clearly, much work is required before fully validated definitions of
cachexia are available. Until then, it appears reasonable to investigate cachexia based on
the present arbitrary definitions.
Patients in the present study were recruited at various stages of the disease process. We
have attempted to address this issue by adjusting the analyses for tumour stage at the time
of recruitment. The amount of weight lost during the cancer journey may be affected by
patients' pre-morbid BMI. The initially overweight/obese cancer patient may be more likely to
lose a greater amount weight compared with a patient with the same cancer type in the
normal BMI range over the same period of time. To account for this variation, the analyses
have also been adjusted for pre-morbid BMI.
The present study represents the first large scale candidate gene association study of
cancer cachexia spanning a wide variety of genes such as genes that regulate inflammation,
muscle and adipose tissue metabolism and appetite. SNPs chosen for the study were based
on a literature review of SNPs with known functional effects and/or clinical relevance with
regard to the development of cachexia. SNPs based on 18 genes identified in a gene
expression study on muscle samples in patients with cancer cachexia were also analysed.
Instead of utilising a tag SNP approach, as it was not realistic to analyze all possible gene
variants and combinations, SNPs most likely to be functional (i.e. within exons, non-
synomymous and with a MAF of >0.1) and hence more likely to be associated with the
development of cachexia were selected.
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To further add strength to the study, a separate validation study was done by replicating the
association study in an independently recruited group of patients. In the initial exploratory
cohort we identified 21 SNPs with significant associations with cachexia phenotypes.
However, when both the exploratory and validation cohorts were considered, only cancer
patients carrying the minor allele (C) of rs6136 were found to be at reduced risk of
developing cachexia as defined by weight loss >10% (main study (OR 0.52, 95% C.I 0.29 -
0.93, p = 0.026); validation study (OR 0.09, 95% C.I 0.01 - 0.98, p = 0.035)). Unfortunately,
the validation study failed to confirm other significant associations found from the main
cohort. This may be due to the small sample size of the validation study which is a key
limitation. In addition, due to the small sample size of the validation cohort, gene group
analysis was only performed on the main cohort.
The gene group analysis performed provides one way of summarising the evidence between
cachexia traits and multiple genetic variants across groups of genes that share functional
similarity. Appetite regulation was found to be most significantly associated with the cachexia
trait weight loss >15% and CRP >10 mg/l (p = 0.008). There has been some evidence to
date that negative regulators of appetite are elevated in cachexia (Doehner et al, 2001; le
Roux et al, 2005). A number of animal studies have also shown prevention or reversal of
cachexia by deletion or blockade of specific appetite pathways (Marks et al, 2001; Nicholson
et al, 2006; Wisse et al, 2001).
In addition to the above link, the glucocorticoid signalling pathway was also found to be
associated with cachexia (weight loss >15% and CRP >10 mg/l) (p = 0.0181). There is
evidence that glucocorticoids and its associated signalling pathway are involved in
accelerating protein degradation in muscle, which results in loss of lean body mass in
cachexia (Tisdale, 2009). Glucocorticoids work thorough a permissive effect on the
upregulation of messenger RNA and the subsequent synthesis of components of the
ubiquitin-proteasome system in muscle. Glucocorticoids inhibit protein synthesis and
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promote gluconeogenesis, and suppress glucose and amino acid muscle uptake by
inhibiting cellular transporters (Lecker et al, 2006). Mitogen activated protein kinases
(MAPK) activity regulation was also found to be associated with cachexia (weight loss >15%
and CRP >10 mg/l) (p = 0.0264). MAPKs are known to mediate lipolysis in cancer cachexia
(Ryden & Arner, 2007), and are also potential regulators of muscle catabolism in cachexia
(Keren et al, 2006).
Previous genetic studies on cancer cachexia have identified associations with cachexia and
polymorphisms in cytokine genes such as the IL1B 3954C/T polymorphism (rs1143634) in
patients with gastric cancer (Zhang et al, 2007), and the IL10 -1082A/G polymorphism
(rs1800896) in patients with gastro-oesophageal cancer (Deans et al, 2009a). Cancer
related anorexia has been associated with the TNF -308G/A polymorphism (rs1800629) in
patients with non-small cell lung cancer (Jatoi et al, 2009). Despite some significant
associations with other polymorphisms in pro-inflammatory cytokines genes (Table 2), the
present study was unable to confirm the previous specific associations in the present study.
However, all these studies have focused only on one particular type of cancer and on a
small number of genetic variants. More widely applicable biomarkers may prove more useful.
One of the strengths of the present study is the analysis of a wide variety of candidate genes
that may influence the development of cachexia in patients with various cancer types.
The nature of cancer cachexia dictates that there are fewer individuals who develop the
most severe aspects of the syndrome. At the severe end of the cachexia spectrum, the
power in the present study to detect weak associations with uncommon variants was low. It
may be that a larger sample size may be required to fully elucidate the effects of such
variants in individuals with severe or refractory cachexia.
The diverse cachexia phenotypes we investigated represent various stages in the cachexia
journey with potential genetic influences at each stage. The present chapter suggests that
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multiple pathways are likely to be involved in the pathogenesis of cancer cachexia and, in
particular, appetite regulation, glucocorticoid signalling, and MAPK activity regulation may
have central roles in this process and should be further investigated. Individuals with the C-




GENERAL DISCUSSION AND FUTURE WORK
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Cancer cachexia significantly impairs quality of life and response to treatment and is
associated with increasing morbidity and mortality. This thesis set out to investigate the time
course changes in regional body fat and lean tissue compartments in the cachexia journey
using pancreatic cancer as a model for cachexia. The prognostic value of body composition,
specifically skeletal muscle was also evaluated. The thesis also sought to determine whether
there is a genetic predisposition to cancer cachexia.
7.1 Evaluation of body composition in patients with pancreatic cancer as a
model of cachexia
Patients with pancreatic cancer have long been associated with the most severe forms of
cachexia. Recent studies have revealed that a substantial proportion of cancer patients at
diagnosis now have a BMI in the overweight range (Irigaray et al, 2007). Chapter 3 showed
a similar finding: patients had a mean BMI of 23.9 with 40% of individuals being in the
overweight/obese range. However, underneath this mantle of adipose tissue the previously
noted tendency to muscle wasting was observed. The use of CT images in the cross-
sectional component of the study identified that 56% of patients had sarcopenia at the time
of presentation. Moreover, in the longitudinal part of the study, the tendency to muscle loss
continued in at least a proportion of patients.
It was interesting, however, that in the longitudinal study a much greater rate of fat loss was
observed as compared with muscle loss. One hypothesis would be that during cancer
cachexia, muscle loss is an early feature but that subsequently at least a proportion of
patients are able to activate compensatory mechanisms aimed at conserving muscle. It is
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also possible that the degree of metabolic change versus reduced food intake (simple
starvation) may vary according to the patients' clinical status and concomitant anti-cancer
therapy. Another possibility is that in at least a proportion of patients there is a genetic
predisposition or resistance to cachexia and that this genotype may relate to phenotype
during different phases of the cancer/cachexia journey. There is increasing evidence that
gene polymorphisms are related to cancer cachexia susceptibility (Deans et al, 2009a;
Vigano et al, 2009).
Overall, the longitudinal study shows that both muscle and fat loss are predominant features
in cancer cachexia. This suggests that any future definitions of cancer cachexia should
include the loss of both muscle and fat and not just muscle alone.
The longitudinal study in Chapter 3 reveals that the loss of fat mass was 40,840 kcal over
135 days which equates to a negative energy balance of approximately 300 kcal/day. These
findings are consistent with previous studies, which have demonstrated that the daily energy
deficit in advanced cancer patients with weight loss is about 300kcal/d (Moses et al, 2004).
This energy deficit is due to a combination of reduced food intake and increased energy
expenditure (Wigmore et al, 1997b).
The use of 1 kcal/mL oral nutritional supplements has not been shown to improve the
nutritional status of patients on chemotherapy (Ovesen et al, 1993). However, recent studies
using a more calorie dense (1.5 kcals/mL) and higher protein supplementation have
suggested that at least weight stabilization can be achieved in some patients (Kumar et al,
2010). Whist patients' energy deficit may be addressed by such nutritional support, it is
evident that attenuation of loss of lean tissue/muscle mass is more difficult to achieve (Nixon
et al, 1981). This suggests that in addition to calorie supplementation, other treatment
options are required to reverse/attenuate the loss of lean body mass such as improving
anabolism and/or treating hypercatabolism. One of the first steps in designing intervention
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trials to address this issue would be to have an accurate measure of lean or skeletal muscle
mass.
A BMI <18.5kg/m2 is considered by many authorities to represent an individual at serious
risk of undernutrition (Shetty, 2003). The study in Chapter 3 showed only 10% of individuals
at baseline fulfilled this criterion. Given the prevalence of overweight/obesity (40%) it would
seem unlikely that even in the presence of ongoing weight loss, the majority would reach this
boundary (i.e. a BMI <18.5kg/m2) at or near the time of death. However, BMI has clear
limitations and a more detailed evaluation of body composition in patients with advanced
pancreatic cancer revealed significant wasting of the lean tissues, with a majority of patients
below or well below benchmark levels of muscularity known to be associated with mortality
and functional disability (Janssen et al, 2002). Current literature reveals that concurrent low
muscle mass (sarcopenia) but a high fat mass is a worst case scenario (Bigaard et al, 2004;
Heitmann et al, 2000; Honda et al, 2007; Prado et al, 2008), and this is clearly apparent in
the study group, where sarcopenic overweight/obese patients had the worst prognosis
overall, even compared with patients who were sarcopenic and had a BMI in the normal or
underweight range.
The mechanism that links sarcopenic overweight/obesity with accelerated demise is not
known. However, muscle wasting is a known complication associated with insulin resistance
found commonly in obesity. Insulin resistance causes muscle wasting by mechanisms that
involve suppression of PI3K/Akt signaling leading to activation of caspase-3 and the
ubiquitin-proteasome proteolytic pathway causing muscle protein degradation.(Wang et al,
2006).
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A weakness of the study in Chapter 3 is that the population assessed in the longitudinal
study is quite small (n=44) and there were no details of treatment and response available to
assess the effects of the latter on changes in body composition. Nevertheless, Chapter 3
has shown that the presence of overweight/obese sarcopenia in pancreatic cancer patients
is an adverse prognostic factor. This finding mirrors a previous study on a cohort of lung
cancer patients (n = 250) undergoing chemotherapy (Prado et al, 2008).
One important issue is that in any intervention trial in cancer patients with sarcopenic
obesity, the emphasis must be on increasing levels of muscularity whilst avoiding making the
obesity worse. Thus the use of simple oral nutritional supplements would need to be
combined with exercise and other promoters of net muscle anabolism. The use of serial
body composition analysis derived from diagnostic CTs would be one way of monitoring the
success of such a regimen.
7.1.1 General application of CT scanning for body composition analysis
CT is capable of distinguishing between different tissue types on the basis of their
attenuation characteristics (Hounsfield units). Regional analysis of fat and lean tissue (e.g.
L3 level) are highly correlated to corresponding whole body compartments and can provide
precise quantification of specific adipose tissues, skeletal muscles and organs (Heymsfield
et al, 1997). CT is currently considered a gold standard imaging method of body composition
analysis at the tissue-organ level (Prado et al, 2009b).
The use of CT analysis to investigate body composition and body composition changes
throughout the disease trajectory represents an optimal choice because of the ability to
discriminate individual tissues and the number of scans available over time for longitudinal
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studies. Within-scanner reproducibility and between-scanner agreement have been shown to
be high for measurements of adipose and muscle tissue area by CT although caveat must
be attached to a standard error (SE) of ~1.1% for repeated measures of muscle tissues and
~5.5% for adipose tissues (Brandberg et al. unpublished work).
A problem with multiple CT images over the whole body is the high radiation absorbed dose,
resulting in effective doses of the order of 10 mSv per investigation (Mattsson & Thomas,
2006). This limitation is accepted for patients with cancer because of the ability to follow
tumour growth and response to therapy. Cancer patients are routinely evaluated by high-
resolution diagnostic imaging and Chapter 3 has shown that routine diagnostic CT scans are
a good resource for detailed nutrition/metabolic assessment of patients and the identification
of overweight/ obese sarcopenia.
One possible issue with CT image-based body composition analysis is that while this is
highly robust in terms of delineating and quantifying muscle and adipose tissue, there have
been few studies on the usefulness of CT images on assessing quality of tissue assessed, in
particular skeletal muscle. Thus, at the most basic level, although the volume of a muscle
may be delineated, the protein content remains unknown and the assumption that this
remains constant is untested.
The recent consensus article on cachexia (Evans et al, 2008) recognises the key importance
of skeletal muscle wasting as a signature event in cancer cachexia. Chapter 3 has
demonstrated that routine diagnostic CT scans can be used to derive an index of muscle
mass. With such methodology it is possible to classify patients as sarcopenic or not.
Sarcopenia has been linked to poorer prognosis in obese/overweight cancer patients.
Recent studies have also shown that cancer patients with sarcopenia may be prone to
severe toxicity during systemic therapy (Prado et al, 2007; Prado et al, 2009a). There is a
strong argument for all cancer patients to have their diagnostic CT scans analysed for body
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composition in terms of stratifying cancer patients' entering cachexia clinical trials, for dose
adjustment of chemotherapy to avoid systemic complications or to guide optimal nutritional
and metabolic care within support care programs.
7.2 Identification of candidate genes for cancer cachexia (a systematic
literature review)
The finding that only a proportion of patients with chronic disease develop cachexia has
prompted studies looking for genetic polymorphisms that may underlie differential
susceptibility (Tan et al, 2008). Based on the hypothesis that continued systemic
inflammation plays a central role to the pathogenesis of cachexia, the most frequent targets
for these studies have been genes encoding pro-inflammatory cytokines. While much
attention has been placed on cytokine polymorphisms and their association with cachexia, it
is of note that mechanisms surrounding the pathogenesis of cachexia is complex and is
likely to involve gene products which act both upstream and downstream of cytokines.
Pathways not affected by cytokines may also play a role in the development of cachexia.
Chapter 4 investigates by means of a systematic literature review all genetic polymorphisms
with known functional or clinical significance in potential candidate genes involved in the
development of cancer cachexia. Domains investigated include systemic inflammation,
central energy balance, control of muscle metabolism/function, control of adipose tissue
metabolism/function, and regulation of appetite all of which have been implicated in the
pathogenesis of cancer cachexia.
Like many complex conditions and diseases, the risk of developing cancer cachexia is
probably determined by multiple genetic factors and environmental factors are likely to add
to the heterogeneity of the condition. Although the number of reports on polymorphic gene
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variants associated with multi-factorial diseases and conditions are growing dramatically,
very few studies provide firm and reliable evidence of causative relationships between these
polymorphisms and risk or pathogenesis. This could be due to issues concerning phenotype
misclassification (which is particularly relevant to cancer cachexia as the agreed definitions
of the syndrome are arbitrary and await validation), epistatic interaction and undetected
genomic heterogeneity in the underlying population (Tan et al, 2008). Of note, in a review of
allelic association with common disease phenotypes, only six of 166 associations subjected
to multiple evaluations were confirmed consistently (Hirschhorn et al, 2002). Possible causes
of false-positive association studies include population stratification, variable linkage
disequilibrium and genotype misclassification. In addition, in many of these studies, the
possible effects of single gene variants were assessed in situations when combined impacts
of multiple factors could be expected (Loktionov, 2003). In chapter 4, a total of 184
polymorphisms with functional and/or clinical significance in terms of cachexia were
identified in 92 genes. However, only 42 polymorphisms have been identified with a potential
role in the development of cachexia and have been independently verified in at least one
repeat study.
Of the 42 polymorphisms with a potential role in the development of cachexia that have been
verified independently in at least one repeat study, 13 polymorphisms have been shown to
have more than one effect on clinical features associated with cancer cachexia (i.e. systemic
inflammation, loss of muscle/adipose tissue mass, reduced cancer survival). These 13
polymorphisms are likely to be the most promising candidates in terms of susceptibility
biomarkers for cancer cachexia.
The analysis of candidate genes relies on an understanding of disease pathophysiology.
However, candidate gene studies are limited by the fact that they rely on an assumed
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knowledge about the pathogenesis of cancer cachexia. The selection of genes for study is
based on an a priori hypothesis about disease causality. A good case can usually be made
to study many of the 30,000 genes on the human genome so, in the context of a disease
that is complex and polygenic, candidate gene analysis based merely on a "scientific hunch"
is a rather naive and approach that will be rarely successful. Chapter 4 has therefore
provided an excellent initial framework in which to select and study the possible genetic
variance associated with developing cancer cachexia.
Since the completion of the literature review, apart from two studies confirming the
association of IL10 and IL8 polymorphisms with cancer cachexia (Bo et al, 2010; Sun et at,
2010), there have not been any other significant genetic association studies on cachexia.
However, a recent study showed that blockade of the activin type-2 receptor (ActRIIB) in
mice results reverses cancer-induced muscle loss and anorexia (Zhou et al, 2010). This
suggests that the ActRIIB pathway is likely to play an important role in the development of
cachexia and variants of genes involved in the pathway should be further investigated for
association with cachexia.
Over the past few years, catalysed in part by technological advances allowing cheaper
genotyping, and the completion of the HapMap project, genome wide association studies
(GWAS) have become increasingly common. This technique is superior to candidate gene
studies alone as it allows researchers the advantage of being able to identify genes in a
"hypothesis free" manner, rather than identify selecting candidate genes on the basis of
likely causality. The genome-wide association approach therefore represents an unbiased
yet fairly comprehensive option that can be attempted even in the absence of convincing
evidence regarding the function of the genes (Hirschhorn & Daly, 2005). The full publication
of the HapMap project data has facilitated genetic mapping studies across a broad array of
164
complex phenotypes for use in genetic case control studies, and to identify sets of SNPs that
take advantage of the LD patterns of the genome and allow more economical genotyping
though indirect association studies (2005).
The ability to simultaneously examine hundreds of thousands of variants throughout the
genome is both the strength and the weakness of the GWAS approach. The power of GWAS
is that they provide a relatively unbiased examination of the entire genome for common risk
variants; their weakness is that in doing so, they swamp the signal from true risk variants
with statistical noise from the vast numbers of markers that are not associated with disease.
To separate true signals from noise, researchers have to set an exceptionally high threshold
that a marker needs to exceed before it is accepted as a likely disease-causing candidate.
The latter reduces the problem of false positives, but it also means that any true disease
markers with small effects are lost in the background noise (Pearson & Manolio, 2008).
GWAS association studies are also considerably more expensive compared with candidate
gene studies and require much larger sample sizes to generate meaningful data.
7.3 Identification of candidate genes for cancer cachexia (gene expression
microarray study)
The maintenance of muscle mass is a balance between protein synthesis and degradation.
In cachexia, this balance is disrupted leading to a decrease in protein synthesis or an
increase in protein degradation or a combination of both.
Gene expression technology using gene microarrays allows a comprehensive picture of
gene expression at the tissue and cellular level, thus helping to understand the underlying
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physiological and pathological processes in cancer cachexia. In chapter 5, the differential
expression of genes in rectus abdominis muscle of cachetic versus non-cachetic patients
was studied. The study revealed an 83-gene signature that correlated with percentage
weight loss (74 genes correlated positively with weight loss and 9 correlated negatively with
weight loss).
A significant weakness of the study was the small sample size. Also, there was a potential
issue that patients with cancer and normal controls were analysed together and perhaps
studies with proper control groups are necessary. Due to statistical issues raised by
microarray technology, it is also essential that findings be confirmed using independent
methodological criteria. A follow-up study done using quantitative RT-PCR on nine selected
genes from the 83 genes validated the results of eight genes from the microarray analysis
while one (SGK) was inconsistent with the microarray data (Stephens et al, 2010).
Although the Affymetrix genechip array allows study of the differential expression of a large
number of genes (approx.38,500 genes), it does not cover all the genes within the human
genome. It is therefore likely that some important genes involved in the pathogenesis of
cachexia may be missed.
Another issue with microarray studies are that steady-state levels of RNA are not necessarily
reflective of the final steady-state level of the functional protein translation product of an
mRNA and further studies might be required involving the use of specific antibody probes in
Western blot or immunocytochemical studies (Murphy, 2002). Although a microarray
experiment might indicate an increase or decrease in the expression of a gene, an
independent method might reveal a greater or a lesser change. Does such a result represent
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sufficient confirmation of the microarray findings, or does a quantitative difference raise new
questions about the validity of the microarray data?
Nevertheless, the study in chapter 5 has shown a variety of genes which are correlated with
weight loss and may represent novel biomarkers for cancer cachexia. Polymorphisms in the
genes identified in this chapter may play a role in the inter-individual variability of developing
cachexia and all genes that were negatively correlated with weight loss and genes with a
positive correlation of r >0.65 with weight loss were further studied in the genetic association
study (see below)
7.4 Candidate gene association study of cancer cachexia
191 SNPs across 99 genes were selected for the candidate gene association study. SNPs
chosen for the study were based on the literature review of SNPs with known functional
effects and/or clinical relevance with regard to the development of cachexia (Chapter 3). A
decision was also made to analyse SNPs based on 18 genes identified in a gene expression
study on muscle wasting in patients with cancer cachexia (Chapter 4). Instead of utilising a
tag SNP approach, as it was not realistic to analyse all possible gene variants and
combinations due to limitation of resources, SNPs selected were those most likely to be
functional (i.e. within exons, non-synonymous and with a MAF of >0.1) and hence more
likely to be associated with the development of cachexia. The study was carried out in 775
patients also carried out using polymorphisms significantly associated with cachexia in the
main cohort of patients.
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7.4.1 The P-selectin (SELP) rs6136 polymorphism is associated with the
development of cachexia
21 SNPs were found to have significant associations with cachexia in the main study.
However, only the C allele (minor allele frequency 10.7%) of the rs6136 (SELP) SNP was
found to be associated with a reduced risk of developing cachexia (weight loss >10%) both
in the main study and the validation study. The C allele of the non-synonymous intronic
variant, rs6136 has been previously associated with decreased serum P-selectin levels
(Miller et al, 2004; Volcik et al, 2006).
The role of P-selectin in the genesis of cachexia remains to be determined. However, P-
selectin has been characterized previously by approaches such as gene knockout or the use
of specific inhibitors to be involved in the recruitment of neutrophils and macrophages in
inflammatory responses (Borges et al, 1997; Chen & Geng, 2006). P-selectin may
participate in intra-tumoural regulation of the genesis of systemic inflammation via the innate
immune system and/or regulation of the complex interaction within muscle between the
endothelium and signalling pathways in muscle fibres (Wagenmakers et al, 2006). The
above suggest that P-selectin is likely to play a causal role in the development of cancer
cachexia.
The results in Chapter 6 should be interpreted considering several limitations. First,
candidate genes in the study were selected based on educated guesses on which
polymorphisms are most likely to be associated with cachexia phenotypes. Given unlimited
resources, it would have been more informative using a tag SNP approach to investigate all
the genes identified in Chapters 4 and 5. Second, the sample size of the main population
was relatively small and for the least prevalent cachexia phenotypes, there was insufficient
power to detect association with an OR >1.5 especially with polymorphisms with a low MAF.
Another key limitation was the small sample size of the validation cohort which may have led
to the inability to confirm other significant associations observed in the main study. Future
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studies should involve recruiting a larger cohort of patients both of the main and validation
cohorts.
Third, there are certain features of the study which may lead to confounding results. Patients
recruited were heterogeneous in terms of diagnosis and across different population groups.
It could be argued, however, to a certain extent that these results should then be replicable
and valid for all types of cancer and across all population groups. Patients were also
recruited at various stages of the disease process therefore there may be significant
variation in the time frame for weight loss. This was addressed by adjusting for stage of
disease assuming that patients who are diagnosed with more advanced disease would
present with greater amount of weight loss.
Chapter 6 has shown that individuals with the C-allele of the rs6136 P-selectin polymorphism
appear to be at reduced risk of developing cachexia. This information may prove useful in
the risk stratification of pre-cachetic cancer patients, although the question may be asked is
genotyping for a SNP that is only present in ~11% of the population worthwhile?
7.4.2 Gene groups regulating appetite, glucocorticoid signalling, and mitogen
activated protein kinases (MAPK) activity may have central roles in the
pathogenesis of cancer cachexia.
Candidate genes (and the SNPs in the corresponding gene regions) were grouped based on
known functional similarity according to gene ontology and the association between grouped
SNPs and cachexia were analysed using subject in the main study cohort. Gene group
analysis performed provides one way of summarising the evidence between cachexia traits
and multiple genetic variants across groups of genes that share functional similarity.
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Gene groups regulating appetite, glucocorticoid signalling, and mitogen activated protein
kinases (MAPK) activity were associated with cachexia (weight loss >15% and CRP
>10mg/l).
Previous studies have shown that negative regulators of appetite are elevated in cachexia
(Doehner et al, 2001; le Roux et al, 2005). The study in Chapter 3 has also identified the
presence of an energy deficit of approximately 300 kcal/day which may result from reduced
food intake. The gene association study further confirms anorexia as an important variable in
the development of cachexia.
A number of animal studies have shown prevention or reversal of cachexia by deletion or
blockade of specific appetite pathways (Marks et al, 2001; Nicholson et al, 2006; Wisse et al,
2001). Since anorexia is a key component of cancer cachexia, one treatment strategy is to
improve appetite by using appetite stimulants to ensure adequate intake of nutrients. These
include orexigenic agents such as Megesterol acetate, cannabinoids, and 5-HT3
antagonists. All these appetite stimulants have been shown to ameliorate or slow anorexia
and unintentional weight loss in other populations but have not shown promise in increasing
lean body mass or markers of protein metabolism in the cachectic cancer patient (Kumar et
al, 2010).
There is evidence that glucocorticoids and its associated signalling pathway are involved in
accelerating protein degradation in muscle, which results in loss of lean body mass in
cachexia (Tisdale, 2009). Glucocorticoids work thorough a permissive effect on the up-
regulation of messenger RNA and the subsequent synthesis of components of the ubiquitin—
proteasome system in muscle. Glucocorticoids also inhibit protein synthesis and promote
gluconeogenesis, and suppress glucose and amino acid muscle uptake by inhibiting cellular
transporters (Lecker et al, 2006). Many pathological conditions characterized by muscle
170
atrophy such as cachexia are associated with increase in circulating glucocorticoids levels
(Lecker et al, 1999), suggesting that these hormones could trigger the muscle atrophy
observed. The study in Chapter 6 reinforces that the glucocorticoid signalling pathway may
play an important role in the development of cachexia.
Experiments with the glucocorticoid receptor antagonist RU-486 in mouse models show
poor results and do not ameliorate the detrimental wasting of muscle and adipose tissues
seen in a well-characterized murine tumour-induced cachexia model (Rivadeneira et al,
1999). Therapies based on other components of the glucocorticoid pathway may, however,
prove beneficial and should be investigated further. For example, glucocorticoids can cause
muscle atrophy by altering the muscle production of IGF-I and myostatin, two growth factors
exhibiting opposite effects on muscle mass development (Schakman et al, 2008). Therefore,
IGF-I stimulation or myostatin blockade constitutes some of the most promising future
therapeutic approaches to prevent muscle atrophy caused by glucocorticoids.
Pathways regulated by pro-inflammatory cytokines include those activated by the MAPKs:
ERK, JNK, and p38. MAPKs are known to mediate lipolysis in cancer cachexia (Ryden &
Arner, 2007), and are also potential regulators of muscle catabolism in cachexia (Keren et al,
2006). ERK appears upregulated in the muscle of animals bearing experimental tumours,
and its inhibition corrects the loss of both muscle weight and function. Interference with ERK
activation is also able to prevent the enhanced expression of the ubiquitin ligase/atrogin-1
involved in muscle catabolism (Penna et al, 2010). These observations suggest that
treatments able to modulate or to interfere with MAPKs may be relevant to the
prevention/correction of cancer cachexia.
Chapter 6 suggests that multiple pathways are likely to be involved in the pathogenesis of
cancer cachexia and, in particular, appetite regulation, glucocorticoid signalling, and MAPK
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activity regulation may have central roles in this process. Indeed, it is now well accepted that
a complex interplay of mediators, such as hormones and cytokines, plays a role in the onset
of cachexia, leading to muscle and adipose tissue depletion and loss of function (Durham et
al, 2009). These findings are highly exciting in terms of isolating potential biomarkers of
cachexia among components of the pathways described above. There is a possibility of
developing biomarker sets based on the above pathways to predict predisposition to
cachexia as well as indices of cachexia progression and/or response to treatment.
These findings also open up new possibilities in terms of identifying new targets for drug
therapy. So far, individual treatments such as those aimed at improving anorexia, and
blocking glucocorticoids have had mixed results in treating cachexia. If further studies prove
that the pathways found in the study in Chapter 6 are indeed central to the development of
cachexia, perhaps a multi-therapy approach against components of each pathway may
prove more efficacious in treating cancer cachexia.
7.5 Future work and direction
One of the main difficulties in research involving cachexia is the lack of a specific phenotype.
However, chapter 3 has demonstrated that CT scans can be used to derive an index of
muscle mass to classify patients as sarcopenic or not using established cut-offs of skeletal
muscle index of <7.26 kg/m2 for men and <5.45 kg/m2 for women. Sarcopenia and
sarcopenic obesity have been linked with multiple relevant clinical outcomes in cancer
patients. Further work would involve examining the potential relationship between patients'
genotype and the propensity to sarcopenia and/or sarcopenic obesity in cancer.
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Chapter 3 has re-iterated that weight-losing advanced cancer patients have an energy deficit
of approximately 300kcal/day. This deficit and the likely associated reduction in protein
intake are factors that may contribute to the development of sarcopenia. It has been shown
that nutritional intervention alone cannot effectively treat cachexia. Many classes of drugs
aimed at treating cancer cachexia have been evaluated with mixed results. Further
randomised clinical trials are therefore required to investigate if early nutritional intervention
coupled with additional therapy targeted at attenuating catabolism and/or improving
anabolism, especially in pre-cachetic cancer patients, improves muscle mass and thus
positively affects outcome.
This thesis chose to examine the cachexia phenotype based on weight loss using cut-offs
set at >5%, >10% and >15% with and without the presence of systemic inflammation.
Despite the limitation of the small sample size in the validation cohort of the candidate gene
study in Chapter 6, the P-selectin (SELP) rs6136 polymorphism appears to be a promising
biomarker in terms of determining susceptibility to cachexia. Future work would involve
recruiting a larger cohort of patients to validate rs6136 and the other polymorphisms
associated with cachexia found in Chapter 6.
Further experiments are also required to investigate the role and importance of P-selectin in
the development of cancer cachexia. Recent work done by collaborators highlight evidence
for the role of P-selectin in the development of cachexia by the induction of muscle atrophy
in mice/rats either by intra-peritoneal injection of LPS or in rats bearing the MCA sarcoma.
qPCR analysis of skeletal muscle RNA following either intra-peritoneal injection of LPS or in
tumour bearing animals showed a striking upregulation of the P-selectin transcript.
Furthermore, preliminary studies also indicate that P-selectin show a similar striking
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upregulation (10-fold) two hours after intracerebroventricular (ICV) injection of interleukin-1
beta in mice (Braun et at, 2011). Acute and chronic infusion of IL-1(3 into the brain leads to
muscle breakdown, anorexia, weight loss and negative nitrogen balance (Hill et at, 1996)
and is a potential central mediator of LPS effects. Identification of P-selectin as a top early
induced gene of the mouse/rat muscle atrophy program and the significant association of the
rs6136 SNP in the P-selectin gene with wasting in cancer patients provide supportive
evidence for the likely involvement of P-selectin in muscle wasting.
Does P-selectin thus play an important causal role in the development of cancer cachexia?
Further work would involve the creation of knockout mice sans the P-selectin gene. If muscle
mass is maintained in these animals following similar induction of the muscle atrophy
program, then it will provide irrefutable evidence of the causal role of P-selectin in cachexia.
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Appendix A Patient Information Sheet
NHS
Lothian
THE IDENTIFICATION OF GENETIC MARKERS OF CANCER-
ASSOCIATED WASTING
You are being invited to take part in a research study. Before you decide, it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully. Talk to
others about the study if you wish.
• Part 1 tells you the purpose of this study and what will happen to you if you take
part.
• Part 2 gives you more detailed information about the conduct of the study.
Ask us if there is anything that is not clear or if you would like more information.
Take time to decide whether or not you wish to take part.
Part 1
What is the purpose of the study?
The purpose of this research study is to find out if there is a genetic basis for
people who have cancer to become wasted, lose weight and feel tired. This
wasting is a significant problem for patients as it causes a reduction in both
quality and quantity of life. In order to find out if there is any way to predict its
development, we would like to see if wasting in cancer is related to the presence
or absence of certain genetic markers.
Why have I been chosen?
You have been chosen because you have been diagnosed with oesophageal,
gastric or pancreatic cancer. We aim to recruit 300 participants in total.
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Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be
given this information sheet to keep and be asked to sign a consent form. You
will still be free to withdraw at any time in the future and without giving a reason.
A decision to withdraw at any time, or a decision not to take part, will not affect
the standard of care that you receive.
What will happen to me if I take part?
If you take part, you will be asked to undergo a single blood test and have your
weight and height measured. This will take place during a routine outpatient clinic
appointment with your consultant. No extra appointments are required if you
choose to take part in this study. We will also ask your permission for access to
your clinical case notes and any CT scan images that are performed as part of
your routine treatment.
• Blood test: The amount of blood taken is approximately the same as one
teaspoonful (15ml), and it will be taken from your arm in the usual fashion.
What do I have to do?
Apart from attendance at the initial appointment, no other responsibilities are
required from your participation.
What are the possible disadvantages and risks of taking part?
There are negligible disadvantages and risks of taking part. Minor discomfort
may occur during blood sampling.
What are the possible benefits of taking part?
We cannot promise that the study will help you, but the information we receive
might help improve the treatment of patients with cancer and cancer-associated
weight loss.
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What happens when the research study stops?
Following your initial appointment, no further appointments are required.
However, if any of your blood, or DNA samples remain, we would ask your
permission to store these samples (in anonymised form) in the University of
Edinburgh so that we can consider them for use in future research studies that
we may carry out (if a local Ethics Committee deems the studies appropriate).
What if there is a problem?
Any complaint about the way you have been dealt with during the study or any
possible harm you might suffer will be addressed. The detailed information on
this, including contact details, is given in Part 2.
Will my taking part in the study be kept confidential?
Yes. All the information about your participation in this study will be kept
confidential. The details are included in Part 2.
Part 2
What if relevant new information becomes available?
If any new treatment for cancer or cancer-associated wasting becomes available
during the time of the study, it will not be withheld from you because of your
participation in this study. Furthermore, if you require any other treatment for
cancer during the course of the study (e.g. chemotherapy or radiotherapy), it will
not be withheld from you because of your participation in this study.
What will happen if I don't want to carry on with the study?
You can withdraw from the study at any time. All information that was collected
during the time of your participation in the study will be destroyed. Any stored
blood or DNA samples that are identified as yours will also be destroyed.
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What if there is a problem?
• Complaints: If you have a concern about any aspect of this study, you
should ask to speak with the researchers who will do their best to answer your
questions. If you remain unhappy and wish to complain formally, you can do this
through the NHS Complaints Procedure. Details can be obtained from the
hospital.
• Harm: In the event that something does go wrong and you are harmed
during the research study, there are no special compensation arrangements. If
you are harmed and this is due to someone's negligence, then you may have
grounds for a legal action for compensation against the University of Edinburgh
but you may have to pay for your legal costs. The normal National Health Service
complaints mechanism will still be available to you.
Will my taking part in this study be kept confidential?
Yes. All information which is collected about you during the course of the
research will be kept strictly confidential. However, we would like to inform your
GP of your involvement in this study but we will require your permission to do
this. All other information about you which leaves the Royal Infirmary of
Edinburgh will have your name and address removed so that you cannot be
recognised from it.
Blood and DNA samples collected during the study may be transferred for the
purpose of analysis to associated researchers within the European Economic
Area. However, all samples will be anonymised prior to sending and therefore
you will not be identifiable.
What will happen to any samples I give?
A portion of the blood sample will be immediately analysed by the Department of
Biochemistry at the Royal Infirmary of Edinburgh or Western General Hospital.
The remainder of the blood sample will be transferred to the University of
Edinburgh for analysis. The only individuals who will have direct access to these
samples will be the members of the study research team. DNA will be extracted
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from the blood sample at the University of Edinburgh. A small portion of the DNA
will be sent from the University of Edinburgh to our collaborators at the
Norwegian University Science and Technology, Trondheim, Norway, for genetic
analysis. The samples that are sent to Norway will already be anonymised so
that you will not be identifiable from them.
Following all of these different analyses, if any of the samples remain, we would
ask your permission to store these samples (in anonymised form) in the
University of Edinburgh so that we can consider them for future research studies
(if a local Ethics Committee deems the studies appropriate). All of the DNA sent
to Norway will be 'used up', and therefore, there will be none left over which will
require storage overseas. Professor Kenneth Fearon, Professor of Surgical
Oncology, will act as custodian for any stored samples. The only other individuals
who will have direct access to the stored samples will be the members of the
research team behind the current study.
Will any genetic tests be done on the samples that I give?
Yes. There will not be any implications, healthcare or otherwise, from the genetic
study. The genetic markers that we aim to test for have not been shown to be
linked with or have any association with inheritable risk for any known diseases.
Therefore, we will not normally feedback any results to you.
What will happen to the results of the current research study?
The results of this study will be published in medical journals, reports and
textbooks. You will not be identifiable in any report/publication or report unless
you have specifically consented to release such information.
Who is organising and funding the research?
The research is being organised and sponsored by the University of Edinburgh.
The research is being funded by the European Commission.
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This study was given a favourable ethical opinion for conduct in the NHS by
Lothian Research Ethics Committee. This study has also been reviewed by
members of the scientific committee of the European Commission.
Contact details
You may contact me (the main researcher) directly by telephoning 0131 242
6520 for further information at any time. Alternatively, you may contact Prof.
Stephen Wigmore, Consultant Surgeon in the Department of Surgery, who is
acting as an independent advisor - contact 0131 242 3615.
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Abstract
Introduction Cancer cachexia is a severe debilitating
disorder, which causes significant morbidity and mortality.
In clinical practice, cachexia is often not treated until a late
stage, when therapeutic options are limited.
Objective It is therefore of great interest to analyse early
biomarkers of this syndrome.
Conclusion In this review article, we summarise recent
biomarkers found in various body compartments. We also
explore the likelihood of a genetic predisposition to cachexia
and focus on the potential role of single nucleotide poly¬
morphisms in genes coding for pro- and anti-inflammatory
cytokines, and 'atrogenes' associated with wasting in
skeletal muscle.
Keywords Cachexia • Cancer - Biomarkers • Genetics •
Polymorphisms
Introduction
Cachexia is a wasting condition that manifests itself in
several life-threatening diseases, including cancer, AIDS,
congestive heart failure and sepsis [3, 41]. Patients exhibit a
loss of both adipose tissue and lean body mass [17], which is
resistant to conventional nutritional support [45], Cachexia is
typically characterised by severe weight loss, anorexia, early
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satiety, weakness, anaemia and oedema [17]. The cachectic
state is particularly problematic in cancer, typified by poor
prognosis and often associated with a lower response to
chemotherapy and radiotherapy than might be expected [43].
Patients are also more likely to report decreased quality of
life (QoL) scores [18]. More than half of cancer patients
suffer from cachexia, and it is responsible for death in up to
20% of cases [43]. Cachexia is therefore a significant cause
ofmorbidity and mortality in cancer patients.
Once the patient becomes immobilised in advanced
cachexia, there is little room for purposeful therapeutic
intervention. Furthermore, it is questionable whether medical
intervention is justified at this very late stage in the patient's life.
In terms of cachexia therapeutics, it is therefore important to
consider the overall journey the patient makes through the
cachexia process and perhaps plan intervention at an early stage.
Although the mechanism for cancer cachexia remains
largely unresolved, it has long been considered to be the result
of a variety of interactions between the host and the tumour
[39], The presence of a tumour results in the initiation of a
host inflammatory response mediated by tumour-derived pro¬
inflammatory cytokines [14]. Systemic inflammation then
initiates a reprioritisation of protein metabolism with induction
of the acute phase response and mobilisation of fat reserves.
This, together with pro-cachetic factors, secreted by the
tumour, promotes protein and fat breakdown [21, 46], Other
overlapping pathways such as upregulation of protein
degradation pathways [e.g., the ubiquitin-proteasome system
(UPS)] and dysregulation of the dystrophin glycoprotein
complex (DGC) facilitate muscle catabolism [1, 42], Finally,
activation of neuroendocrine pathways may also contribute to
hypermetabolism and increased catabolism [2]. Based on
these mechanisms, predictive or early biomarkers of cachexia
could be developed, which would aid in the selection of
patients for early therapeutic intervention.
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Biomarkers of cachexia
There is substantial literature relating to a variety of potential
biomarkers for cachexia derived from different body compart¬
ments, including plasma, urine, tumour, skeletal muscle and
the patient's genome (Fig. 1). This review aims, primarily, to
consider the great potential of isolating markers for cachexia
in the patient's genome. To make this review more complete,
we will also briefly summarise some of the aforementioned
phenotypic biomarkers found in other body components.
Plasma
Plasma is easily sampled and, therefore, an important
compartment to study for potential biomarkers of cachexia.
The positive hepatic acute phase reactant, C-reactive protein
(CRP) has been shown to be a robust marker of systemic
inflammation in cancer patients and has been associated with
the presence of anorexia, hypermetabolism, accelerated
weight loss and shortened survival [16, 26, 51]. CRP has
been studied in a wide variety of tumour types and has been
incorporated into a three-factor mathematical definition of
cachexia for patients with pancreatic cancer [18]. CRP is
therefore a key potential biomarker for cachexia.
The plasma concentration of a variety ofpro-inflammatory
cytokines has been evaluated in numerous studies in human
subjects in relation to the development of cancer cachexia,
including tumor necrosis factor alpha (TNF-a), interleukin 1
(IL-1), IL-6 and interferon gamma (IFN-y) [2, 8, 29, 48],
These studies, unfortunately, have not given a clear,
reproducible pattern whereby the plasma concentration of
any individual cytokine can be related to the development of
cachexia. Controversy has surrounded the use of different
cytokine assays, their variable sensitivity, the short half life
of cytokines and the presence of natural cytokine inhibitors.
Recently parathyroid hormone-related peptide (PTHrP)
has been described as a potential mediator ofcancer cachexia.
PTHrP has been shown to be present in approximately 17% of
patients with gastro-oesophageal malignancy (in the absence
of hypocalcaemia) and to be associated with markers of
systemic inflammation and adverse prognosis [13]. Thus,
PTHrP might well serve as a useful biomarker, but this
awaits confirmation in other types ofmalignancy.
In terms of the neuroendocrine axis, insulin resistance and
hypercortisolaemia have been documented in the cachectic
cancer patient [30, 35]; however, these have not been studied
in detail in terms of the early cachectic process. Hypogonad¬
ism in males is associated with sarcopenia and has been
Plasma
IL-6-174CC. Ilt0-10$2GG, TNFo-308AA
Fig. 1 Potential biomarkers for the development of cancer cachexia
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shown to be highly prevalent in male patients with advanced
cancer [11]. However, it is not clear just how independent of
systemic inflammation the development and effects of
hypogonadism in advanced cancer might be. Moreover, it is
not clear how sex hormone levels influence muscle mass
maintenance in female patients with cachexia. Angiotensin n
has been shown to produce muscle catabolism and weight loss
in murine models, and these effects are attenuated by
angiotensin-converting enzyme (ACE) inhibitors [33], Angio¬
tensin II may therefore be an interesting marker for cachexia.
Finally, other potentially useful plasma markers include
peptides that are involved in the control of food intake such as
leptin and ghrelin [37, 53]. Whilst both factors have been
implicated in the anorexia component of the cachexia
syndrome, the complexity of their interaction with other
factors (e.g., end-organ sensitivity) that control appetite
makes them unlikely as robust biomarkers that can be used
in isolation.
Urine
Compared with plasma, urine represents a relatively simple
matrix to look for novel biomarkers. Indeed, it was from
urine that a potential human homolog of proteolysis-
inducing factor (PIF) was isolated initially. PIF is a 24-kDa
glycoprotein produced by tumour cells in both mice and
humans that has been hypothesised to be responsible for
cancer cachexia [46]. A putative human homolog ofmurine
PIF has been found in many human tumour types, including
breast, ovarian, pancreatic and colorectal cancers [44]. PIF
appeared to be present in patients with tumour-related
cachexia but was absent from normal subjects, patients with
weight loss due to trauma and cancer patients with little or
no weight loss [5]. Mice administered with PIF showed
rapid muscle catabolism, whilst PIF-induced weight loss in
mice is reversed with anti-PIF monoclonal antibodies [5],
Recently however, the specificity of the antibody used to
isolate the human homolog of PIF has been called into
question, and this has hampered isolation of bioactive PIF
for confirmation of its role in human biology [50].
Lipid-mobilising factor (LMF) is a43-kDa lipolytic factor
derived from both tumour and brown adipose tissue. It has
also been isolated from urine ofboth cachetic cancer patients
and cachetic mice [9, 21], LMF is thought to be responsible
for atrophy of adipose tissue in cachetic patients [9]. One
study had found that cancer patients with weight loss had
detectable concentrations of LMF in their urine, whilst
cancer patients without weight loss did not [47].
Tumour
The systemic inflammatory response frequently observed in
patients with cancer cachexia is thought to originate from
within the tumour [14, 27]. As such, inflammation can be
generated by a tumour mass either from constitutive pro¬
inflammatory cytokine production by the tumour cells or
via activation of host microphages or more likely by a
combination of the two. From studies in human pancreatic
cancer, it has been suggested that upregulation of IL-6 may
be a key initiating factor of cachexia from within the
tumour [27], However, a recent study into oesophageal
cancer has suggested that IL-1|3 is perhaps of more
importance [14], Thus, it is not clear that there is a single
tumour-associated cytokine, which could serve as a generic
biomarker. However, it may be that within a single tumour
type, the pattern of cytokine expression might provide a
useful signature. Clearly, however, not all patients have
tumour biopsies available for such characterisation, and
thus there, are clear practical limitations to this approach.
Muscle
Various aspects of the molecular mechanisms of muscle
atrophy or hypertrophy have now been described in detail
[32]. It would appear that in cancer cachexia, there is
suppression of the hypertrophy pathways and upregulation
of the atrophy pathways [38]. The hypertrophy pathways
seem to predominate and in particular activation of the UPS,
which is the major catabolic pathway in cancer cachexia
[25]. Overactivation of UPS has been documented in rodent
models of cancer-associated muscle wasting [23]. Research
on human subjects with cancer has also demonstrated UPS
overactivation [4]. Activation of the ubiquitin proteosome
pathway has been ascribed in part to the presence of
systemic inflammation [15]. Recent data has suggested that
such systemic inflammation may act in part through
dysregulation of the DGC [1]. The DGC is a muscle-specific
protein manifold that anchors muscle fibre membranes in
place and prevents them from being torn by shear forces
produced during muscle contraction. The dysregulation of
DGC has been shown to correlate positively with weight loss
in patients with gastro-oesophageal adenocarcinoma [1]. It
remains, however, difficult to use skeletal muscle as an early
biomarker, as at present, this would require percutaneous
biopsy or open biopsy.
Rationale for a genetic component to cachexia
Based on current knowledge of demographic and clinical
factors, it is not possible to predict, for any given cohort of
patients, who will develop cancer cachexia and who will not.
Moreover, even with all the potential biomarkers described
above, it is not possible to predict accurately who will develop
cachexia quickly vs those who may develop the syndrome at a
47) Springer
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slower pace. Such variation may, in part, be due to the
patient's genotype rather than the tumour phenotype. The case
to support a genetic predisposition to cachexia is strengthened
from the known genetic contribution to the activity of a
variety of key mechanisms that underlie the cachexia
syndrome (e.g. systemic inflammation). However, it must be
said that, unlike other common diseases where twin studies
have suggested a clear heritable component to the disease (e.g.
Crohn's disease, etc), no such studies support a heritable
component to cachexia.
Genotyping cachexia
In terms of linking a patient's genotype with a pro-cachectic
phenotype, there are two basic methods. One could undertake
human linkage studies with genome-wide linkage scans to
identify quantitative trait loci. This methodology is complex,
expensive and, in some instances, is limited by the current
development of bioinformatics. On the other hand, one could
undertake analysis of specific candidate genes. In this regard,
the commonest form of analysis is allelic association studies
using single nucleotide polymorphisms. Single nucleotide
polymorphisms (SNPs) are specific positions within the
genome that are represented by more than one nucleotide in a
population. The definition of polymorphism is that it has an
allele frequency >1%. SNPs occur in approximately one in
evety thousand bases. Only 4% ofSNPs are within genes [40].
An allelic association is where there is non-random
distribution of allele frequencies with respect to disease
status. There are a variety of problems with allelic
association studies; in particular, many studies have suffered
from small sample size. There have also been issues
concerning phenotype misclassification (which is particular¬
ly relevant to cancer cachexia where there is no agreed
definition of the syndrome), epistatic interaction and
undetected genomic heterogeneity in the underlying popu¬
lation. Taken together, these limitations are exemplified by
the fact that in a recent review of 600 published reports of
allelic association with common disease phenotypes, only 6
of 166 associations subjected to multiple evaluations were
confirmed consistently [22],
Selection of candidate genes
Systemic inflammation
Pro-inflammatory cytokine genotype
In studies linking cytokine genotype to the outcome of acute
sepsis, a variety of important principles have emerged. One
key question is whether the product of the gene plays an
important role in the pathogenesis of the disease. Certainly in
relation to systemic inflammation and its fundamental role in
cachexia, this can be answered affirmatively for pro¬
inflammatory cytokines [8, 29]. The second important issue
is whether the gene polymorphism produces a relevant
alteration in the level or function of the gene product.
Fortunately, there are firmly established functional sequelae
for a variety of polymorphisms in connection with pro¬
inflammatory cytokines [19, 31, 52], It would therefore seem
reasonable to consider such polymorphisms as candidate
biomarkers in human cancer cachexia.
A small number ofpreliminary studies have related single
nucleotide polymorphisms in a variety of pro-inflammatory
cytokine genes to the presence of systemic inflammation,
cachexia and accelerated demise in advanced cancer [6, 12].
These studies will now be reviewed in detail.
Deans et al. [12] have recently evaluated the role of a
variety of pro-inflammatory and anti-inflammatory cytokines
in the genesis of systemic inflammation and adverse prognosis
in patients (n=203) with oesophago-gastric cancer. The IL-6
174CC polymorphism was found to be associated with both
systemic inflammation and high levels of intra-tumoural
cytokines. In turn, the presence of systemic inflammation
was related to adverse prognosis. The 1082GG polymorphism
in the IL-10 gene was also related to systemic inflammation
and adverse prognosis. Thus, polymorphisms in the IL-6 and
the IL-10 genes were candidates for disposition to cachexia.
In contrast, the 308AA polymorphism in the TNFa gene was
associated with adverse prognosis but did not relate to
systemic inflammation or intra-tumoural cytokine levels.
Finally, the 51 ICC polymorphism on the IL-1|3 gene was
found not to be associated with tumour cytokine levels,
systemic inflammation or adverse prognosis. The main
drawback of this type of study is that, although a potential
mechanism (systemic inflammation) and effect (shortened
survival) of cachexia was examined, the actual development
of wasting was not documented. In contrast, a recent study of
advanced gastric cancer patients («=214) from China [54]
demonstrated that patients with the IL-1(3+3954 T allele
showed an increased prevalence of cachexia (relative risk of
developing cachexia increased by a factor of 2.5).
Patients with pancreatic cancer have a very high incidence
of cachexia and have been studied in relation to poly¬
morphisms within both the IL-1 [3 gene and TNF gene [6,
7], TNF-308 and TNFB and were not found to relate to
enhanced peripheral blood mononuclear cell IL-1 produc¬
tion, systemic inflammation or adverse prognosis. In
contrast, the IL-1 (3 2/2 polymorphism was related to all
three. There was, however, no specific measurement of
cachexia in these studies.
Finally, in relation to COPD cachexia, a recent study has
demonstrated that polymorphisms of the IL-1 (3-511 SNP are
associated with the development of cachexia [10]. However,
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polymorphisms on the TNFa gene, the IL-10 gene and the
IL-6 gene did not relate to cachexia or the development of
systemic inflammation.
Anti-inflammatory cytokine genotype
If there are polymorphisms that lead to a pro-inflammatory
cytokine genotype, it would be logical to expect that certain
polymorphisms would favour an anti-inflammatory cytokine
genotype.
There are studies that demonstrate increase of anti¬
inflammatory cytokines in the plasma due to polymorphisms
in the anti-inflammatory cytokine genes [20, 34], However,
there is a paucity of studies linking these polymorphisms to
cachexia or resistance to cachexia.
Available studies have looked at survival and not the
actual development of cachexia. Vuoristo [49] examined 108
patients with melanoma and found that the IL-10 poly¬
morphisms -1082A, -819T and -592A formed a haplotype,
which confers longer survival. In patients with renal cell
carcinoma, a study («=80) found that individuals homozy¬
gous for the IL-4 polymorphisms -589C and -33C formed a
haplotype that increased survival duration [24].
Muscle atrophy genes ('atrogenes')
Recent studies of the Belgian Blue strain of cows, which
develop grossly enlarged muscles, have revealed this
phenotype to be due to a mutation in the myostatin gene
[28]. A similar syndrome in children has also been linked to
a similar mutation [36], This has highlighted the potential for
genetic variation in either the hypertrophy or atrophy
pathways within skeletal muscle to account for a predispo¬
sition either to the presence of a high or low muscle mass.
Such genes are therefore candidates for a pro-cachectic
genotype. However, although a number of array studies have
linked differential expression of these genes with models of
muscle atrophy [32], there are no specific studies in relation
to human cancer cachexia.
Conclusion
There are a wide range of potential biomarkers (derived from
different body compartments) for the cachexia syndrome.
Probably the most robust at present is the inflammatory
marker CRP measured in plasma or serum. As such, there is
a reasonable argument to explore genetic predisposition to
systemic inflammation and the development of cancer
cachexia. Other target genes may be involved such as those
of skeletal muscle atrophy pathways. Different patterns of
genes are likely to be involved in different tumour types
associated with cancer cachexia and in different benign
diseases associated with the cachectic process.
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Purpose of review
Cachexia is a progressive deterioration of body habitus associated with certain chronic
diseases (e.g., cancer, chronic obstructive pulmonary disease, chronic heart failure,
and chronic kidney disease). The aim of this article is to describe the prevalence and
impact of cachexia (and precachexia) in such patients.
Recent findings
Owing to the wide spectrum of clinical presentation and lack of an 'all-inclusive'
definition, it is difficult to estimate the true prevalence of cachexia. Perhaps 2°/o of the
population suffer from precachexia (characterized by weight loss in association with
a chronic disease). The significant increase in obesity of the general population
(which can mask significant muscle wasting) confounds such simple estimates of the
true prevalence of cachexia. In contrast, a multidimensional characterization of the
cachectic state (including weight loss, reduced food intake, and systemic inflammation)
may be more meaningful in terms of altered clinical outcomes. Such a multidimensional
view of cachexia has been shown to impact on patients' survival and quality of life and
therefore constitutes a major public health issue.
Summary
There is a high prevalence of (pre)cachexia in patients with chronic diseases. The
cachexia syndrome is probably less frequent but has a significant impact in terms of
morbidity and mortality.
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1363-1950
.. .the shoulders, clavicles, chest and thighs melt away.
This illness is fatal...
(Hippocrates 460-370 BC)
Introduction
Cachexia is a complex syndrome that combines weight
loss, loss of muscle and adipose tissue, anorexia, and
weakness [1]. The origin of the term 'cachexia' is from
the Greek words kakos (bad) and hexis (condition or
appearance) and throughout medical history has been
associated with the gravely ill patient.
Cachexia significantly impairs quality of life (QoL) and
response to treatment and is associated with increasing
morbidity and mortality. Cachexia typically manifests in
chronic diseases such as cancer, chronic obstructive
pulmonary disease (COPD), chronic heart failure
(CHF), and chronic kidney disease (CKD) [1], The
aim of this article is to describe the prevalence of
cachexia (and precachexia) in such chronic diseases
and the impact of cachexia on patients' function and
survival.
1363-1950 © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins
Precachexia versus the cachexia syndrome
Every journey begins with a single step and it is import¬
ant to remember that cachexia represents a spectrum.
Patients may first notice simple weight loss and then
progress through degrees of severity to the point where
they are depleted of energy reserves (fat), have gross
muscle wasting, are immunocompromised, and will die
primarily as a result of these issues (Fig. 1). When trying
to describe cachexia and its impact, the initial phase
(precachexia) may have little impact, whereas the
advanced phase (cachexia syndrome) will impact on both
quality and quantity of life. In a recent study of patients
with advanced pancreatic cancer [2], we have sought to
define the features of cachexia that impact on patients'
function and survival. Three key features were identified:
weight loss (>10%), systemic inflammation (C-reactive
protein >10mg/l), and reduced food intake (<1500kcal
per day). When patients were grouped according to
weight loss alone, nearly 80% fell into this category yet
this did not define patients with altered body composition
or reduced subjective functional health status. In con¬
trast, when grouped according to the presence of all three
factors, patients demonstrated reduced lean body mass,
reduced objective and subjective indices of function,
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Figure 1 The cachexia journey
Normal Mild Moderate Severe Death
cachexia cachexia cachexia
Weight Below Muscle
loss ideal body wasting
weight obvious
Not all patients progress along the entire pathway.
and reduced health status. Importantly, the number of
patients who fulfilled the three-factor profile was only
about 20% of the total population (Fig. 2). Thus, although
the prevalence of cachexia may be less when considered
in a more multidimensional form, its impact on the
patient is more devastating.
Equally not all patients will progress down the full
cachexia spectrum. Some may die of their primary disease
before they develop advanced cachexia, others may
stabilize as a result of treatment of their primary disease
or due to other clinical factors that preclude further
progression. Such heterogeneity makes it particularly
difficult to target prophylactic therapy successfully. Pro¬
phylaxis would be best initiated in the precachexia phase,
yet there are few robust predictors to guide such strategy.
The situation is made even more complex when one
considers that a substantial portion of the patients 'at risk'
will be obese initially (see later). Weight loss in obese
patients (or any group) may simply reflect increasing
severity of the underlying disease. As such, early weight
loss will indicate increased risk of morbidity/mortality,
but it will not necessarily indicate those who are going to
develop advanced cachexia.
Prevalence of precachexia
Considering the United States (population of approxi¬
mately 290 million) as a representative country for
Figure 2 Prevalence of cachexia in patients with unresectable
pancreatic cancer according to components of a multi¬
dimensional definition of cachexia
Percentage 90%
of
Weight loss 2 of 3 All 3 factors
alone factors
The three-factor profile of cachexia consists of weight loss (>10%),
reduced food intake (<1500kcal per day), and presence of systemic
inflammation (C-reactive protein >10mg/l). Adapted from [2].
the Western World, the approximate prevalence of
the four major chronic diseases associated with cachexia
are presented in Table 1. Together some 30.5-
34.5 million patients suffer from cancer, COPD,
CHF, and end-stage renal failure (ESRF). Using
recently published definitions of (pre)cachexia [3—6],
approximately 5-5.7 million patients are likely to suffer
from (pre)cachexia, giving a prevalence in the general
population of approximately 2%. Clearly this estimate
is open to many confounders that make it either
an overestimate (e.g., patients having both COPD
and cancer) or an underestimate (failure to include
children or rarer diseases associated with cachexia).
More fundamental issues affecting the accuracy of this
estimate include the lack of a uniform definition for
cachexia and considerations whether the general
increase in obesity in the general population is leading
to inappropriate patients being considered as having
cachexia.
Table 1 Prevalence of (pre)cachexia in United States (total population =290 million)
Number in United States (millions) Risk index Number at risk (millions)
Cancer 11-13 WL > 5%a 2.4-2.9
COPD 15-16 FFMI: men <16, women <15b 2-2.1
CHF 4-5 WL>6%° 0.5-0.6
ESRF 0-4 MISd 0.1
Total 30.5-34.5 5-5.7
CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; ESRF, end-stage renal failure; FFMI, fat free mass index; MIS, malnutrition
inflammation score; WL, weight loss.
"Data from [3].
b Data from [4],
c Data from [5].
dData from [6].
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Figure 3 Risk factor paradox in chronic disease
When patients develop certain chronic diseases (e.g., cancer, COPD, CHF or ESRF), the risk ofmortality can be paradoxically lower in high BMI categories.
CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; ESRF, end-stage renal failure; LBM, lean body mass. Adapted from [7**].















Obesity, reverse epidemiology, and the nature
of the risks associated with weight loss
In epidemiology of the general population, the relation¬
ship between the risk of mortality and BMI is U-shaped
with increased risk associated with either very low BMI
(cachexia) or very high BMI (morbid obesity). However,
emerging data indicate that once patients have devel¬
oped certain chronic diseases (e.g., cancer, COPD, CHF,
ESRF), conventional risk factors such as obesity are
associated paradoxically with better survival [7**]
(Fig. 3).
There is no doubt that patients with the chronic diseases
normally associated with cachexia are becoming increas¬
ingly obese. For example, despite a predicted prevalence
of weight loss affecting nearly 50% of patients [8], those
newly diagnosed with incurable cancer commonly have a
mean BMI higher than 25 [9]. When such obese persons
lose weight, their reduced risk of mortality may move
back towards the mean, but the nature of their risk is
surely different from that of the severely wasted indi¬
vidual (Fig. 4) and the specifics of therapeutic interven¬
tion are also likely to be different. Indeed, in the obese
population, it might be said that if the increased risk of
early weight loss reflects increased severity of the
patients' primary disease, then nutritional intervention
would have little role in the management of such
patients.
However, the above discussion represents an oversim¬
plification. It is well known that in obesity, a small degree
of weight loss can mask a proportionately higher loss of
skeletal muscle mass [10]. This has been shown recently
by Baracos and coworkers (personal communication) who
demonstrated that in advanced cancer patients with a
mean BMI of 25.5, the prevalence of sarcopenia in those
below the mean BMI approaches 80%. Separating out
'who' is at risk from 'what' remains a major challenge for
the characterization of patients at risk from cachexia.
Prevalence of (pre)cachexia in specific
diseases
An estimate of the extent of (pre)cachexia in various
chronic diseases is presented below.
Cancer
Approximately one quarter of all deaths in Western
Society are due to cancer. Half of all patients with cancer
lose some body weight; one third lose more than 5% of
their original body weight and up to 20% of all cancer
deaths are caused directly by cachexia (through immo¬
bility, cardiac/respiratory failure) [11*]. The incidence of
weight loss upon diagnosis varies greatly according to the
tumour site (Fig. 5). The greatest incidence ofweight loss
is seen among patients with solid tumours, for example,
gastric, pancreatic, lung, colorectal, and head and neck
[12]. Eighty percent of the patients with pancreatic
cancer have at least 10% weight loss at diagnosis and
the cachexia syndrome is present in 25% [2]. The overall
prevalence of weight loss in cancer patients may rise as
high as 86% in the last 1-2 weeks of life [8].
Chronic heart failure
Approximately 1.5-2% of the population in the United
States suffer from CHF [13]. The prevalence of CHF
rises nearly exponentially with age, from 0.02 per 1000
population per year in those aged 25-34 years to 11.6
in those aged 85 years or older [14*]. Although every
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•Resistant to energy depletion
•Relatively excess LBM
•?Endotoxin resistant
•Near complete energy depletion
•Near hypostatic pneumonia
•Immunocompromised
Obese patients who lose 10% of their body weight may not have significant nutritional sequelae, but their mortality risk may increase as a result of their
primary underlying disease. In contrast, wasted patients who lose 10% of their body weight may die as a result of protein-calorie malnutrition.
clinician is familiar with the classical 'skin-and-bone'
appearance of a small group of patients with end-stage
mitral valve disease, modern drug trials have revealed a
potentially greater population of cardiac patients at risk
from weight loss.
Using a cut-off of more than 7.5% weight loss over a
period of at least 6 months, 28 out of 171 patients (16%)
with CHF have been diagnosed as 'having cachexia' in a
pilot study [15]. The observed weight loss in these
28 patients ranged from 9 to 36%. In a retrospective
analysis of the SOLVD treatment trial [5], 702 of
1929 CHF patients (36%) with a weight loss of more
than 6% were identified as being at increased risk of
mortality. Unfortunately, these studies probably only
reflect the prevalence of precachexia (based on weight
loss). So far, there is no longitudinal nutritional data to
record the proportion ofCHF patients that complete the
'cachexia journey'.
Chronic obstructive pulmonary disease
There are approximately 15 million patients with COPD
in the United States [16]. Weight loss in patients with
COPD is associated with muscle weakness, diaphrag¬
matic dysfunction, respiratory failure, poor QoL and
death [17].
In a study of 389 patients with COPD [18], 27% were
found to have nutritional depletion [i.e., BMI <21 kg/m2
and/or fat free mass index (FFMI) <15 kg/m2 (women) or
<16 kg/m2 (men)]. Using the same cut-offs to define
cachexia, Schols et al. [4] showed that the prevalence of
cachexia is much higher in severe COPD [Global Initiat¬
ive for Chronic Obstructive Pulmonary Disease (GOLD)
stage IV], In a more recent study [19], 33% of patients
with COPD were found to have cachexia (weight loss
>7.5%). However, the interpretation of these prevalence
values is limited by the use of simple weight loss in a
population that is often obese.
COPD is a unique disease associated with cachexia, as
there is grade A evidence to show that the cachexia
syndrome can be treated successfully as part of a multi¬
modal rehabilitation programme [20],
Chronic kidney disease
It is estimated that over 1.1 million patients with ESRD
currently require maintenance dialysis worldwide [21].
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Figure 5 Frequency and severity of weight loss in patients with advanced cancer attending for outpatient chemotherapy
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This number is increasing at a rate of 7% per year, and is
expected to exceed 2 million by 2010 [21].
In patients with advanced CKD and those on dialysis,
there is a high prevalence of protein-energy malnutrition
of up to 40% or more [22]. The term malnutrition-
inflammation—cachexia syndrome (MICS) has been
coined to reflect the high prevalence of malnutrition,
inflammation, and wasting in patients with CKD [23].
MICS is reported to have a prevalence of 30-60% [24**].
It is, however, unclear to what extent the increased risk of
mortality for patients with MICS comes from systemic
inflammation perse versus any specific nutritional deficit.
Impact of cachexia
The following section describes the impact of cachexia in
terms of increased morbidity and mortality, as well its
socioeconomic consequences.
Impact on survival
Based on the three-factor profile (weight loss, reduced
food intake, and systemic inflammation) of cancer
cachexia syndrome, we have noted that pancreatic cancer
patients who met at least two of the components had a
significantly worse prognosis [2]. Alternatively, in a study
of patients with oesophageal cancer, we have found that
weight loss of more than 2.75% per month is an inde¬
pendent prognostic indicator of decreased survival [25],
Paradoxically, high levels of absolute weight prior to
diagnosis and substantial weight gain following diagno¬
sis/treatment are associated with decreased survival in
patients with breast cancer [26]. Thus, the impact of
cachexia on cancer survival and the factors that contribute
to such risk are probably tumour-type specific.
In a group of 171 patients with CHF, Anker et al. [15]
demonstrated that the 'cachectic state' is an independent
risk factor for poor outcome with a mortality rate after 18
months of 50% compared with 17% in patients without
cachexia. In patients enrolled in the SOLVD trial
(« = 1929), the poor outlook for weight-losing CHF
patients was confirmed. Weight loss of more than 6%
at any time was the strongest predictor of impaired
survival [5].
In patients with COPD, survival is significantly
decreased in patients with cachexia and muscle atrophy
[4], A low FFMI appears to be an independent prognostic
factor leading to reduced survival [4],
Kalantar-Zadeh et al. [6] have developed a quantitative
score as an indicator of MICS. The malnutrition inflam¬
mation score (MIS) utilizes seven components of the
conventional Subjective Global Assessment of Nutrition
(SGA) and combines it with three new elements [BMI,
serum albumin, and total iron binding capacity (TIBC)].
In 378 patients, those who were in the highest quartile for
MIS, survival was significantly reduced [6]. A more recent
study confirmed that low BMI is associated with greater
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Figure 6 Symptom prevalence in patients with incurable cancer
(/i = 25 074)
Derived from [8].
mortality in patients with CKD not yet on dialysis
therapy [27].
Impact on quality of life
Cachexia has a detrimental effect on a patient's QoL.
Patients with cancer cachexia report altered body image,
which impacts their emotions, spirituality, relationships,
and social functioning. Lives are restricted and isolated,
which is compounded by emotional distancing by carers
and healthcare professionals [28*]. These patients also
experience anorexia and increased fatigue (Fig. 6) [2,8].
Overall, this results in decreased performance status and
QoL indices [29*]. COPD, CHF, and CKD patients with
cachexia report similar decrease in QoL [30**,31,32].
The devastating effect of cachexia is further character¬
ized by considering the free-living physical activity
of patients. We have recently characterized patients
using an electrical activity monitor worn over a period
of 1 week. Patients with cancer cachexia demonstrate a
40% reduction in the level of physical activity [33].
Impact on treatment
Cachexia has a significant impact on cancer treatment.
DeWys et al. [12] defined weight loss of more than 5%
prior to the onset of chemotherapy as the defining point
for risk of poor response to therapy and shortened survi¬
val. A separate study in patients with lung cancer showed
that patients with weight loss more frequently failed to
complete at least three cycles of chemotherapy and had
decreased survival duration [34].
Moderate exercise training has been shown to improve
exercise capacity in patients with CHF by reversing
muscular metabolic abnormalities and atrophy as well
as impaired blood flow and neurohormonal abnormalities
[35]. However, due to inability to mobilize, the benefits
of exercise are probably not an option for patients with (at
least) severe cachexia.
Maintenance treatment for many patients with COPD
consists of corticosteroids. In patients with established
pulmonary cachexia, muscle wasting secondary to treat¬
ment with steroids affect the respiratory muscles whose
consequent weakness further exacerbates respiratory
failure, prevents weaning from ventilators, and impairs
outcome of treatment during acute exacerbations [36],
Elements ofMICS have been shown to blunt the respon¬
siveness of anaemia to recombinant human erythropoie¬
tin (EPO) in CKD patients [37],
Cachexia and costs to society
The economic costs of cachexia extend much further
than the costs of therapeutic diets, nutritional supple¬
ments, medications, laboratory tests, and supplies. Staff
salaries, service costs, and other indirect medical costs
related to the provision of medical care must also be
included. Unfortunately, it is difficult to assess accurately
the financial costs of cachexia due to paucity of data. The
extent of the problem can, however, be highlighted by
examining the conditions in which cachexia is prevalent.
Estimates for overall yearly costs of chronic diseases such
as cancer, CHF, COPD, and ESRF in the United States
exceed $286 billion [13,16,38,39]. These include approxi¬
mately $25 billion in indirect morbidity costs (cost of
lost productivity due to illness) and $120 billion in
indirect mortality costs (cost of loss of productivity
due to premature death).
Less apparent are the costs associated with managing the
consequences of involuntary weight loss. Involuntary
weight loss is associated with anaemia, postural hypoten¬
sion, cognitive dysfunction (i.e., confusion and impaired
cognition), falls, and hip fractures [40]. Pressure ulcers are
another frequent complication seen in patients near the
end of the 'cachexia journey' [41]. Currently, billions of
dollars are spent each year to treat these complications.
For example, the total direct cost of falls is approximately
$20 billion and the estimated cost of pressure ulcer
management is currently about $7 billion annually
[42,43],
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Conclusion
In summary, (pre)cachexia (at least defined by weight
loss) is present in approximately 2% of the general
population. Weight loss in obese patients is associated
with increased risk of mortality, which is probably due
partly to increased activity of the underlying disease and
partly to the development ofwasting. Cachexia syndrome
(in its more multidimensional form) is probably some¬
what less prevalent but associated with greater functional
impairment. In all chronic diseases, the development of
cachexia carries a significant worsening of an often grave
prognosis and has a clear impact on at least the physical
function domains of QoL.
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Imaging, Diagnosis, Prognosis
Sarcopenia in an Overweight or Obese Patient Is an Adverse
Prognostic Factor in Pancreatic Cancer
Benjamin H.L. Tan,1 Laura A. Birdsell,2 Lisa Martin,2 Vickie E. Baracos,2 and Kenneth C.H. Fearon1
Abstract Purpose: The average weight-losing pancreatic cancer patient undergoing palliative
therapy is frequently overweight rather than underweight, and this can confound con¬
ventional measures used for risk stratification. The aim of this study was to evaluate if
weight and body composition, specifically sarcopenia, assessed from diagnostic com¬
puted tomography (CT) scans, is of prognostic value in patients with pancreatic cancer.
The nature and extent of tissue loss over subsequent months was also evaluated.
Experimental Design: A total of 111 patients entering a palliative therapy program, who
had CT images and had undergone nutritional screening, were studied. In patients for
whom folluw-up scans were available (n = 44), longitudinal changes in body composi¬
tion were studied at a mean of 230 ± 62 and 95 ± 60 days prior to demise.
Results: Sixty-two patients (55.9%) were sarcopenic, 44 (39.6%) were overweight/
obese, and 18 (16.2%) were both. Age s59 years (hazard ratio, 1.71; 95% confidence
interval, 1.10-2.66; P= 0.018), and overweight/obese sarcopenia (hazard ratio, 2.07; 95%
confidence interval, 1.23-3.50; P = 0.006) were identified as independent predictors of
survival on multivariate analysis. Longitudinal analysis revealed that total fat-free mass
index decreased from 15.5 ± 2.5 kg/m2 to 14.5 ± 2.0 kg/m2 (P= 0.002), and total fat mass
index decreased from 7.5 ± 2.0kg/m2 to 6.0 ± 1.5kg/m2 (P< 0.0001) over 135 days.
Conclusions: Sarcopenia in overweight/obese patients with advanced pancreatic cancer
is an occult condition but can be identified using CT scans. This condition is an indepen¬
dent adverse prognostic indicator that should be considered for stratification of patients'
entering clinical trials, systemic therapy, or support care programs. (Clin Cancer Res
2009;15(22);6973-9)
Pancreatic cancer is the fourth leading cause of cancer-related
death in Western countries (1). At the time of diagnosis, tumor
resection with curative intent is only possible in 10% to 15% of
subjects (2, 3), leaving a large population with poor prognosis
and limited therapeutic options. Overall, the 5-year survival
rate is only about 4% (4).
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One of the most distressing features of pancreatic cancer is
marked and progressive weight loss. Cachexia occurs in up to
80% of deaths in patients with advanced pancreatic cancer
(5). Cachexia has been shown to worsen prognosis and has also
been associated with impairment of physical function, in¬
creased psychological distress, and low quality of life (6, 7). Pa¬
tients with pancreatic cancer often report a decreased dietary
intake and many symptoms such as anorexia, early sadety, anx¬
iety, depression, pain, and nausea (8).
Due to the epidemic of obesity in Western society, a substan¬
tial proportion of oncology patients at the start of palliative
therapy now have a body mass index (BM1) in the overweight
range (9), and this can confound conventional measures used
for risk stratification. Indeed recent studies have reported that
obesity (i.e., BMI >30 kg/m2) in the presence of sarcopenia is
predictive of morbidity and mortality in both malignant and
nonmalignant disease (10, 11). The development of novel
methods of image analysis enabling routine derivation of body
composition data from diagnostic computed tomography (CT)
scans (and in particular the esrimation of skeletal muscle mass)
provides an opportunity to assess if measures of body compo¬
sition have any prognostic value in patients with pancreatic
cancer. The present study focused on sarcopenia specifically,
both in the presence or absence of an elevated BMI.
When considering the significance of sarcopenia in a given
population, it is important to know the likely longitudinal
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Translational Relevance
In the present study, patients had a mean body
mass index of 23.9 with 40% of individuals being in
the overweight/obese range. However, underneath
this mantle of adipose tissue the previously noted
tendency to muscle wasting continues. The use of
computed tomography (CT) images in the present
study identified that 56% of patients had sarcopenia
at the time of presentation. This study also shows
that sarcopenia in overweight or obese pancreatic
cancer patients is an independent determinant of
poor prognosis. Routine diagnostic CT scans are a
good resource for detailed nutrition/metabolic assess¬
ment of patients and the identification of overweight/
obese sarcopenia. The presence of overweight/obese
sarcopenia should be considered in the stratification
of patients' entering clinical trials, systemic therapy,
or support care programs.
pattern ofwasting and how this may be altered by concomitant
systemic oncologic therapy. The nutritional and metabolic sta¬
tus of patients who respond to chemotherapy may improve
spontaneously, and a substantial proportion of patients now
receive antineoplastic therapy even in the last weeks of life.
Another aim of the present study was to assess time course
changes in regional body fat and lean tissue compartments by
analyzing CT images in a subset of pancreatic cancer patients
being managed within a regional palliative therapy program.
Materials and Methods
Patients. All patients referred to the regional cancer center in
Edmonton, Alberta, Canada from January 2004 to October 2008 were
considered for the study. Patients with a primary diagnosis of pancreatic
cancer entering a palliative program who had an abdominal CT scan
within 60 d of initial assessment were selected for the study (n = 111).
Patients with ampullary carcinoma, cholangiocarcinoma, or neuro¬
endocrine tumors were excluded. Coding of the primary cancer by its site
and morphology, clinical information, and demographic information
were obtained from the Alberta Cancer Registry for every patient in the
cohort. The Alberta Cancer Registry is a computerized database of all
cancer cases in the region (population 1.8 million). Patient-reported
height, weight, and weight history were collected during this visit by
use of the Patient-Generated Subjective Global Assessment (12). Height
and weight data were subsequently used to compute a common anthro¬
pometric descriptor, BMI (kg/m2). Height and weight recorded by hospi¬
tal staff on the same date were used for verification where available, and
classification ofpatients' BMI with the use ofpatient-reportingwas found
to be accurate. Patient-reported height, weight, and weight history have
been shown to be reliable (13). Stage of disease was based on the
American Joint Committee on Cancer stage groupings I, II, III, and IV.
From the initial cohort of 111 patients, 44 patients were further iden¬
tified who: (a) had had at least one further follow-up CT scan, and (b)
had a documented duration of survival for inclusion into the study of
longitudinal changes of body composition.
CT image analysis. CT scans used for analysis were done solely for
routine cancer care. Two consecutive transverse CT images extending
from the third lumbar vertebrae (L3) in the inferior direction were as¬
sessed for each scan date and then averaged, the foremost image being
the one in which both transverse processes were first clearly visible.
Images were analyzed with SliceOmatic V4.3 software (Tomovision),
which enables specific tissue demarcation using Hounsfield unit
(HU) thresholds. Skeletal muscle was identified and quantified by
HU thresholds of -29 to +150 (14). The muscles in the L3 region con¬
tain psoas, erector spinae, quadratus lumborum, transversus abdominus, exter¬
nal and internal obliques, and rectus abdominus. The following HU
thresholds were used for adipose tissues: -190 to -30 for s.c. and i.m.
adipose (15), and -150 to -50 for visceral adipose (16). Tissue bound¬
aries were manually corrected as needed. Cross-sectional areas (cm2)
were computed automatically by summing tissue pixels and multiply¬
ing by pixel surface area. All CT images were analyzed by a single
trained observer. Cross-sectional area for muscle and adipose tissue
was normalized for stature (cm2/m2) and reported.
Routine diagnostic CT scans usually only evaluate the chest, abdomen,
and pelvis, and therefore only partial images are available to determine
skeletal muscle mass. Estimates of whole body stores were generated
from the raw data (cm2) using the following regression equations by
Table 1. Overall patient demographics, nutritional









Head of pancreas 57 (61.3)t
Body of pancreas 18
Tail of pancreas 4
Pancreatic duct 1










BMI (kg/m2)* 23.9 ± 4.9
Underweight (BMI <18.5 kg/m2) 11 (9.9)
Normal (BMI 18.5-24.9 kg/m2) 56 (50.5)
Overweight/obese (BMI >25 kg/m2) 44 (39.6)
Percentage weight loss (in preceding 12.14 ± 6.35
6 mo)*
Lumbar total muscle cross-sectional 126.0 ± 30.7
area (cm2)*
Lumbar total adipose tissue cross- 243.7 ± 162.3
sectional area (cm2)*
Lumbar skeletal muscle index (cm2/m2)* 43.8 ± 7.9
Lumbar adipose tissue index (cm2/m2)* 86.1 ± 57.4
Estimated total fat-free mass (kg)* 43.9 ± 9.2
Estimated total fat mass (kg)* 21.2 ± 6.9
Sarcopenic 62 (55.9)




NOTE: Values are number of patients with percentages in paren¬
theses unless indicated otherwise.
*Values are mean ± SD.
tUnknown tumor site was excluded from calculation of overall
percentage.
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Mourtzakis et al. (17), which show a close correlation between muscle
and fat areas in CT images at the third lumbar vertebrae and whole body
compartments of fat-free mass (FFM) and fat mass (FM) respectively.
Total body fat-lfee mass (FFM) (kg) = 0.3 x [skeletal muscle at L3 (cm2)] +
6.06 (r = 0.94)
Total body fat mass (FM) (kg) = 0.042 x [total adipose tissue at L3 (cm2)] +
11.2 (r = 0.88)
The respective indexes for FFM and FM (kg/m2) were also reported.
CT dates were expressed in terms of the number of days to death. Any
change in tissue area was expressed as either an absolute change (cm2)
or as a percentage change per 100 days. This provided a standardized
unit and allowed for comparison across different intervals.
Cutoffs for sarcopenia were based on a CT-based sarcopenic obesity
study of cancer patients by Prado et al. (i.e., L3 skeletal muscle index:
<38.5 cm2/m2 for women and <52.4 cm2/m2 for men; ref. 10).
Statistical analysis. Data are presented as mean + SD unless other¬
wise stated. Survival was determined from the time of initial assessment
until death or until the censor date of January 5, 2009.
Univariate and multivariate survival analyses and calculation of
hazard ratios were done using a Cox regression model. Owing to
the large number of covariates examined, only those that were signif¬
icant on univariate analysis were included in multivariate analysis.
Receiver-operator characteristic curves were used to select cutoff values
for continuous variables. Values with the best combination of sensi¬
tivity and specificity were chosen. A backward stepwise procedure was
done to derive a final model of the variables that had a significant
relationship with survival. To remove a variable from the model,
the corresponding P value had to be >0.05.
Comparisons between groups of patients were assessed using one¬
way ANOVA or Pearson's x2 test. Survival curves were constructed
using the Kaplain-Meier technique. Log-rank test was used to compare
survival between groups of patients. Comparison of data at different
time points for body composition analysis was done using the paired
t-test. P values <0.05 were regarded as statistically significant. Statisti¬
cal analysis was done using SPSS 15.0 statistical package (SPSS Inc.).
Results
Details of the 111 pancreatic cancer patients identified at the
time of referral to the cancer center are shown (Table 1). About
Fig. 1. Venn diagram of BMI classes and sarcopenic patients.
two thirds of the patients had tumors at the head of the pancreas.
Approximately 75% of patients had biopsy-proven adenocarci¬
noma. At the time of censoring, 101 patients (91.0%) had
died. Overall median survival was 130 days [interquartile
(IQ) range, 71-302 days]. Percentage weight loss in the preced¬
ing six months was 12 ± 6%, with 89 patients (80.2%) losing
>5% of their normal body weight. BMI at the time of assess¬
ment was 23.9 ± 4.9 kg/m2, and 44 patients (39.6%) were
overweight or frankly obese (BMI >25 kg/m2). Body composi¬
tion parameters of patients are also reported in Table 1. Sixty-
two patients (55.9%) were sarcopenic at this point; 18 patients
were overweight/obese (BMI >25 kg/m2) and sarcopenic. The
prevalence of sarcopenia within the various BMI categories is
presented in Fig. 1.
Patients were then divided into four groups: neither sarcope¬
nic nor overweight/obese, overweight/obese, sarcopenic, and
both sarcopenic and overweight/obese (Table 2). There were
no significant differences in age, sex, tumor site, histology, stage
of disease, and weight loss among the groups.
On univariate analysis, age and overweight/obese sarcopenia
were associated with outcome for the patient group. Over¬
weight/obesity (BMI >25 kg/m2) alone as well as sarcopenia
on its own failed to reach statistical significance for patient out¬
come (Table 3). In contrast, median survival for patients who
were both overweight/obese and sarcopenic was 55 days (IQ
range, 43-207 days) compared with 148 days (IQ range, 80-
369 days) for the rest of the patient cohort without over¬
weight/obese sarcopenia (log-rank test, P = 0.003; Fig. 2). Using
receiver-operator characteristic curves, the cutoff value with the
best discriminatory value for age was >59 years.
On multivariate analysis, age >59 years (hazard ratio, 1.71;
95% confidence interval, 1.10-2.66; P = 0.018) and over¬
weight/obese sarcopenia (hazard ratio, 2.07; 95% confidence
interval, 1.23-3.50; P = 0.006) retained independent prognostic
value (Table 3).
Longitudinal analysis of body composition. A subset of 44
patients underwent repeated CT scans as part of their medical
management and was therefore available for study of longitudi¬
nal changes in body composition. This cohort of patients had a
significantly longer survival compared with the entire group
(median survival, 189 days versus 130 days; P= 0.019, log-rank
test). Seventy-one percent of patients with follow-up CT scans
received active treatment compared with just 28% of patients
who had no follow-up CT scans (P < 0.0001, x2 test). Patients
had their first CT scan at a mean of 230 ± 62 days before death.
The second CT scan was done at a mean of 95 ± 60 days before
death.
The changes in cross-sectional area of skeletal muscle and
adipose tissue between the two scans are presented in Table 4.
Patients displayed a significant loss of both skeletal muscle
and adipose tissue. Overall, 32 patients (72.7%) lost skeletal
muscle and all but one patient (97.6%) lost adipose tissue.
The measurements for cross-sectional area were used to esti¬
mate whole body FFM and whole body FM using regression
equations and then normalized for height (kg/m2; Table 4).
Twenty patients (45.5%) were sarcopenic at the time ofthe first
CT, with an estimated FFM index of 15.5 ± 2.5 kg/m2. By the time
of the second CT, 27 patients (61.4%) were sarcopenic and FFM
had decreased to 14.5 ± 2.0kg/m2. Estimated FM index decreased
from 7.5 ± 2.0 kg/m2 (1st CT) to 6.0 ±1.5 kg/m2 (2nd CT).
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Table 2. Comparison of demographic characteristics and body composition of patients who were neither
overweight nor sarcopenic, sarcopenic alone, overweight alone, and both overweight and sarcopenic
BMI <25 kg/m2 BMI £25 kg/m2 P
Not overweight, Not overweight, Overweight/Obese Overweight/Obese
not sarcopenic sarcopenic (n = 28; 25%) and sarcopenic
(n = 23; 21%) (n = 42; 38%) (n = 18; 16%)
Age (y)
Mean ± SD 60.7 ± 7.5 65.8 ± 10.2 64.3 ± 9.0 66.0 ± 9.3 0.169*
Sex, n (%)
Male 8 (34.8) 20 (47.6) 11 (39.3) 13 (72.2) 0.084t
Female 15 (65.2) 22 (52.4) 17 (60.7) 5 (27.8)
Tumor site, n (%)
Head 8 (34.8) 26 (61.9) 14 (50.0) 9 (50.0) 0.088t
Body 9 (39.1) 3(7.1) 4 (14.3) 2(11.1)
Overlapping lesion 3 (13.0) 3(7.1) 2(7.1) 3(16.7)
Histology, n (%)
Adenocarcinoma 18 (78.3) 28 (66.7) 22 (78.6) 16 (88.9) 0.287+
Stage, n (%)
IV 20 (87.0) 37 (88.1) 28 (100) 18 (100) 0.149t
BMI (kg/m2)
Mean ± SD 22.2 ± 1.9 20.5 ± 2.8 27.6 ± 2.7 28.5 ± 6.3 <0.0001*
% Weight loss
Mean ± SD 12.83 ± 5.80 13.08 ± 6.45 11.36 ± 6.72 10.45 ± 6.24 0.435*
Lumbar total muscle cross-sectional area (cm2)
Mean ± SD 129.5 ± 31.8 115.0 ± 29.2 138.5 ± 29.6 128.0 ± 27.6 0.014*
Lumbar total adipose tissue cross-sectional area (cm2)
Mean ± SD 185.0 ± 137.7 168.8 ± 130.6 344.2 ± 148.0 348.6 ± 155.1 <0.0001*
Lumbar skeletal muscle index (cm2/m2)
Mean ± SD 46.2 ± 7.1 39.3 ± 6.2 49.4 ± 7.3 42.7 ± 6.6 <0.0001*
Lumbar adipose tissue index (cm2/m2)
Mean ± SD 68.4 ± 52.3 57.6 ± 42.0 125.6 ± 55.7 117.1 ± 50.7 <0.0001*
Estimated total fat-free mass (kg)
Mean ± SD 44.9 ± 9.5 40.6 ± 8.8 47.6 ± 8.9 44.5 ± 8.3 0.014*
Estimated total fat mass (kg)
Mean ± SD 19.0 ± 5.8 18.3 ± 5.5 25.7 ± 6.2 24.2 ± 7.7 <0.0001*
*One-way ANOVA.
tPearson's x2 test.
A distinct distribution for muscle and adipose tissue changes
over time is more clearly revealed by analysis of population ter-
tiles (Fig. 3). The overall change of skeletal muscle was -3.1 ±
12.0%/100 days. However, the 1st fertile gained a small amount
of muscle tissue (7.9 ± 14.4%/100 days) whereas the 3rd tertile
lost muscle at a rate of -12.7 ± 5.2%/100 days. In comparison,
adipose tissue was lost across all three tertiles and the overall
change of adipose tissue was -40.4 ± 25.4%/100 days (P <
Table 3. lidAcud idliu fur risk of death associated with clinical variables and body composition in pancreatic
cancer patients (n - 111)
Univariate analysis Multivariate analysis
Hazard ratio 95% CI P* Hazard ratio 95% CI Pf
Age 1.025 1.002-1.048 0.03
>59 y 1.708 1.097-2.660 0.018
Sex 0.793 0.534-1.178 0.25
Tumor site 1.031 0.977-1.087 0.268
Histology 0.791 0.499-1.254 0.32
Stage 1.829 0.910-3.677 0.09
Overweight/obese vs. normal/under weight 1.454 0.969-2.181 0.071
Percentage weight loss 0.991 0.959-1.025 0.599
Lumbar skeletal muscle index (cm2/m2) 1.001 0.976-1.026 0.964
Lumbar adipose tissue index (cm2/m2) 1.003 0.999-1.007 0.153
Sarcopenia vs. no sarcopenia 1.284 0.863-1.910 0.217
Sarcopenia plus overweight/obese vs. other patients 2.177 1.292-3.670 0.003 2.071 1.227-3.496 0.006
Abbreviations: 95% CI, 95% confidence interval.
*Cox univariate analysis.
tBackward conditional method of Cox proportional hazards model.
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Fig. 2. Survival curves of patients with overweight/obese sarcopenia and
patients without overweight/obese sarcopenia.
0.0001, paired t-test). The proportion of patients receiving che¬
motherapy was not significantly different across all three tertiles
ofmuscle (P= 0.372, x2test) or adipose tissue loss (P= 0.804, x2
test). Moreover, the changes in muscle (P = 0.113, Student's £-
test) and fat mass (P = 0.862, Student's t-test) were not signifi¬
cantly different between those who did or did not receive che¬
motherapy. There was also no significant difference in survival
across all three tertiles for both muscle loss (P = 0.142, log-rank
test) and adipose tissue loss (P = 0.542, log-rank test).
Discussion
Patients with pancreatic cancer have long been associated
with the most severe forms of cachexia. In a similar study
undertaken more than 10 years ago, the present authors
documented median BMI at diagnosis to be 20.7, and this fell
to 17.7 near to the time of death (18). Average weight loss over
this time increased from 15% to 25%. Loss ofmuscle and fat to
levels consistent with significant undernutrition increased from
30% to 70% and from 65% to 90%, respectively. This was con¬
sistent with the conventional view of cancer cachexia (i.e.,
marked weight loss, severe muscle wasting and gross loss of s.c.
fat; ref. 19). In the present study, patients had a mean BMI of
23.9 with 40% of individuals being in the overweight/obese
range. Thus, the average physiognomy seems to have changed
with patients showing large energy reserves (fat) at the time of
presentation with advanced disease. However, underneath this
mande of adipose tissue the previously noted tendency to mus¬
cle wasting continued. The use of CT images in the present
study identified that 56% of patients had sarcopenia at the time
of presentation (Table 1) and the tendency to muscle loss con¬
tinued in at least a proportion of patients (Fig. 3).
A BMI <18.5kg/m2 is considered by many authorities to rep¬
resent an individual at serious risk of undernutrition (20). In
the present study, only 10% of individuals at baseline fulfilled
this criterion. Given the prevalence of overweight/obesity
(40%) it would seem unlikely that even in the presence of on¬
going weight loss, the majority would reach this boundary at
or near the time of death. However, BMI has clear limitations,
and more detailed evaluation of body composition clearly re¬
vealed wasting of the lean tissues, with a majority of patients
below or well below benchmark levels of muscularity known
to be associated with mortality and functional disability (21).
The estimated lean body mass of patients classified as sarco-
penic was within the range described for a variety of wasted/
emaciated patient populations with and without malignant
disease (10, 22). In the current literature it is becoming in¬
creasingly evident that concurrent sarcopenia and high fat
mass is a worst case scenario (10, 11, 23, 24), and this was
clearly apparent in our study group (albeit small), in which
sarcopenic overweight/obese patients had the worst prognosis
overall, even compared with patients who were sarcopenic and
had a lower body weight.
There is ongoing controversy as to what the best definition
for sarcopenia is. Mourtzakis et al. have previously shown that
CT cross-sectional area at L3 is strongly related to appendicular
skeletal mass, measured by dual-energy X-ray densitometry,
used commonly in the definition of sarcopenia (17). Subse¬
quent derived cutoffs for sarcopenia, based on CT, used in this
study are in fact close to that described by Baumgartner et al.
Table 4. Change in body composition over time in pancreatic cancer patients (n = 44)
First CT scan Second CT scan A P*
Time to death (d) 230 ± 62 95 ± 60 135 ± 57
Skeletal muscle (cm2) 126.5 ± 31.1 119.6 ± 28.6 -7.0 ± 13.6 0.002
Adipose tissue (cm2)
Visceral adipose tissue 91.2 ± 69.9 45.4 ± 47.0 -45.8 ± 47.5 <0.0001
Intramuscular and subcutaneous adipose tissue 148.5 ± 85.8 87.0 ± 66.4 -61.5 ± 53.9 <0.0001
Total 236.6 ± 145.5 128.6 ± 102.6 -108.0 ± 89.1 <0.0001
Estimated whole body FFM (kg) 44.0 ± 9.3 41.9 ± 8.6 -2.1 ± 4.1 0.002
Estimated whole body adipose tissue (FM) (kg) 21.1 ± 6.1 16.6 ± 4.3 -4.5 ± 3.7 <0.0001
Estimated FFM index (kg/m2) 15.5 ± 2.5 14.5 ± 2.0 -1.0 ± 1.5 0.002
Estimated FM index (kg/m2) 7.5 ± 2.0 6.0 ± 1.5 -1.5 ± 1.5 <0.0001
NOTE: Values are mean ± SD.
*Paired t-test.
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Fig. 3. Intensity of changes in body composition
presented by tertiles. A, skeletal muscle. B, adipose
tissue.
(ref. 22; i.e., appendicular skeletal mass >2 SDs below a young
healthy adult population). Equally, the optimal regression for
conversion of CT image data to conventional units of whole-
body composition measures has yet to be resolved in large pop¬
ulation studies. In the present study, previously reported regres¬
sion equations determined from a heterogeneous group of
cancer patients were used (17).
Sarcopenia alone had no discemable effect on mortality, yet
being overweight/obese and sarcopenic was associated with de¬
creased survival duration. However, a variable can only serve a
predictive function where it varies in the relevant population. It
should be noted that all patients with a BMI <18.5 were sarco¬
penic, and the majority were sarcopenic in the BMI range of
18.5-24.9. Thus, one explanation for the finding that sarcope¬
nia was not predictive for the overall population, but was pre¬
dictive for those with obesity, would lie in the differential
frequency distribution of sarcopenia in the different BMI cate¬
gories. Evaluation of this question in a much larger patient pop¬
ulation would help resolve this issue. There has also been some
evidence that body composition changes in advanced cancer may
have different impacts on survival in males and females (25).
However, the present study was not powered sufficiently to ana¬
lyze the differences in gender due to the small sample sizes. It
would be interesting to evaluate this in a larger population.
In the present study, patients entering the palliative phase of
their pancreatic cancer management had a remarkably high
prevalence of sarcopenia compared with reports in the literature
for healthy elderly in a similar age bracket (22), thereby suggest¬
ing that substantial muscle wasting had occurred prior to initial
evaluation of these patients. The pre-existing nature of this mus¬
cle loss makes it difficult to comment as to its mechanisms, ex¬
cept perhaps to suggest that it may be driven by the primary
malignancy, by weight loss, and/or by comorbid conditions that
include obesity, insulin resistance, various types oforgan failure,
and low levels ofphysical activity. The muscle loss that occurred
thereafter, which was characterized during the 135-days scan-
scan interval, may be driven by disease progression, increased
metabolism, and inflammation (26, 27), and by negative
energy balance that might be inferred from the loss of fat mass
(i.e., 4.54 kg x ~9,000 kcal/kg = 40,840 kcal) in 135 days.
The mechanism that links sarcopenic overweight/obesity
with accelerated demise is not known. Muscle wasting is a
known complication associated with insulin resistance found
commonly in obesity (28). Adipose tissue synthesizes and se¬
cretes circulating hormones and "adipokines" that act as sys¬
temic inflammatory mediators and signals of nutritional
status (29). These adipocyte factors, such as tumor necrosis
factor-a and interleukin-6, are thought to play a major role in
the induction of insulin resistance in skeletal muscle leading to
an increase in muscle protein loss. The main mediators thought
to be involved in this process are inhibitor kB kinase and its
downstream effector NF-kB (30). However, not all patients
who are overweight/obese have sarcopenia. It may be that
cancer-related factors stimulate the initial loss of muscle, and
being overweight/obese perpetuates and/or enhances muscle
loss/loss of muscle function leading to poorer survival. The ob¬
servation that overweight/obesity may be associated with better
survival in patients with weight-losing cardiac failure (31) may
seem to contradict the present observations in cancer patients.
However, the studies in patients with cardiac failure have not
been stratified for body composition (specifically sarcopenia)
and may represent a disease-specific phenomenon.
Current published results on body composition changes in
cancer are varied. Some studies confirm a decline in lean body
mass (32, 33), whereas others emphasize a loss of body fat
(34, 35). There are also reports that suggest a proportional loss
of lean tissue and fat leading to an unchanged body composi¬
tion (36, 37). In the present study, roughly half of the patients
were found to be already sarcopenic at the time of assessment.
Subsequently, a much greater rate of fat loss was noted as com¬
pared with muscle loss (see longitudinal study). In fact, some
patients were able to maintain or even gain muscle mass. The
patients that gained muscle could have been positive respon¬
ded to chemotherapy. However, in patients with pancreatic
cancer, the use of CT scans to determine response to chemo¬
therapy is complicated by factors such as peritumoral inflam¬
mation, therefore duration of survival was regarded as a more
robust measure (accepting the small numbers involved in this
study). In the present study the survival of patients was not
significantly different across all three tertiles of loss of muscle
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mass. Thus, response to chemotherapy as the main reason for
patients to gain muscle mass cannot be confirmed. An alterna¬
tive hypothesis would be that a proportion of patients were
able to activate compensatory mechanisms aimed at conserving
muscle. There is increasing evidence that gene polymorphisms
are related to cancer cachexia susceptibility (38, 39).
Systemic inflammation is known to be a key mediator in ca¬
chexia (40), and has been associated with poor prognosis in
previous studies on pancreatic cancer (41, 42). The present
study lacks uieasuies of systemic inflammation such as C-
rcactivc protein, which may bt significant when assessing
factors influencing survival in pancreatic cancer. Nevertheless,
this study has shown that advanced pancreatic cancer patients
who are both overweight/obese and sarcopenic can be identi¬
fied using diagnostic CT scans. Due to the very short median
survival of such patients (55 days) overweight/obese sarcopenia
should be taken into consideration when planning whether sys¬
temic anticancer therapy is appropriate. Moreover, overweight/
obese sarcopenia should be considered for stratification of
patient's entering clinical trials.
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Abstract
Background: Cancer cachexia is a multi-organ tissue wasting syndrome that contributes to morbidity and mortality
in many cancer patients. Skeletal muscle loss represents an established key feature yet there is no molecular
understanding of the disease process. In fact, the postulated molecular regulators of cancer cachexia originate largely
from pre-clinical models and it is unclear how these translate to the clinical environment.
Methods: Rectus abdominis muscle biopsies were obtained from 65 upper gastrointestinal (UGI) cancer patients
during open surgery and RNA profiling was performed on a subset of this cohort (n = 21) using the Affymetrix
U133+2 platform. Quantitative analysis revealed a gene signature, which underwent technical validation and
independent confirmation in a separate clinical cohort.
Results: Quantitative significance analysis of microarrays produced an 83-gene signature that was able to identify
patients with greater than 5% weight loss, while this molecular profile was unrelated to markers of systemic
inflammation. Selected genes correlating with weight loss were validated using quantitative real-time PCR and
independently studied as general cachexia biomarkers in diaphragm and vastus lateralis from a second cohort (n = 13;
UGI cancer patients). CaMKlip correlated positively with weight loss in all muscle groups and CaMKII protein levels
were elevated in rectus abdominis.T\El was also positively associated with weight loss in both rectus abdominis and
vastus lateralis muscle groups while other biomarkers demonstrated tissue-specific expression patterns. Candidates
selected from the pre-clinical literature, including FOXO protein and ubiquitin E3 ligases, were not related to weight
loss in this human clinical study. Furthermore, promoter analysis identified that the 83 weight loss-associated genes
had fewer FOXO binding sites than expected by chance.
Conclusion: We were able to discover and validate new molecular biomarkers of human cancer cachexia.The
exercise activated genes CaMKIIfl and TIE 1 related positively to weight-loss across muscle groups, indicating that
this cachexia signature is not simply due to patient inactivity. Indeed, excessive CaMKlip activation is a potential
mechanism for reduced muscle protein synthesis. Our genomics analysis also supports the view that the available
preclinical models do not accurately reflect the molecular characteristics of human muscle from cancer cachexia
patients.
Background
Cancer cachexia is a syndrome associated with malignant
tumor disease defined by weight loss, asthenia and
anorexia. Up to half of all cancer patients are affected,
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leading to increased morbidity and poor prognosis [1]
with perhaps 20% of cancer deaths being related to
cachexia rather than direct tumor effects [2]. Cachectic
patients suffer loss of both muscle mass and adipose
tissue (with comparative sparing of visceral protein) and
this tissue loss appears resistant to nutritional support
[3,4]. A PubMed analysis indicates that almost one-third of
documents discussing cancer cachexia are review articles,
highlighting the need for more primary investigations to
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shed light on the detailed mechanisms that produce the
syndrome in patients. Furthermore, most molecular hypo¬
theses have been generated using pre-clinical models or
reflect biochemical concepts [5] and there has been little
progress in relating these potential mechanisms to
changes observed in the patient.
Muscle mass is maintained by physical activity, reflect¬
ing a balance between protein synthesis and degradation.
Intracellular protein breakdown involves the ubiquitin
proteasome pathway (UPP) and the autophagy (lyso¬
somal), caspase, cathepsin and the calcium-dependent
calpain pathways. The individual prominence of each of
these pathways in muscle wasting conditions is still
debated. Many of the molecular signaling pathways that
are postulated to contribute to muscle atrophy in pre¬
clinical models mediate their effects through activation
of the UPP [6]. Identification of two muscle-specific E3
ubiquitin ligases, MuRF-1 and MAFbx/atrogin-1, in a
large number of animal models of atrophy [7,8] has been
used to provide an argument for a major contribution of
the UPP in muscle wasting, such that these genes are now
measured as surrogate indicators of UPP activation. It
should be kept in mind that active tissue remodeling,
even with net protein accretion, may well rely partly on
the protein degradation pathways and, as such, they may
not represent logical surrogates for commenting on net
protein degradation.
In humans, reduced levels of phosphorylated (inactive)
F0X03a have been observed in the skeletal muscle of
cachectic compared with non-cachectic cancer patients,
but an unexplained twofold reduction in the amount of
FOXOl and F0X03a was also observed [9], making the
data challenging to interpret. F0X03 also appears to
induce expression of autophagy-related genes [10-13],
suggesting a link between the lysosomal and proteasomal
systems. However, there is also evidence that the UPP is
first activated with increasing weight loss then declines
as the disease severity progresses [14]. This suggests that
UPP is a marker of protein turn-over rather than wasting
per se (with turn-over increasing as the muscle weakens,
but only while the patient continues to be ambulatory)
or that UPP proteins are not reliable biomarkers.
Furthermore, recent data indicates a dissociation
between protein dynamics in vivo and activation or
expression of the UPP-related signaling molecules in
human skeletal muscle [15]. Overall, it is not clear what
regulates muscle mass in vivo nor is it clear to what
extent protein degradation contributes over inhibition of
protein synthesis [15,16]. Given the paucity of data
derived from cancer cachexia patients, including study
of the UPP and autophagy systems, we sought to carry
out both targeted and global molecular profiling in the
skeletal muscle of cancer patients and relate our findings
to clinical status.
Methods
Men and non-pregnant women over 18 years of age were
recruited to the study from two separate centers. Written
informed consent was obtained from all subjects and
ethical approval received from Lothian Research Ethics
Committee (UK) and the Regional Ethics Committee in
Stockholm (Sweden). Participating patients had a
diagnosis of upper gastrointestinal cancer (esophageal,
gastric, pancreatic) and were undergoing surgery with
the intent of resection of the primary tumor. A small
number of weight stable (WS) patients undergoing
surgery for benign, non-inflammatory conditions (n = 7)
were also included in the analysis. In center 1 (Edinburgh,
UK) a fasting venous blood sample was taken and serum
C-reactive protein measured as a marker of systemic
inflammation (SI). Body mass index (BMI) and mid-arm
muscle circumference were calculated. Clinical details
and degree of weight loss from self-reported pre-illness
stable weight were recorded. A weight loss >5% identified
weight-losing (WL) cancer patients as opposed to weight
stable (WS) individuals. A serum C-reactive protein
>5 mg/1 was used to define the presence of SI. For
patients from center 2 (Stockholm, Sweden) weight and
self-reported change in weight over time were recorded.
Rate of weight loss was therefore used in these subjects.
Due to the small number of controls (otherwise considered
as non-cancer patients but with other co-morbidities) and
the lack of detailed knowledge of their physical capacity,
the primary analysis strategy was chosen to generate
molecular changes that varied with the severity of weight
loss in patients in center 1 and validate such changes in the
independent cohort from center 2 using more than one
muscle type. This strategy was devised to provide a
stringent test of the molecular changes, as the conclusions
are based on a relatively large number of patients with
otherwise similar clinical characteristics.
All biopsies were taken at the start of open abdominal
surgery. In center 1, the edge of the rectus abdominis was
exposed and a 1-cm3 specimen removed using sharp
dissection. The biopsy was snap frozen in liquid nitrogen
and stored at -80°C until further analysis. In center 2,
vastus lateralis muscle biopsies were taken with a
Bergstrom needle and diaphragm biopsies were obtained
by sharp dissection when possible. Both samples were
snap frozen and stored at -80°C for further analysis.
Approximately 20 mg of frozen tissue was homogenized
in 0.5 ml of lysis buffer (Triton - X100 (1%), NaCl (150 mM),
Tris-HCl (50 mM), EDTA (1 mM), PMSF (1 mM),
protease inhibitors (Roche Diagnostics, Burgess Hill, UK);
1 tablet per 10 ml), water to 10 ml) using a Powergen 125
(Fisher Scientific, Loughbourgh, UK)) electric homogen-
izer. Samples were left on ice for 15 minutes prior to
centrifuging at 13,000 rpm for 15 minutes. The super¬
natant was removed, and protein concentration was
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determined by comparing equal volumes of sample
solution to known standards using the Lowry method.
Samples were then stored at -80°C.
Approximately 20 mg of muscle was re-suspended in
180 pi of low salt lysis buffer (10 mM HEPES, 10 mM
KC1,1.5 mM MgCl2,0.1 mM EDTA, 0.1 mM EGTA, 1 mM
DTT, 0.5 mM PMSF, protease inhibitors (Roche Diag¬
nostics; 1 tablet per 10 ml)) and ground using a handheld
homogenizer. Samples were incubated on ice for
5 minutes before two cycles of freeze-thaw lysis. After a
brief vortex, samples were centrifuged at 4,000 rpm for
3 minutes. The supernatant was removed and the pellet
(containing the nuclei) re-suspended in 40 pi high salt
extraction buffer (20 mM HEPES, 420 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 25% glycerol, 1 mM DTT, protease
inhibitors (Roche Diagnostics; 1 tablet per 10 ml)).
Samples were incubated on ice for 30 minutes with gentle
mixing of the tubes every 5 to 10 minutes. Samples were
centrifuged at 4,000 rpm for 5 minutes at 4°C. An aliquot
of supernatant (containing the nuclear proteins) was
stored at -80°C.
Protein from each sample (20 pg) was added to 3 pi of
4 x loading buffer solution (0.5 M Tris-HCl pH 6.8, 20%
glycerol, 4% SDS, 0.05% (3-mercaptoethanol, 0.004%
bromophenol blue) and boiled for 3 minutes. Proteins
were resolved using SDS-PAGE at 160V for 45 minutes.
Proteins were transferred to a nitrocellulose membrane
(80 mA for 1 hour) using semi-dry transfer (Biorad,
Hemel Hempstead, UI<). Membranes were blocked with
either 3% bovine serum albumen/tris-buffered saline
(TBS) with Tween 20 (TBST; 0.05% Tween) overnight at
4°C or with 5% milk/TBST for 1 hour at room tempera¬
ture. Incubation with primary antibody (1:1,000) was
carried out in either 3% bovine serum albumen/TBST or
0.5% milk/TBST solution at room temperature for
2 hours or overnight at 4°C. Membranes were washed
with TBST and primary antibody binding detected using
horseradish-peroxidase conjugated secondary antibodies
(1:2,000 to 1:5,000; anti-mouse, anti-rabbit (Upstate,
Dundee, UK)). Specific signal was detected using ECL
reagent (GE Healthcare, Little Chalfont, UI<) and expo¬
sure on photographic film (Kodak). Films were scanned
and densitometry values estimated using ImageJ (NIH)
software. The primary antibodies used in the study were
against phos-CaMKII(Thr286), FOXOl and FOX03a
(New England Biolabs, Hitchin, UK), Lamin A/C (Insight,
Wembely, UI<), alpha-skeletal actin (Novocaestra,
Newcasde, UI<) and calcium/calmodulin-dependent
protein kinase (CaMK)II (BD Biosciences, Oxford, UK).
Total RNA was extracted from approximately 20 mg of
muscle using TRIzol (Invitrogen, Paisley, UI<) reagent
according to the manufacturer's directions. The RNA
pellet was re-suspended in diethylpyrocarbonate-treated
water and RNA concentration was determined using a
Nanodrop spectrophotometer (LabTech International,
Ringmer, UI<). RNA quality was assessed using 260/280,
230/260 ratios and the RNA integrity number (RIN)
score from the BioAnalyzer 2100 instrument (Agilent
Technologies, Stockport, UK). Total RNA (3.5 pg) was
reverse transcribed and processed according to the
protocol provided by Affymetrix Inc. for the GeneChip
Expression 3' Amplification One-Cycle Target Labeling
and Control Reagents kit (Affymetrix, High Wycombe,
UI<). Reverse transcription and second strand cDNA
synthesis were followed by in vitro transcription and
biotinylation. Biotinylated cRNA products were cleaned
up using columns (Affymetrix). The quality of the
biotinylated cRNA was assessed by Nanodrop (LabTech
International, UI<) and BioAnalyzer (Agilent Technolo¬
gies) instruments and the cRNA was then fragmented
according to Affymetrix protocols. Samples were hybrid¬
ized to the HGU-133plus2 GeneChip array (covering
approximately 54,000 sequences). The raw data files can
be accessed at the Gene Expression Omnibus using the
ID [GEO:GSE18832],
For quantitative real time PCR (qRT-PCR), cDNA was
prepared using 1 pg RNA, TaqMan reverse transcription
reagents (Applied Biosystems, Warrington, UI<) and
random hexamer primers (Applied Biosystems). Primers
were designed to span introns using Primer Express 3.0
software (Applied Biosystems) and constructed by
Invitrogen (Paisley, UI<); primer sequences are detailed in
Table SI in Additional data file 1. Samples were run on an
ABI 7900HT Fast Real-Time PCR system (Applied
Biosystems) in triplicates of 20 pi per well using SYBR
Green PCR Master Mix (Applied Biosystems) as per the
manufacturer's instructions. Expression levels were
normalized to ribosomal 18S RNA and results examined
using the ACt method [17], SPSS (SPSS Inc, Chicago, IL,
USA) or GraphPad (GraphPad Software, La Jolla, CA,
USA) statistical software was utilized. Student's two
tailed t-test or one way ANOVA (analysis of variance)
was used to compare means between groups. Log trans-
ormation was used when appropriate. Mann-Whitney
was used for nonparametric analysis. Contingency tables
were constructed where relevant and analyzed by Fisher's
exact test. Statistical significance was set at P < 0.05.
Microarray data were analyzed using the Microarray
Suite software (MAS) version 5.0 (Affymetrix). To
improve the accuracy of the gene to probe relationship, a
custom chip definition file (CDF) [18] was used defining
the Affymetrix probes by Ensembl transcript ID. Data
were normalized using MAS5 and robust multi-array
average [19]. Genes called absent on every array by the
MAS5 software were filtered from the data and remain¬
ing genes analyzed using the quantitative function in
significance analysis of microarrays (SAM) [20] imple¬
mented in the Bioconductor suite [21]. Percentage weight
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Microarray analysis: novel genes associated with weight
loss in cancer (centre 1)
The microarray study was undertaken on rectus abdominis
muscle from a subgroup of center 1 patients (Table 2).
Hierarchical and k-means clustering were undertaken
with normalized data, using a gene list where those with
a low standard deviation were removed. No pattern
emerged from this analysis. Using the probe-sets that
detect atrogenes (genes reproducibly detected in pre¬
clinical models of cachexia), which we have previously
demonstrated reliably change in human skeletal muscle
sepsis [27], we carried out hierarchical and k-means
clustering. No pattern emerged from this analysis. Thus,
our first attempted analysis did not yield any data in
support of pre-clinical studies [32] and also demonstrated
that muscle cancer cachexia appears distinct from the
inflammation-driven skeletal muscle remodeling observed
in the intensive care unit [27].
We then identified genes that varied with percentage
weight loss using the quantitative SAM methodology
[20]. In this multiple comparison corrected correlation
analysis, the WS group contained both cancer patients
and three non-cancer controls in order to identify bona
fide cachexia associating genes. SAM identified 74 genes
with a FDR between 0 and 10% (most <5% FDR) that
covaried positively with weight loss, and nine genes with
a FDR between 0 and 10% (most <5% FDR) that covaried
negatively with weight loss (Additional data file 2). Corre¬
lation coefficients (R) for these 83 genes were generated
using Pearson's product moment correlation. Positive
coefficients ranged from 0.82 to 0.57 (P < 0.01), and for
negatively correlating genes, R ranged from -0.74 to -0.65
(P < 0.01). Each relationship was visually inspected by
plotting the data.
Most of the genes correlating with weight loss had not
been associated previously with cachexia in humans or
animal models. Notably, FOXO transcription factors and
the E3 ligases MURF1 and MAFbx were absent from this
list. Simple cluster analysis revealed visual distinction of
patients with <5% reported weight loss from those with
>5% reported weight loss (Figure 1). This Affymetrix-
derived WL gene signature was technically validated by
qRT-PCR of the 9 genes (.APCDD1, CaMKIIfi, EIF3I,
HGS, NUDC, POLRMT, SGK, TIE1 and TSC2). Eight
validated the microarray data, with only SGK expression
being inconsistent with the Affymetrix analysis (Table 3
and Figure 2; Supplemental figure 1 in Additional data
file 3).
Candidate gene approach: analysis of FOXO transcription
factors and components of the ubiquitin proteasome and
autophagy pathways (centre 1)
While the microarray analysis did not yield any evidence
for proteolytic pathways being upregulated, as seen in
intensive care unit patients with the same gene chip
technology [27], investigation of components of these
pathways was nevertheless undertaken in parallel to the
gene-chip study. There was no difference in the nuclear
level of FOXOl and FOX03a protein by western blotting
when patients were grouped according to weight loss.
Expression of the E3 ligases MURF1 and MAFbx was
examined by qRT-PCR and no relationship between
mRNA expression and weight loss was found (data not
shown). The autophagy-related genes GABRAPL1 and
BNIP3 were modestly increased in WL patients com¬
pared to WS patients or controls (fold change = 1.46
versus 1.23 versus 1.07, respectively; P = 0.047). However,
this P-value is unadjusted for the previous array analysis
and may not be reliable. Both genes demonstrated a
positive association with systemic inflammation
(Table S2 in Additional data file 1 and Figure S2 in
Additional data file 3).
Confirmation of genes associated with weight loss in
cancer cachexia (center 2)
To validate the WL gene signature generated in rectus
abdominis muscle from the center 1 cohort, nine genes
were profiled using qRT-PCR (.APCDD1, CaMKIIfi, EIF3I,
HGS, NUDC, SKG, POLRMT, TIE1 and TSC2) in two
additional types of skeletal muscle obtained from cancer
cachexia patients. The significant association between
CaMKII|3 and weight loss observed in rectus abdominis
muscle from center 1 (R = 0.82, P = 0.01; Table 1) was
reproduced (Figure 3a) in both vastus lateralis (R = 0.45,
P = 0.06) and diaphragm muscle (R = 0.5; P = 0.03) from
center 2 patients. In addition, TIE1, which significantly
correlated with weight loss in rectus abdominis (R = 0.67,
P = 0.01; Table 1) demonstrated a similar (Figure 3b)
relationship in vastus lateralis (R = 0.7, P = 0.003) but not
in diaphragm. Given the changes observed for CaMKIIji
mRNA, the protein and phosphorylation level of CaMKII
in all of the rectus abdominis muscle obtained in center 1
was evaluated. Material from a total of 59 patients was
available at the time the analysis was carried out
(recruitment was ongoing beyond the time the microarray
was carried out). Western blotting for both CaMKII
(Figure 3c) and phosphorylated CaMKII (Figure 3d)
revealed a small but significant (P = 0.04 and 0.07,
respectively) increase in WL patients compared with the
expression determined inWS patients and controls.
Gene interaction and promoter analysis
In order to generate valid pathway or ontological
enrichment scores, it is essential to relate the modulated
gene list with the genes detectably expressed in the tissue
of interest and not with the genome as a whole (or the
entire gene-chip content). The nature of the 83-gene WL
gene signature was explored in detail using GO. The
Stephens etal. GenomeMedicine 2010,2:1
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Figure 1. Cluster analysis identifies high and low weight loss groups. Using SAM and limma, 83 genes were identified as correlating with
weight loss. Expression data from these genes were used to drive cluster analysis. This revealed two clusters of subjects; high weight loss (a5%) and
low weight loss (<5%).
highest ranked GO biological process activity from the
DAVID webtool [33] was proline metabolism (P = 0.03).
This was confirmed with the topGO [29] and GOStats
[34] tools in Bioconductor. Proline metabolism has a role
in collagen formation and increased collagen deposition
has been noted in the muscle of cachectic cardiac failure
patients [35]. Network analysis using Ingenuity [30]
revealed several interactions that involve the 83 WL
genes, including a calmodulin kinase gene network
(Figure S3A in Additional data file 3), supporting the wet-
lab data and indicating that CaMKII(3 activation appears
to be a general marker of muscle wasting in human
cancer cachexia. A second illustrative pathway (Figure
S3B in Additional data file 3) features GLUT-4 (glucose
transporter type 4) and interleukin-6, both of which are
implicated in skeletal muscle metabolism [36], This
Stephens etal. Genome Medicine 2010, 2:1
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Table 3. Genes correlating with weight loss
Center 1 (n = 21) Center 2 (n = 13)
Gene-chip RT-qPCR
CC rectus CC rectus Regression CC vastus Regression CC Regression
Gene abdominis abdominis P-value lateralis P-value diaphragm P-value
APCDD1 -0.74 -0.51 0.03 0.26 NS -0.20 NS
CAMk2B 0.82 0.50 0.01 0.45 0.06 0.50 0.03
EIF3I 0.64 0.50 0.02 0.10 NS 0.20 NS
HGS 0.7 0.67 0.00 0.17 NS 0.20 NS
NUDC 0.65 0.72 0.00 0.13 NS 0.0 NS
P0LRMT 0.6 0.51 0.02 0.07 NS 0.0 NS
TIE1 0.67 0.53 0.01 0.70 0.003 0.0 NS
TSC2 0.69 0.47 0.03 0.40 0.1 0.0 NS
Significance analysis ofmicroarrays (SAM) identified 82 genes correlating with weight loss. qRT-PCR validated eight of nine selected targets from this list (correlation
coefficient (CC)). These eight genes were also examined in the cohort from center 2 using RNA extracted from anatomically distinct regions. For each gene the

































Figure 2. qRT-PCR validates array-identified genes covarying
with weight loss. For each of the genes validated by qRT-PCR
Pearson correlation coefficients were generated for expression and
percentage weight loss for both the Affymetrix data and the qRT-PCR
data. All yei les except SGK1 validated the array data. P-values for the
correlations ranged from 0.03 to below 0.01. Yellow indicates positive
correlation: blue indicates negative correlation.
V
network also forms numerous connections with the
glucocorticoid and androgen receptors, which may be
involved in regulating skeletal muscle mass. It should be
noted that despite using a back-ground gene expression
file in Ingenuity [30] for genes only detected as being
expressed in human skeletal muscle (approximately
21,000 probe sets, based on MAS5 present-marginal
calls) the Ingenuity network analysis still included genes
that may not be robustly expressed and should be used in
a qualitative hypothesis generation manner.
Gene sequence analysis of the WL gene-set was carried
out to provide insight into the potential coordinators of
this expression signature. Interestingly, FOXO trans¬
cription binding sites tended to be, if anything,
significantly under-represented in the human cachexia
WL gene set, supporting the wet-lab analysis. Binding
sites for SP1, ARNT.AHR (the hypoxia signaling partner)
and TFAP2A (Transcription factor AP2-alpha or AP2) in
particular, were over-represented in the proximal
promoters of the WL-associated genes (Figure S4 in
Additional data file 3). The analysis further supports the
idea that this list is distinct. Interestingly, the enriched
TF binding sites may function as clock genes, controlling
circadian rhythm [37]. Another strategy for generating
hypotheses for factors that might regulate a set of genes
is to carry out comparative expression analysis [25],
where two physiological studies are contrasted using
global gene chip data. In this case we present data that
patients with greater weight loss do not appear to have a
common overlap with muscle damage, muscle degenera¬
tion in sepsis or muscle remodeling in exercise training
(Figure 4).
Discussion
Cancer cachexia is thought to arise due to an imbalance
of the anabolic and catabolic pathways partly driven by
pro-inflammatory cytokines with consequent loss of
muscle mass (along with an accompanying loss of adipose
tissue). In the present study, the expression of 74 genes
correlated positively with weight loss in cancer cachexia
Stephens et al. GenomeMedicine 2010,2:1
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Figure 3. CAMklip and TIE1 correlate with weight loss in cancer cachexia. In order to validate the findings from the rectus abdominis, qRT-PCR
was used to examine mRNA expression of (a) CAMklip and (b) TIE1 in diaphragm (open circles) and vastus lateralis (closed circles) in a separate
clinical cohort. Correlation plots for mRNA level against rate of weight loss are shown. Correlation coefficients were significant with P < 0.05. CAMkll
protein and phospho-protein levels are increased in subjects with weight loss, (c) Protein levels of CAMkll and (d) phosphoCAMkll were assessed
in the rectus abdominis muscle from center 1 subjects by western blot. Intensity levels were normalized against alpha-skeletal actin and the mean
ratio of CAMkll/actin or phosphoCAMkll (pCAMkll)/actin are shown for subjects with less than (black) or more than (white) 5% weight loss. *P-value
<0.05, one-sided MannWhitney test; n = 59. Error bars represent SEM.
subjects and that of 9 correlated negatively with it.
Validation of these genes by qRT-PCR provided excellent
technical confirmation of the microarray results.
Biological validation of TIE1 and CaMKII|3 expression in
an independent clinical cohort across distinct muscle
groups, along with supportive network analysis, provides
weight to the claim that these are useful markers of
cancer cachexia in humans. Contrary to evidence from
animal models [7,8,11], there were no significant differ¬
ences in expression of the E3 ligases MURF1 and MAFbx,
while FOXO protein activity was unchanged in WL
compared to WS patients. These observations, combined
with the array and promoter analysis, make it seem
unlikely that FOXO transcription factors regulate the
molecular signature of cachexia in human skeletal
muscle, challenging the relevance of the pre-clinical
literature in this field.
Novel human cancer cachexia markers
The significant correlation of CaMKlIfi mRNA expres¬
sion with weight loss along with the small but significant
change in protein levels in rectus abdominis suggests that
CaMKIIp could be directly involved in human cancer
cachexia. CaMKIIfi mRNA also increased with weight
loss in vastus lateralis and diaphragm. The serine/
threonine kinase CaMKII holoenzyme is activated by
Ca2+/calmodulin, leading to autophosphorylation and
maintenance ofCaMKII activity even after the Ca2+ signal
has diminished [38]. CaMKIip is expressed in skeletal
muscle, and levels of the protein as well as its
phosphorylation status and activity increase after
exercise training [39], The relationship between CaMKIip
expression and cachexia observed in the present study
implies that the cancer cachexia profile is not simply
'physical inactivity'. In addition, it has recently been
demonstrated that Ca(2+)-CaM-eEF2I< signaling may be
responsible for acute exercise-induced inhibition of
muscle protein synthesis [40] and it is thus conceivable
that chronic inappropriate activation of this 'endurance
training'-related signaling molecule [24] subdues normal
maintenance of skeletal muscle mass. Additional factors
that could modulate CaMKII activity include alterations
in lipid metabolism [41].
The significant positive correlation for TIE1 mRNA
expression with weight loss in both the rectus abdominis
and vastus lateralis muscle groups supports the idea that
some chronic training-related genes are up-regulated in
cachexia. In animal models TIE1 is required for normal
vascular network development [42] while increased TIE1
mRNA levels in human skeletal muscle in response to
physiological adaptation to exercise training has been
demonstrated [43]. Whilst the ligands and signaling
Stephens etal. GenomeMedicine 2010, 2:1
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Genes altered in eccentric muscle damage
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Figure 4. Gene expression signatures demonstrate lack of
relationship between weight loss and muscle damage, muscle
sepsis and exercise training status.The top 20 most regulated
genes by (a) eccentric muscle damage, (b) muscle obtained from
intensive care unit patients and (c) in response to exercise training
were obtained from three published articles (see Methods). The
mean values for these selected genes were then plotted for patients
in the present study that had either less than or more than 5%
weight loss. As can be observed, no single gene, for each of these
'comparative'conditions, was differentially expressed; thus, the gene
expression profile of cancer cachexia does not resemble muscle
damage, sepsis-induced degeneration or exercise training status.
Error bars represent SEM.
pathways of TIE1 are poorly understood, this receptor
can interact with phosphoinositide 3-kinase and lead to
phosphorylation and activation of Akt, protecting cells
from apoptosis [44], In functional terms, the
up-regulation of TIE1 may therefore represent a
protective mechanism to oppose apoptosis of some
components of skeletal muscle tissue, for example, the
vascular endothelium. TIE1 has also recently been linked
to an in vitro endothelial inflammatory response [45]
while an inflammatory gene signature has been shown to
develop throughout surgical procedures in muscle [46];
thus, it could be argued that some component of our
gene signature may be related to surgery. However, all
biopsies were taken at the earliest point in surgery after
the initial incision.
Furthermore, the correlation of TIE1 expression with
weight loss and the lack of any further appreciable inflam¬
matory signature would argue against this possibility. In
addition, there was no evidence that the muscle profile
was that of damage or that observed with systemic
inflammation associated with multiple organ failure
(Figure 4). It is also notable that (other than TIE1,
CaMKII, CTSA and PRODH) the WL gene signature
does not share similarities with the approximately
500-gene endurance exercise training gene signature [24],
suggesting that the reason for elevated TIE1 and CaMKII(3
remains to be determined. It may be inappropriate partial
muscle activity signaling but clearly is not simply
increased muscle usage (however unlikely that might
have seemed in such patients). However, the increased
CaMKIIfi mRNA levels associated with weight loss
across a range of muscle tissues imply that these muscle
groups develop dysregulation of calcium sensing or are
burdened by greater loading in the face of failing muscle
function connected with, for example, loss of contractile
machinery or impaired energy metabolism [47].
Finally, recent work has clarified two potential calcium-
independent activation pathways for CaMKII. Genera¬
tion of reactive oxygen intermediates can increase or
prolong CaMKII activity, perhaps through inhibition of
protein phosphotases that normally limit CaMKII activa¬
tion [48]. CaMKII has also been implicated in muscle
adaptation through phosphorylation of HDAC5 leading
to MyoD/MEF2-driven differentiation of muscle cells
[49], It is plausible, therefore, that CaMKII activation is a
compensatory strategy in the face of failing protein
synthesis. Alternatively, the CaMKII|3 response may
indicate failure of calcium homeostasis, a factor that
would also activate proteolytic activities such as calpains
and caspases [50,51]. It is thus possible that CaMKIIJl
activation occurs at an early stage of cachexia in humans,
providing an early 'read-out' on altered calcium handling.
Human versus animal-model cancer cachexia markers and
study limitations
Given the robust increase in expression of the E3 ligases
reported previously in various animal models of cachexia
[7,8,32], it is surprising that neither microarray nor
Stephens et al. GenomeMedicine 2010,2:1
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qRT-PCR detected any regulation ofMuRFl and MAFbx.
Furthermore, the 83-gene WL gene signature bore no
resemblance to the Atrogene gene expression signature
[27,32] generated using gene-chips. This is not due to
gene-chip technology being unable to establish parallels
between animal models and humans, as it has previously
been demonstrated that gene expression in skeletal
muscle of intensive care unit patients resembles, in part,
that found in these animal models [27,32]. Indeed, results
of E3 ligase expression analysis from other human models
of cachexia have been contradictory. Studies including
patients following bed rest, amputation for vascular
disease, limb immobilization, chronic obstructive pulmo¬
nary disease, amyotrophic lateral sclerosis and ageing
have demonstrated both increased and decreased expres¬
sion of MuRFl and MAFBx [52-56]. This would suggest
that the ubiquitin E3 ligases do not play the same role in
human cancer cachexia as that previously demonstrated
in animal and cell studies. In lung cancer patients with
mean weight loss of 2.9%, there was no evidence of UPP
activation [57] while other human studies in patients
with gastric cancer and mean weight losses of 5.2% and
5.6% have shown increases in components of the UPP
[58,59]. In the present study we could not find any support
for this finding, despite similar degrees of cachexia.
However, cancer cachexia encompasses a spectrum
progressing from early weight loss through to severe
muscle wasting. The prominence of the individual
proteolytic pathways at different time points along this
spectrum is yet to be determined and one must keep in
mind that during severe tissue wasting, both breakdown
(and of course synthesis) may well be reduced with the
net balance between the two widened.
A role for autophagy in human cancer cachexia has not
been investigated extensively. Increased cathepsin D and
acid phosphatase activity has been demonstrated in
patients with varying tumor types and degrees of weight
loss, suggesting that increased lysosomal activity may
contribute to the development of cachexia [60]. More
recently, lung cancer patients undergoing resection were
shown to have increased levels of cathepsin B mRNA in
skeletal muscle compared with controls [57]. The analyses
examined GABARAPL1 and BNIP3. GABARAPL1 is an
Atg8 homologue important in the formation of the
autophagosome [61] and BNIP3 has been found to play a
predominant role in induction of autophagy in rodent
skeletal muscle [11]. Autophagy can be induced by
starvation of amino acids, which may explain the modest
increase in BNIP3 and GABARAPL1 in patients with SI
where the acute phase response is activated (mobilizing
amino acid from muscle to liver for consumption) and
where food intake may be reduced due to anorexia or
dysphagia. However, no relationship was found between
these genes and patient weight loss.
A limitation of the current study is that we focus on
changes in total body mass and this does not tell us about
the relative contributions from lean body mass and
adipose tissue. Our muscle gene expression clustering
results indicate, however, that there is a skeletal muscle
molecular signature that reflects changes in whole body
mass and it is hard to conceive that this is not somehow
reflecting the changes in the muscle tissue. A further
consideration is adequate control for confounding
parameters, such as inflammation, damage and physical
activity. While these are difficult to directly control, we
produced an analysis to suggest that such processes were
unrelated to our new human muscle cancer cachexia
signature (Figure 4).
Conclusions
Human cancer cachexia is a chronic process and weight
loss is not as rapid and generally not as severe as the
acute muscle wasting observed in animal models. Thus,
the physiological regulators are most likely very distinct
in each scenario. We found increased expression of two
'endurance exercise'-activated genes, CaMKIIfi and TIE1,
across different muscle groups in human cancer cachexia.
Whether these could contribute to a reduction in protein
synthesis remains to be ascertained.
Additional data file 1. Primers used in the study, genes associated
with systemic inflammation and data on autophagy pathway genes.
Additional data file 2. Genes associated with weight loss or
systemic inflammation in cancer cachexia.
Additional data file 3. Figures and figure legends for supplementary
figures referred to in the text.
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Purpose of review
Cachexia is a progressive deterioration of body habitus associated with chronic
diseases. The finding that only a proportion of patients with chronic disease develop
cachexia has prompted studies looking for genetic polymorphisms that may underlie
differential susceptibility. The aim of this review is to explore how inflammation and gene
polymorphisms influence susceptibility to cachexia.
Recent findings
There has been evidence that certain cytokine gene polymorphisms are associated with
cachexia. However, only the IL10 — 1082 G allele, which is associated with an increased
risk of developing cachexia has been replicated in more than one study. Variation in
genes outwith inflammation pathways (e.g. genes involved in protein metabolism) is also
likely to contribute the susceptibility of developing cachexia. The insertion/deletion
angiotensin converting enzyme (ACE) gene polymorphism has recently been linked with
lower lean body mass in cancer patients with cachexia.
Summary
Although there is an increasing body of evidence of genetic susceptibility to cachexia,
most studies so far have only focussed on a small number of polymorphisms and have
small sample sizes. Large-scale candidate gene studies or genome-wide association
studies are required to further elucidate the link between genotype and cachexia.
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Introduction
Cachexia is a complex syndrome that combines weight
loss, loss of muscle and adipose tissue, anorexia, and
weakness [1]. The origin of the term 'cachexia' is from
the Greek words kakos (bad) and hexis (condition or
appearance) and throughout medical history has been
associated with the gravely ill patient. Cachexia signifi¬
cantly impairs quality of life (QoL) and response to
treatment and is associated with increasing morbidity
and mortality. Cachexia typically manifests in chronic
diseases such as cancer, chronic obstructive pulmonary
disease (COPD), chronic heart failure (CHF), and
chronic kidney disease (CKD) [1].
Inflammation in chronic diseases
An organism usually responds to the presence of infec¬
tion, tumour, immunological disorders, tissue injury,
trauma, or surgery by developing an inflammatory
response that may help limit tissue injury. However, in
certain circumstances when the inflammatory response is
prolonged or severe, it can lead to detrimental effects.
The idea that cancer and inflammation are linked has
been around since the hypothesis of Virchow in the 19th
1751-4258 © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
Century [2]. Apart from a role in cancer development and
progression, cancer-associated inflammation may also
contribute to the development of cachexia [3**].
The inflammatory response in the lungs is central to the
structural changes leading to COPD. Studies show that
reduced lung function is associated with elevated systemic
inflammatory factors that increase during exacerbations
[4], and these factors may contribute to the comorbidities
observed in patients with COPD such as cachexia.
Heart failure is associated with elevated circulating levels
of inflammatory mediators. In the Framingham Study,
elderly individuals with no history of myocardial infarc¬
tion or congestive heart failure had a significant increase
in congestive heart failure risk per tertile increment in
cytokine concentration [5]. The presence of a more
pronounced inflammatory response has also been
observed in patients with cardiac cachexia [6].
Inflammation and cachexia are prevalent in patients with
CKD and worsen as the CKD progresses toward end-stage
renal disease (ESRD) [7]. The deterioration of renal
function has been associated with increased serum cyto¬
kine levels and their soluble receptors in patients with
varying degrees of renal failure [8,9**].
: DOI:10.1097/SPC.0b013e32833e4a5d
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The role of inflammation in cachexia
Cachexia is brought about by a synergistic combination of
a dramatic decrease in appetite and an increase in metab¬
olism of fat and lean body mass. Although the specific
molecular mechanisms leading to the development of
cachexia are not fully understood, systemic inflammation
appears to play a central role [10] (Fig. 1). Inflammation
results in a number of metabolic changes that are often
characterized by negative energy balance, increased
thermogenesis and anorexia. These responses are
mediated by cytokines [11,12*].
Anorexia
Cytokines produced during inflammation can affect the
brain by several pathways: they can act on peripheral
tissues producing hormones such as leptin which influence
the activity of the brain; they can act on peripheral neurons
that project to the brain through the vagus nerve; and they
can also directly enter the brain and act locally [13].
Many cytokines are known to have an effect on appetite,
including interleukin (IL)-la, IL-lp and IL-6 as well as
tumour necrosis factor-a (TNF-a) [14], IL-1, in particular,
has been clearly associated with the induction of anorexia
[15], by blocking neuropeptide Y (NPY)-induced feeding.
The levels of this molecule (a feeding-stimulating pep¬
tide) are reduced in anorectic tumour-bearing rats and a
correlation between food intake and brain IL-1 has been
found in anorectic rats with cancer [16],
Increased energy expenditure
Resting energy expenditure (REE) is significantly higher
in those with an elevated acute phase response (APR)
Figure 1 Role of inflammation in cachexia
[17]. The APR is a series of changes in liver protein
synthesis, which shifts from production of albumin to
acute phase proteins (APP), such as C-reactive protein
(CRP), fibrinogen, serum amyloid A, and a-1 antitrypsin,
in response to an insult such as inflammation.
There is a known association between the development
of an APR and the rate of loss of body mass in lung and
gastrointestinal cancers [18], and in patients with non-
small cell lung cancer (NSCLC), serum levels of IL-6
were found to correlate with concentrations of circulating
CRP [19].
Altered lipid metabolism
The multifunctional cytokine, TNF-a exerts a series of
biological actions in different cells, tissues, organs and
species and has been demonstrated to regulate and inter¬
fere with energy metabolism, especially lipid homeostasis.
A large body of research suggest that the effects ofTNF-a
on lipid metabolism mainly include five aspects: suppres¬
sion of free fatty acid (FFA) uptake and promotion of
lipogenesis; induction of lipolysis; inhibition of lipid-
metabolism-related enzyme activity; regulation of choles¬
terol metabolism; and regulation of other adipocyte-
derived adipokines [20*].
Although TNF-a is the first cytokine reported to have
catabolic effects on fat cells, subsequent studies have
shown that multiple cytokines acting through multiple
receptors have similar activities. TNF-(3, interferon-a,
interferon-y, IL-1 and IL-6 decrease lipoprotein lipase
activity and increase lipolysis in cultured fat cells [21].
TNF-f) and both interferons also decrease de-novo fatty
Inflammation is thought to influence pathways leading to skeletal muscle wasting, adipose tissue loss, anorexia, and increased resting energy
expenditure (REE).
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acid synthesis in cultured fat cells [21]. The catabolic
effects of cytokines on adipose tissue triglyceride metab¬
olism have been proposed as a contributor to the devel¬
opment of cachexia [3**].
Impaired protein synthesis
Inflammatory-mediated signalling may limit muscle
protein synthesis by several mechanisms. Inflammatory
cytokines such as TNF-a and IL-6 are likely to play an
important role. TNF-a can activate the transcription
factor nuclear factor-kappa B (NF-kB), which inhibits
the synthesis of the muscle specific transcription factor
MyoD, thereby inhibiting differentiation [22]. In
addition, a recent study found that skeletal muscle
protein synthesis was dramatically reduced by relatively
low-dose IL-6 infusion in humans [23].
Preliminary reports have described marked elevations in
myostatin (a negative regulator of muscle mass that inhi¬
bits myogenic proliferation and differentiation) in cachetic
cancer patients. Animal models suggest that the inflam¬
matory cytokine TNF-a is at least partially responsible for
this increase [24]. TNF-a is also known to influence the
anabolic mTOR signalling pathway, which is a major
mediator of anabolic responses in skeletal muscle [25].
IL-15 is a cytokine that is highly expressed in skeletal
muscle [26]. IL-15 is anabolic in nature and acts by
activation of protein synthesis and concomitant inhibition
of protein degradation in cultured skeletal muscle cells
[27], IL-15 administration in an in-vivo rodent model of
cancer cachexia has been shown to inhibit skeletal
muscle wasting [28], Muscle and serum IL-15 levels
are thought to be reduced in cachexia [29].
Increased protein degradation
Inflammatory stimulation activates pathways associated
with muscle protein breakdown [30*]. In cancer cachexia,
the ubiquitin proteasome pathway is greatly influenced
[31], Many of these effects are thought to occur through
activation of NF-kB by upstream factors such as TNF-a
[32]. NF-kB stimulates transcription of the ubiquitin E3
ligase muscle ring finger (MuRF)-l, which is known to
positively regulate activity of the ubiquitin proteasome
pathway [33].
Genetic susceptibility to cachexia
The finding that only a proportion of patients with
chronic disease develop cachexia has prompted studies
looking for genetic polymorphisms that may underlie
differential susceptibility [34]. The most frequent targets
for these studies have been genes encoding pro-inflam¬
matory cytokines, such as TNF-a and some of the
interleukins. This is based on the hypothesis that con¬
tinued systemic inflammation plays a central role to the
pathogenesis of cachexia (see above).
One of the earliest genetic susceptibility studies by
Broekhuizen et al. [35] found that a —511 polymorphism
in the IL1B gene (rs 16944) correlated strongly with
cachexia in patients with COPD. The C/C genotype at
this position in the gene was associated with frequent
cachexia, whereas the T/T genotype was not associated
with cachexia ('Fable 1).
Table 1 Summary of cytokine gene polymorphisms associated with cachexia
Minor allele frequency8
Gene Polymorphism European Chinese Clinical studies
IL-1B 511T> C [rs16944] 64% 54%
3954C>T [rs1143634] 21% 2%
IL-10 1082G > A [rs1800896] 53% 5%
819C>T [rs1800871] 17% 74%
IL-6 634G > O [rs1800796] 4% 77%
IL-8 781 C>T [rs2227306] 4% 37%
C/C genotype associated with frequent cachexia in patients with
COPD (n = 99) [35]
T allele more prevalent in gastric cancer patients with cachexia;
C/T genotype associated with OR 2.5 of developing cachexia
(n = 214) [36]
Patients with metastatic gastric and GOJ cancer with C/T and T/T
genotype showed greater improvements in weight over time
(n = 44) [37]
G allele associated with increased weight loss in patients with
gastro-oesophageal cancer; G/G genotype associated with OR 2.3
of developing cachexia (n = 203) [38]
G allele more prevalent in gastric cancer patients with cachexia;
A/G genotype associated with OR 2.0 of developing cachexia
(n = 223) [39]
C/C genotype associated with OR 3.4 of developing cachexia in
gastric cancer patients (n = 223) [39]
G allele more prevalent in pancreatic cancer patients with cachexia
(n = 126) [40]
T allele more prevalent in gastric cancer patients with cachexia;
T/T genotype associated with OR 3.0 of developing cachexia
(n = 125) [41]
COPD, chronic obstructive pulmonary disease; GOJ, gastro-oesophageal junction; OR, odds ratio.
"Minor allele frequency data obtained from International HapMap project database (http://hapmap.ncbi.nlm.nih.gov).
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Although this finding has not been confirmed in sub¬
sequent studies, Zhang et al. [36] have found that a
separate polymorphism within the IL1B gene is associ¬
ated with cachexia. Gastric cancer patients in China with
cachexia showed a significantly higher prevalence of the
(rsl 143634) IL1B +3954 T allele than those without, and
the IL1B +3954C/T genotype was associated with an 2.5
times increased risk of developing cachexia (Table 1).
Unfortunately, the reverse association was found in
another study involving patients with gastric and gas-
tro-oesophageal junction cancer [37]. Patients with the
IL1B +3954C/T and T/T genotypes showed greater
improvements in their weight and in survival over time
than did patients with the C/C genotype (Table 1).
We have recently investigated the relationship between
five cytokine polymorphisms and markers of nutritional
status among patients with gastro-oesophageal cancer
[38]. Possession of the (rsl800896) IL10 —1082 G allele
was found to be associated with increased weight loss and
the G/G genotype was associated with a 2.3 times
increased risk of developing cachexia (Table 1). In a
separate study involving patients with gastric cancer in
China, Sun etal. [39] confirmed that the G allele was more
prevalent in patients with cachexia. The study also found
that individuals with the (rsl800871) IL10 —819C/C
genotype were at increased risk of developing cachexia
(Table 1).
A further two cytokine polymorphisms have been associ¬
ated with cachexia. The (rsl800796) IL6 —634 G allele
has been shown to be significant more prevalent in
Chinese pancreatic cancer patients with cachexia com¬
pared with those without cachexia [40] (Table 1). In
patients with gastric cancer in China, the frequency of
(rs2227306) IL8 +781 T allele was noted to be signifi¬
cantly increased in patients with cachexia and the
+781 T/T genotype was observed to be associated with
a significantly increased risk of cachexia [41] (Table 1).
It is perhaps worth noting that the minor allele frequen¬
cies (MAFs) of polymorphisms in the studies mentioned
above vary across different populations (Table 1). MAF
distributions for polymorphisms assessed in the Chinese-
based studies were significantly different in most cases
compared with European populations. These variations
in gene allele frequencies can contribute to differences in
the risk of developing complex conditions like cachexia
among different populations [42*].
Although much attention has been placed on cytokine
polymorphisms and their association with cachexia, it is
important to note that mechanisms surrounding the
pathogenesis of cachexia is complex and is likely to
involve gene products with act both upstream and down¬
stream of cytokines. Pathways not affected by cytokines
may also play a role in the development of cachexia. It is
therefore highly likely that genetic variations in non-
cytokine genes may also contribute to the susceptibility
of developing cachexia. For example, a study by Vigano
et al. [43*] has shown that the angiotensin-converting
enzyme gene {ACE) insertion/deletion polymorphism
(rs4646994) is associated with lower total fat mass and
lean body mass in patients with gastro-intestinal cancer
and NSCLC.
A recent gene microarray study by Stephens et al. [44**]
on muscle samples of cachectic gastro-oesophageal can¬
cer patients revealed 83 new candidate genes associated
with the development of cachexia. Another study on
regulatory gene pathways that accompany loss of adipose
tissue in cancer cachexia revealed 71 downregulated
genes and five upregulated genes [45**]. Variants in genes
discovered in both these studies could well contribute to
the differential susceptibility to cachexia.
The search for altered genes associated with cachexia is
still in its infancy and, even though some associations
have surfaced, cause and effect remains to be established.
The studies are also plagued by a variety of problems, in
particular phenotype misclassification (which is highly
relevant to cachexia where there is no validated definition
of the syndrome). It is worth noting that some studies
have small sample sizes with inadequate statistical power.
In addition, epistatic interaction, and undetected geno¬
mic heterogeneity in the underlying population also exist
[34], Of note, in a recent review of allelic association with
common disease phenotypes, only 6 of 166 associations
subjected to multiple evaluations were confirmed con¬
sistently [46]. Possible causes of false-positive association
studies include population stratification, variable linkage
disequilibrium and genotype misclassification. In
addition, in many of these studies, the possible effects
of single gene variants were assessed in situations when
combined impacts of multiple factors could be expected
[47],
It should also be emphasized that although certain variant
combinations can predispose to a condition, others may
be protective against the same condition. For example,
polymorphisms result in an increase in systemic inflam¬
mation, a decrease in lean or fat mass and decreased
survival in cancer are likely to be more cachexia-prone
variants. On the contrary, polymorphisms that result in a
decrease in systemic inflammation, an increase in body
mass and improved survival in cancer are likely to be less
cachexia-prone variants.
Conclusion
Although there is an increasing body of evidence of
genetic susceptibility to cachexia, most studies so far
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have only focussed on a small number of polymorphisms
and have small sample sizes. It can be assumed that
analysis of combinations of gene variants encoding inter¬
acting factors within a biological chain or cascade, rather
than isolated investigation of its single components, may
have more chances to reveal real causative connections
between gene polymorphisms and phenotypes; there¬
fore, large-scale candidate gene studies or genome-wide
association studies are required to further elucidate the
link between genotype and cachexia.
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Abstract
Cancer cachexia is a polygenic and complex syndrome. Genetic variations in regulation of the inflammatory response, muscle
and fat metabolic pathways, and pathways in appetite regulation are likely to contribute to the susceptibility or resistance to
developing cancer cachexia. A systematic search ofMedline and EmBase databases, covering 1986-2008 was performed for
potential candidate genes/genetic polymorphisms relating to cancer cachexia. Related genes were then identified using path¬
way functional analysis software. All candidate genes were reviewed for functional polymorphisms or clinically significant
polymorphisms associated with cachexia using the OMIM and GeneRIF databases. Genes with variants which had functional
or clinical associations with cachexia and replicated in at least one study were entered into pathway analysis software to
reveal possible network associations between genes. A total of 184 polymorphisms with functional or clinical relevance to
cancer cachexia were identified in 92 candidate genes. Of these, 42 polymorphisms (in 33 genes) were replicated in more
than one study with 13 polymorphisms found to influence two or more hallmarks of cachexia (i.e. inflammation, loss of fat
mass and/or lean mass and reduced survival). Thirty-three genes were found to be significantly interconnected in two major
networks with four genes (ADIPOQ, IL6, NFKB1 and TLR4) interlinking both networks. Selection of candidate genes and
polymorphisms is a key element of multigene study design. The present study provides an initial framework to select genes/
polymorphisms for further study in cancer cachexia, and to develop their potential as susceptibility biomarkers of developing
cachexia.
[Tan B. H. L., Ross J. A., Kaasa S., Skorpen F., Fearon K. C. FI. and European Palliative Care Research Collaborative 2011 Identification of .
possible genetic polymorphisms involved in cancer cachexia: a systematic review. J. Genet. 90, 165-177]
Introduction
Cancer cachexia is a multi-factorial syndrome characterized
by chronic wasting involving loss of both adipose tissue
and lean body mass (LBM). Depending on the tumour type,
weight loss occurs in 30%-80% of the cancer patients and
is severe (with loss of >10% of the initial body weight) in
15% (Dewys et al. 1980). Although certain tumour types
are more commonly associated with cachexia, even with the
same tumour type there are variations in the extent to which
patients exhibit cachexia. Such variation maybe, in part, due
to the patient's genotype rather than the tumour phenotype
and/or tumour interaction. It is therefore likely there may
*For correspondence. E-mail: benjamin.tan@ed.ac.uk.
Keywords, human genetics; polymorphisms; cachexia.
be cachexia prone genotypes as well as cachexia resistant
genotypes.
The cachexia syndrome is thought to result from a com¬
plex interplay of mechanisms involving the initiation of
a host inflammatory response mediated by tumour-derived
proinflammatory cytokines; the reprioritization of protein
metabolism with induction of the acute phase response
and mobilization of fat reserves; and activation of neu¬
roendocrine pathways which may lead to hypermetabolism
and increased catabolism (Tan et al. 2008). The wealth
of known genetic variation in genes regulating the above
mechanisms suggests their exploitable potential as biomark¬
ers of inter-individual predictability of developing cachexia.
Single nucleotide polymorphisms (SNPs) are the most
common type of stable genetic variations in the population
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(Brookes 1999). SNPs occur in approximately one in every
thousand bases. There are several ways that SNPs can lead
to an aberrant gene product. Promoter polymorphisms that
alter DNA binding of transcription factors have the poten¬
tial to decrease or increase gene expression; sequence varia¬
tion in the 5' untranslated region (UTR) could disruptmRNA
translation, and mutations in the 3' UTR could affect mRNA
cleavage, stability and export; finally, nonsynonymous SNPs
in exons could alter protein function or activity. It has been
estimated that 10% ofall SNPs in the genome are functional,
thereby having the potential of altering some biological
process (Wjst 2004).
Over the past 10 years, considerable information has
emerged on mechanisms of cancer cachexia ofwhich inflam¬
mation is postulated to play a significant role. These mech¬
anisms can be broadly grouped into five domains of inter¬
est: systemic inflammation, central energy balance, control
of muscle metabolism/function, control of adipose tissue
metabolism/function, and regulation of appetite.
This systematic literature review aims to explore genetic
polymorphisms with known functional or clinical signifi¬
cance in potential candidate genes involved in the devel¬
opment of cancer cachexia within the above-mentioned
domains. It also aims to identify the polymorphisms with
the most likely potential as susceptibility markers for cancer
cachexia.
Methods
The scientific literature published between 1986 and 2008
was searched in Medline and EmBase databases. In order
to maximize the potential of identifying potential candi¬
date genes, we utilized search terms that took into account
the effects of cachexia. For example, 'survival' as a surro¬
gate for accelerated death which may be due to cachexia.
The term 'body composition' was used to identify poten¬
tial genes of interest that may predispose individuals to
higher/lower body mass which may influence the propen¬
sity to the development of cancer cachexia. 'Inflammation'
was used as a main search term due to its postulated cen¬
tral role in the development of cancer cachexia. Overall,
the following search terms were used to identify poten¬
tial candidate genes/polymorphisms of interest: ((genes/
genetics) or polymorphism(s)) and (inflammation or cancer
or cachexia or weight loss or body composition or survival).
The search was limited to studies on humans, in English
language.
Following the initial retrieval ofpossible candidate genes,
the genes were entered into a pathway functional analy¬
sis software (Ingenuity Pathways Analysis (IPA), Ingenu¬
ity Systems, Redwood, USA) to further identify related
genes.
All identified candidate genes were then reviewed for
functional polymorphisms or clinically significant poly¬
morphism in terms of cachexia using OMIM and GeneRIF
databases. Candidate genes were grouped into categories
according to genes that regulate or code for the following:
• Inflammation
o Innate immune receptors and mediators of the
immune response
o Cytokines
o Cytokine receptors and related binding proteins
o Acute phase protein reactants
• Central homeostasis
o Energy production
o Insulin like growth factors and related proteins
o Corticosteroid signalling proteins
• Muscle




o Lipid turnover and transport
o Adipokines and adipokine receptors
• Appetite
• Others
Summary tables of polymorphisms are also presented
according to each category with 'easy to see' boxes that
denote whether a polymorphism has any effect on inflamma¬
tion, weight/body composition (i.e. lean mass/fat mass) and
cancer survival. The summary tables also denote if a func¬
tional or clinical association with a polymorphism was repli¬
cated in more than one study. In addition, polymorphism ref¬
erence numbers (rs numbers) were also recorded if known,
as well as the minor allele frequency of the polymorphism
based on a population with European ancestry derived from
the HapMap or dbSNP databases.
Pathway analysis
It is likely that single genes are not adequate by them¬
selves to affect disease risk; however, multiple genes within
a single pathway may affect function enough to increase
risk. To provide a more comprehensive assessment in terms
of pathway involvement in cancer cachexia, we performed
pathway-based analyses using the ingenuity pathway analy¬
sis (IPA) software. Based on the systematic literature review,
the genes with variants that had functional or clinical asso¬
ciations replicated in at least one study were entered into
the IPA analysis tool. These genes were termed focus genes.
The IPA software was used to measure associations of these
genes with other molecules, their network interactions, and
biologic functions stored in its knowledge base. Our focus
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genes served as seeds for the IPA algorithm, which rec¬
ognizes functional networks by identifying interconnected
molecules, including molecules not among the focus genes
from the IPA knowledge base. The software illustrates net¬
works graphically and calculates a score for each network,
which represents the approximate 'fit' between the eligible
focus molecules and each network. The network score is
based on the hypergeometric distribution and is reported as
the -log (Fisher's exact test result).
Results
A total of 184 polymorphisms with functional and/or clinical
significance in terms of cachexia were identified in 92 genes.
Inflammation
Inflammation has long been associated with cancer cachexia.
Systemic inflammation could result from tumour cell or host-
cell-mediated production (Stewart et al. 2006). In experi¬
mental models, pro-inflammatory cytokines such as inter-
leukin 1-beta (IL-l/J), interleukin 6 (IL-6), tumour necro¬
sis factor alpha (TNFa), and interferon gamma (IFNy) may
lead to an acute phase response and trigger tissue catabolism
(Argiles et al. 2003).
Innate immune receptors and mediators of the immune response
Table 1 of electronic supplementary material at http://www.
ias.ernet/jgenet/ explores the possible genetic determinants
in the generation or suppression of the inflammatory
response and how they may relate to cancer cachexia. These
include variants in gene coding for the Toll-like receptor
(TLR) family, and associated genes, which play an instruc¬
tive role in innate immune responses as well as the subse¬
quent induction of adaptive immune responses. TLRs are
involved in triggering intra-cellular signals, culminating in
the activation of nuclear factor (NF)-rB, where it partic¬
ipates in enhancing expression of other immuneregulatory
substances (Kawai and Akira 2006). NF-kB is a transcrip¬
tional regulator that plays a central part in responses to
inflammatory signalling. Polymorphisms in genes encoding
for NF-/cB and genes involved in the activation or inhibition
of NF-/cB are also shown in table 1 of the electronic sup¬
plementary material. Also of interest are variants in genes
coding for cell adhesion molecules (CAMs) that are pro¬
teins located on the cell surface involved in binding with
the other cells or with the extracellular matrix. CAMs are
known to mediate migration of cells to sites of inflammation.
Functional polymorphisms in the heat-shock proteins genes
HSPA1L and HSPA1B have been noted in relation to inflam¬
mation and these are also displayed in table 1 of electronic
supplementary material.
Cytokines and cytokine receptors
Cytokines are secreted proteins that play a role in the induc¬
tion and effector phases of all immune and inflammatory
responses. They serve diverse functions including induction
of cell proliferation, mediating intercellular communication,
chemotaxis and cell killing. Genetic variants of genes encod¬
ing pro-inflammatory and anti-inflammatory cytokines are
presented in table 2 of electronic supplementary material.
Cytokines exert their effects via matching cell-surface
receptors. Subsequent cascades of intracellular signalling
then alter cell functions. This may include the upregulation
and/or downregulation of several genes and their transcrip¬
tion factors, resulting in the production of other cytokines,
an increase in the number of surface receptors for other
molecules, or the suppression of their own effect by feed¬
back inhibition (Ihle 1995). Table 3 ofelectronic supplemen¬
tary material summarizes the variations in genes encoding
cytokine receptors and related binding proteins.
Acute phase protein reactants
Acute-phase protein reactants (APPR) are proteins whose
plasma concentrations increase (positive acute-phase pro¬
teins) or decrease (negative acute-phase proteins) in response
to inflammation (Stephens et al. 2008), and are also predic¬
tors ofadverse outcomes in cancer patients. Some APPR also
have roles in modulating the immune response such as C-
reactive protein (CRP). Variants in genes coding for APPR
are shown in table 4 of electronic supplementary material.
Central homeostasis
Body mass is controlled by the balance of energy intake
and expenditure, like all thermodynamic systems. In cer¬
tain forms of cancer, patients with cachexia have been
observed to have much higher resting energy expenditure
(REE) (Fredrix et al. 1991). Gene polymorphisms in the reg¬
ulatory pathways controlling energy intake and expenditure
are discussed below. The following section also explores
genes involved in growth and development, and metabolic
pathways common to both muscle and adipose tissues.
Energy production
Uncoupling proteins (UCPs) are transporters, present in the
mitochondrial inner membrane, that mediate a regulated dis¬
charge of the proton gradient that is generated by the respi¬
ratory chain. This energy-dissipatory mechanism can serve
functions such as thermogenesis, maintenance of the redox
balance, or reduction in the production of reactive oxygen
species (Ledesma et al. 2002). There are a total of five UCP
homologs in humans. There are known significant polymor¬
phisms within three UCP genes that may have a role in the
development of cachexia and these are presented in table 5
of electronic supplementary material.
Journal of Genetics, Vol. 90, No. 1, April 2011 167
Benjamin H. L. Tan et al.
A polymorphism in the gene coding for triose phosphate
isomerase (TPI) which plays an important role in glycoly¬
sis and is essential for efficient energy production is also
shown in table 5 of electronic supplementary material. TPI
deficiency leads to a metabolic block of the glycolytic path¬
way and hence a generalized impairment of cellular energy
supply causing generalized skeletal muscle deficiency.
Insulin-like growth factors and relatedproteins
Insulin-like growth factors (IGFs) are polypeptides with high
sequence similarity to insulin. IGFs are part of a complex
system that cells use to communicate with their physio¬
logic environment. This complex system (often referred to
as the IGF 'axis') consists of two ligands (IGF-1 and IGF-
2), two cell-surface receptors (IGF1R and IGF2R), and a
family of six high-affinity IGF-binding proteins (IGFBP1-
IGFBP6) (Jones and Clemmons 1995). This system regulates
normal cellular metabolism, proliferation, differentiation and
protecting against apoptotic signals (Jerome et al. 2003).
High levels of IGF-1 and IGFBP3 have been implicated
with poorer prognosis in certain types of cancers. Polymor¬
phisms in genes coding for components of the IGF axis have
been shown to affect serum levels of their respective pro¬
teins as well as body composition (see table 6 in electronic
supplementary material).
Also shown in table 6 of electronic supplementary mate¬
rial are polymorphisms in the iodothyronine deiodinase, type
1 gene (DIOl) which activates thyroid hormone by convert¬
ing the prohormone thyroxine (T4) by outer ring deiodina-
tion to bioactive triiodothyronine (T3). Thyroid hormone is
known to interact with the GH-IGF-1 axis although the exact
mechanism is unknown (Peeters et al. 2005).
Corticosteroid signalling proteins
Corticosteroids are essential steroid hormones that are
secreted by the adrenal cortex and affect multiple organ sys¬
tems. Corticosteroids are involved in a wide range of physio¬
logic systems such as stress response, immune response and
regulation of inflammation, carbohydrate metabolism and
protein catabolism. The genetic variants of the components
in the mechanism of corticosteroid signalling are examined
in table 7 of electronic supplementary material.
Muscle
Muscle atrophy is known to occur in cancer cachexia. This
results from the depression of muscle protein synthesis, an
increase in muscle protein degradation, or a combination of
both (Eley and Tisdale 2007). Experimental studies have also
shown a shift in the myosin isoform content of skeletal mus¬
cle in cancer cachexia from type I to type II (Diffee et al.
2002). The following section examines the genetic variations
that affect the structure and function of muscle as well as
those that regulate muscle proteolysis.
Muscle structure andfunction
Genes involved in regulating muscle structure and function
include those coding for ACTN3 (Alpha-actinin 3), which
bind to actin at the Z-line within muscle fibres and act to
anchor actin filaments, and IL15 (interleukin-15). IL-15 sig¬
nals through IL-15 receptor alpha (IL-15RA) and is found in
abundance in skeletal muscle. IL-15 is shown to be anabolic,
marked by an increase in myosin heavy chain accumulation
(Quinn et al. 2002). Polymorphisms in ACTN3, IL15 and
IL15RA are shown in table 8 of electronic supplementary
material.
Steroid androgens play an important role in determining
LBM and muscle strength. Variants in the gene coding for
the androgen receptor (AR), which is activated by binding
of either androgenic hormones testosterone or dihydrotestos-
terone and are known to be capable of activating myogenic
genes (Vlahopoulos et al. 2005), are also displayed in table 8
of electronic supplementary material. Polymorphisms asso¬
ciated with alterations fat free mass in the gene encoding the
vitamin D receptor (VDR) are also included in table 8 of
electronic supplementary material.
Muscle proteolysis
Angiotensin converting enzyme (ACE) plays a critical role in
the renin-angiotensin system by catalysing the conversion of
the inactive angiotensin I to angiotensin II, which is the phys¬
iologically active form of the hormone. Acute and chronic
exposure to angiotensin II in animal models are associated
with weight loss and enhanced protein breakdown in skeletal
muscle (Brink et al. 1996, 2001).
In atrophying muscles, the ubiquitin ligase, atrogin-1, is
induced and this response is necessary for rapid atrophy.
FOX03 is known to act on atrogin-1 promoter to cause
atrogin-1 transcription and this leads to dramatic atrophy of
myotubes and muscle fibres (Sandri et al. 2004). Polymor¬
phisms in ACE and FOX03A genes are presented in table 9
of electronic supplementary material.
Adipose tissue
Body-fat depletion is a major component of weight loss in
cancer cachexia. Increased lipolysis appears to be a key fac¬
tor underlying fat loss, though decreases in lipid deposition
and adipocyte development may also contribute (Legaspi
et al. 1987). The following section examines polymorphisms
in genes regulating adipose tissue metabolism.
Adipogenesis
Peroxisome proliferator-activated receptors (PPARs) are
a group of nuclear receptor proteins that function as
transcription factors regulating the expression of genes.
There are three subtypes of the receptor (PPARa, PPAR/3
and PPARy). PPARa is most commonly expressed in organs
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and tissues in which fatty acid oxidation is active. PPARa
is known to participate in the regulation of key proteins
involved in extracellular lipid metabolism, fatty acid oxi¬
dation and inflammation (Torra et al. 2001). PPARy is an
important regulator of fat cell function by orchestrating dif¬
ferentiation of new adipocytes and by inducing expression
of genes promoting uptake of fatty acids, triglyceride syn¬
thesis and insulin sensitivity (Lehrke and Lazar 2005). Poly-
mophisms in the PPARA and PPARG genes are shown in
table 10 of electronic supplementary material.
Also of interest are the lipin proteins (lipin-1, lipin-2 and
lipin-3) which are thought to be required for glycerolipid
biosynthesis. They also act as transcriptional coactivators
that regulate expression of lipid metabolism genes (Reue
2009). Variants of genes coding of lipin-1 (LPIN1) and
lipin-2 (LPIN2) are also presented in table 10 of electronic
supplementary material.
Lipid turnover and transport
During lipolysis, trigylcerides are broken down in a stepwise
fashion to free fatty acids (FFAs). This process is partly mod¬
ulated by the sympathetic nervous system-induced secretion
of cathecholamines which act through 1, /32 and /33 adren¬
ergic receptors (/f-ARs) (Large et al. 2004). Signals between
/^-adrenergic receptors and effector proteins are integrated by
G proteins which are composed of alpha, beta, and gamma
subunits. Polymorphisms of genes coding for /3-ARs and the
beta subunits of the G proteins (GNB3) are shown in table 11
of electronic supplementary material.
Lipoprotein lipase (LPL) is an enzyme that hydrolyses
lipids in lipoproteins and plays a central role in the overall
lipid metabolism and transport (Mead et al. 2002). Fatty acid
binding proteins (FABPs) are a family of carrier proteins for
fatty acids and other lipophilic substances. These proteins are
thought to facilitate the transfer of fatty acids between extra¬
cellular and intra-cellular membranes (Chmurzynska 2006).
Polymorphisms in the LPL and FABP genes are shown in
table 11 of electronic supplementary material.
Adiopkines and adipokine receptors
Adipose tissue is also recognized as a major endocrine organ,
because the tissue synthesizes and secretes an array ofprotein
hormones and signals (Fantuzzi 2005). These adipokines act
locally in an autocrine/paracrine manner and/or as endocrine
signals to regulate appetite, energy expenditure and a range
of physiological processes including insulin sensitivity and
inflammatory response which may have an important role in
the pathogenesis of cancer cachexia (Kerem et al. 2008).
Resistin is an adipocyte-derived proinflammatory
cytokine. Resistin also appears to have effects on substrate
metabolism through impairment of insulin action and insulin
independent pathways (McTernan et al. 2006). There are
three polymorphisms within the RETN gene which codes for
resistin that may influence the development of cachexia (see
table 12 in electronic supplementary material).
Adiponectin is a protein hormone that is exclusively
secreted from adipose tissue and modulates a number of
metabolic processes, including glucose regulation and fatty
acid catabolism (Diez and Iglesias 2003). Adiponectin binds
to a number of receptors including adiponectin receptors
1 and 2. An increase in adiponectin concentration has
been assoicated with cachexia in patients with heart fail¬
ure (McEntegart et al. 2007). Leptin is a protein hormone
secreted by adipose tissue that plays a key role in regulat¬
ing energy intake and energy expenditure, including appetite
and metabolism. Leptin acts through the leptin receptor.
Polymorphisms in genes coding for adiponectin, leptin and
their respective receptors are given in table 12 of electronic
supplementary material.
Appetite regulation
Anorexia, defined as the loss of desire to eat, is common
in patients with cancer cachexia. In addition to any effects
of the tumour on the gastrointestinal tract and psychological
depression, patients with cancer frequently have a decreased
taste and smell of food (DeWys and Walters 1975). Cancer
anorexia may be a result of an imbalance between orexi-
genic signals and anorexigenic signals. The following section
explores the variants in the genes encoding these signals.
Ghrelin is synthesized principally in the stomach and is
released in response to acute and chronic changes in nutri¬
tional state. In addition to having a powerful effect on
the secretion of growth hormone, ghrelin stimulates food
intake and transduces signals to hypothalamic regulatory
nuclei that control energy homeostasis (Hosoda et al. 2002).
The melanocortin 4 receptor, a G-protein coupled recep¬
tor, binds a-melanocyte stimulating hormone (a-MSH).
Melanocortin 4 receptors have been found to be involved
in feeding behaviour and the regulation of metabolism (Fan
et al. 1997). Endocannabinoids, acting at brain cannabinoid
type 1 receptors, play a role in stimulating appetite and
ingestive behaviours, partly through interactions with more
established orexigenic and anorexigenic signals (Kirkham
2005). Ciliary neurotrophic factor (CNTF) has been shown
to activate hypothalamic leptin-like pathways which sup¬
press food intake without triggering hunger signals or asso¬
ciated stress responses that are otherwise associated with
food deprivation (Lambert et al. 2001). CNTF acts via
CNTF receptors (CNTFRs) which are located in hypothala¬
mic nuclei involved in feeding. Polymorphisms of interest in
the genes encoding ghrelin (GHRL), melanocortin 4 recep¬
tor (MC4R), cannabinoid type 1 receptor (CNR1) and the
CNTFR are given in table 13 of electronic supplementary
material.
Others
Metallothionein (MT) is a family of cysteine-rich, low
molecular weight proteins. MTs are encoded by a family
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of genes consisting of 10 functional MT isoforms, and the
encoded proteins are conventionally subdivided into four
groups: MT-1, MT-2, MT-3 and MT-4 proteins. The physi¬
ological roles of MTs are not well understood but they are
thought to play a role in the control of oxidative stress and
protection against inflammation (Simpkins 2000).
The P2Y-receptors belong to the superfamily ofG-protein-
coupled receptors and mediate the actions of extracellular
nucleotides in cell-to-cell signalling. The P2Y11 receptor is
highly expressed in immunocytes and may play a role in the
differentiation of these cells (von Kugelgen 2006).
Glutamine: fructose-6-phosphate aminotransferase (GFAT)
is the rate-limiting enzyme of the hexosamine biosynthetic
pathway (HBP), which catalyses the conversion of fructose-
6-phosphate to glucosamine-6-phosphate. The flux through
the HBP has been shown to be linked to the regulation of
energy intake and energy expenditure (Obici et al. 2002).
Fat mass and obesity associated (FTO) is thought to play a
role in energy homeostasis but its exact function is unknown.
Genetic variants encoding the proteins discussed above
may play a role in the development of cachexia and are listed
in table 15 of electronic supplementary material.
Analysis of results
Out of 184 polymorphisms that have been identified, the
functional or clinical significance of only 42 polymorphisms
have been verified in more than one study.
Of these 42 polymorphisms, 13 have been shown to have
more than one effect on clinical features associated with can¬
cer cachexia (i.e. inflammation, changes in lean and/or fat
mass, and overall survival). These 13 polymorphisms repre¬
sent the most promising candidates in terms of susceptibility
biomarkers of cancer cachexia (table 1) and are explored in
more detail below.
The C allele of the A37674C SELF polymorphism
(rs6136) is associated with decreased serum P-selectin levels
(Miller et al. 2004; Volcik et al. 2006). P-selectin is required
for efficient recruitment of neutrophils in acute inflamma¬
tion and ofmacrophages in later stages of the inflammatory
response and serum levels of P-selectin have been found to
be significant prognostic factors in survival in patients with
gastric and colorectal malignancies (Alexiou et al. 2001,
2003)
TNF-a is a cytokine involved in systemic inflammation
and is a member of a group of cytokines that stimulate the
acute phase reaction. Within the TNF gene, the -308A allele
(rsl800629) has been associated with an increased TNF-a
production as well as a 6-fold increase in transcription of the
TNF gene (Wilson et al. 1997; Sallakci et al. 2005). Inter¬
estingly, the A/A genotype has been linked to increased fat
accumulation in women (Hoffstedt et al. 2000). The -863A
allele (rsl800630) associated with decreased transcriptional
activity and reduced serum TNF-a levels (Day et al. 1998;
Skoog et al. 1999; Kaluza et al. 2000; Sharma et al. 2006). Of
note, obese individuals express 2.5-fold more TNF mRNA in
fat tissue (Hotamisligil et al. 1995).
LTA, a member of the tumour necrosis factor family, is
a cytokine produced by lymphocytes, and mediates a large
variety of inflammatory and immunostimulatory, responses.
The G allele of the 252 A>G polymorphism (rs909253) has
been associated with increased serum TNF-a levels (Stuber
et al. 1996; McArthur et al. 2002), and patients who are A/A
homozygotes have been linked with better prognosis in lung
cancer and gastric cancer (Shimura et al. 1994, 1995).
IL-l/J is a cytokine protein which is encoded by the
IL1B gene and is an important mediator of the inflamma¬
tory response. The -31 C>T (rsl 143627) and -511 C>T
(rsl 6944) polymorphisms in the promoter region of the IL1B
gene have been linked with increased transcriptional activity
of the IL1B gene and subsequently increased IL-1/3 produc¬
tion (Wen etal. 2006). The -31C and -51 IT alleles are linked
with poorer progression-free survival and overall survival in
advanced gastric cancer (Graziano et al. 2005). Increased IL-
1 p levels have been linked to a synonymous C to T polymor¬
phism at nucleotide position 3953 (rsl 143634) (Hernandez-
Guerrero et al. 2003). The T/T genotype has also been asso¬
ciated with lower plasma levels of IL-1 receptor antagonist
(IL-1RA) (Tolusso et al. 2006). In addition, the T allele has
found to be a major risk factor for cachexia in gastric cancer
(Zhang et al. 2007), as well as being linked to lower total fat
mass (Strandberg et al. 2006). The T/T genotype was found
to be associated with shorter survival in pancreatic cancer
(Barber et al. 2000).
IL-6 is a cytokine involved in a wide variety of biological
functions. It is critical for B-cell differentiation and matura¬
tion, immunoglobulin secretion, cytotoxic T-cell differentia¬
tion and acute-phase protein production (Kishimoto 2005).
The -174 G>C promoter polymorphism (rsl800795) in the
IL6 gene has been associated with lower serum levels of IL-6
(Fishman et al. 1998). The G allele has been linked to higher
fasting insulin and lower adiponectin levels which may have
a role in the regulation of adiposity (Yang et al. 2005). In
addition the C/C genotype has been associated with lower fat
free mass and increased waist circumference (Berthier et al.
2003; Roth et al. 2003).
IGF-1 plays an important role in childhood growth and
continues to have anabolic effects in adults. IGF-1 is one
of the most potent natural activators of the Akt signalling
pathway, a stimulator of cell growth and multiplication. IGF-
1 also mediates many of the growth-promoting effects of
growth hormone (GH) (Jones and Clemmons 1995). A CA
repeat polymorphism is found within the promoter region
of the IGF1 gene. The 19CA repeat allele is associated
with both lower serum IGF-I levels and IGFBP-3 levels
(Rosen et al. 1998; Morimoto et al. 2005). The 19CA
repeat allele is also associated with reduced risk of weight
gain (Landmann et al. 2006; Voorhoeve et al. 2006). Of
note, increasing IGF-1 levels have been associated with
poorer prognosis in oesophageal cancer patients (Sohda et al.
2004).
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Angiotensin converting enzyme (ACE) plays a critical role
in the renin-angiotensin system by catalysing the conver¬
sion of the inactive angiotensin I to angiotensin II, which is
the physiologically active form of the hormone. Acute and
chronic exposure to angiotensin II in animal models are asso¬
ciated with weight loss and enhanced protein breakdown in
skeletal muscle (Brink et al. 1996, 2001). A common inser¬
tion/deletion (I/D) polymorphism (rs4646994) is present in
intron 16 of the ACE gene. The I allele is associated with
lower circulating ACE levels (Tiret et al. 1992). The D allele
is associated with increased strength gains thorough isomet¬
ric training (Folland et al. 2000) and also associated with
obesity (El-Hazmi and Warsy 2003; Riera-Fortuny et al.
2005). The D/D genotype is linked with increased survival in
women with colorectal cancer (Rocken et al. 2007).
Lipoprotein lipase (LPL) is an enzyme that hydrolysis
lipids in lipoproteins and plays a central role in the overall
lipid metabolism and transport (Mead et al. 2002). The rs328
polymorphism in the LPL gene results in a premature stop
codon at amino acid 447. The stop codon results in lower
LPL activity (Kozaki et al. 1993; Groenemeijer et al. 1997),
and is associated with lower levels of IL-8 (Ak et al. 2007).
Individuals not in possession of the stop codon are associated
with central obesity (Huang et al. 2006).
Resistin is an adipocyte-derived pro-inflammatory
cytokine. Resistin also appears to have effects on substrate
metabolism through impairment of insulin action and insulin
independent pathways (McTernan et al. 2006). The —420
C>G polymorphism (rs 1862513) is shown to be linked to
increased plasma resistin (Cho et al. 2004; Osawa et al.
2007), and individuals with the G/G genotype are associ¬
ated with an increased prevalence of obesity (Norata et al.
2007). Overall, increased plasma resistin has to shown
to correlate with increased CRP and insulin resistance
(Degawa-Yamauchi et al. 2003; Silswal et al. 2005; Nagaev
et al. 2006; Kusminski et al. 2007; Osawa et al. 2007).
Adiponectin is a protein hormone that is exclusively
secreted from adipose tissue and modulates a number of
metabolic processes, including glucose regulation and fatty
acid catabolism (Diez and Iglesias 2003). An increase in
adiponectin concentration is associated with cachexia in
patients with heart failure (McEntegart et al. 2007). The
ADIPOQ gene, which codes for adiponectin, has a 45 T>G
polymorphism (rs2241766) that is associated with increased
plasma adiponectin (Berthier et al. 2005; Mackevics et al.
2006). Individuals with G/G genotype have been observed to
be leaner with less abdominal fat (Loos et al. 2007).
Pathway analysis
The 42 polymorphisms which have been verified in more
than one study were found across 33 genes. These genes
were entered into the IPA algorithm as focus genes and were
found to be significantly interconnected in two major net¬
works (table 2). Using the 'overlapping network' feature of
IPA, we found that these networks were joined together by
few genes, namely ADIPOQ, IL6, NFKB1 and TLR4. The
two networks are presented in figures 1 and 2.
Discussion
Support for a heritable component to cachexia has recently
been highlighted in several studies. The IL6 -634G allele
is associated with increased susceptibility to cachexia and
decreased survival time of Chinese patients suffering from
pancreatic cancer (Zhang et al. 2008). Another study by
Table 2. Ingenuity pathway analysis of genes that were replicated in more than one study (n = 33).
Network Molecules*
Calculated Focus
score genes Top functions of network
ADIPOQ, Akt, Apl, CCL2, ERK, ERK1/2, 24
Gm-csf, histone h3, histone h4, IFN beta,
IFNG, IGF1,IGFBP3, IgG, IL6, IL12 (complex),
IL1B, immunoglobulin, interferon alpha, Jnk,
LDL, LEP, Mapk,NFKBl, NFkB (complex),
P38 MAPK, PDGF BB, PI3K, PPARG, RETN,
Sod, TLR2,TLR4,TNF, Vegf
ADIPOQ, ADRB2, B1RC3, BTG2, CAMP, 13
CREBBP, CRP, CSF1, F2, GSK3B, HDAC3,
HGF, HMGB1 (includes EG:3146), HSPD1,
1KBKB, IL6, IL17A (includes EG:3605), IL6R,
IRS 1, LPL, LTF, NFIC, NFKB1, NOS2, NR3C1,
OSM, PLD1, PLG, RELA, SELP, SIRT1, TLR4,
TNFSF12, TP53,TSC22D3
14 Connective tissue disorders, inflammatory
disease, skeletal and muscular disorders
Skeletal and muscular system development
and function, cell death, cellular movement
*Focus genes are in bold.
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Figure 1. Connection map for first ranked network. Genes with variants that had functional or clinical associations replicated
in at least one study were entered into the ingenuity pathway analysis software for an unsupervised functional analysis to
discern regulatory networks that involved these molecules. Focus genes are shaded in grey. Solid lines show direct interaction
(binding/physical contact); dashed lines show indirect interaction that is supported by the literature but possibly involving
> 1 intermediate molecules that have not been investigated definitively. Molecular interactions that involved only binding are
connected with a line without an arrowhead because directionality cannot be inferred.
Deans et al. (2009) revealed that the IL10 -1082GG genotype
was associated with 2.3 times increased risk of developing
cachexia in patients with gastroesophageal malignancy.
However, like many complex conditions and diseases, the
risk ofdeveloping cancer cachexia is probably determined by
multiple genetic factors and environmental factors are likely
to add to the heterogeneity of the condition. Although the
number of reports on polymorphic gene variants associated
with multi-factorial diseases and conditions are dramatically
growing, very few studies provide firm and reliable evidence
of causative relationships between these polymorphisms and
risk or pathogenesis. Indeed, in a recent review of allelic
association with common disease phenotypes, only six of the
166 associations subjected to multiple evaluations were con¬
firmed consistently (Hirschhorn et al. 2002). Possible causes
of false-positive association studies include population
stratification, variable linkage disequilibrium and genotype
misclassification. In addition, in many of these studies, the
possible effects of single gene variants were assessed in
situations when combined impacts ofmultiple factors could
be expected (Loktionov 2003). In the present study, we have
identified 42 polymorphisms out of 184 with a potential role
in the development of cachexia that have been independently
verified in at least one repeat study.
It can be assumed that analysis of combinations of gene
variants encoding interacting factors within a biological
chain or cascade, rather than isolated investigation of its
single components, may have more chances to reveal real
causative connections between gene polymorphisms and
phenotypes. In this study, functional polymorphisms in genes
with a possible role in cachexia have been recorded as
well as polymorphisms with clinical consequences related
to cachexia such as inflammation, weight/body composition
changes and cancer survival.
Of the 42 polymorphisms with a potential role in the devel¬
opment of cachexia that have been independently verified in
at least one repeat study, 13 polymorphisms have been shown
to have more than one effect on clinical features associated
with cancer cachexia. These 13 polymorphisms are likely
to be the most promising candidates in terms of suscepti¬
bility biomarkers of cancer cachexia and should be further
investigated.
Journal of Genetics, Vol. 90, No. 1, April 2011 173
Benjamin H. L. Tan et al.
en
Figure 2. Connection map for second ranked network. Genes with variants that had functional or clinical associations replicated in at
least one study were entered into the ingenuity pathway analysis software for an unsupervised functional analysis to discern regulatory
networks that involved these molecules. Focus genes are shaded in grey. Solid lines show direct interaction (binding/physical contact);
dashed lines show indirect interaction that is supported by the literature but possibly involving > 1 intermediate molecules that have not
been investigated definitively. Molecular interactions that involved only binding are connected with a line without an arrowhead because
directionality cannot be inferred.
Pathway analysis of the independently verified genes has
revealed four genes interlinking two putative major networks
involved in the development of cancer cachexia. These four
genes (ADIPOQ, IL6, NFKB1 and TLR4) may have central
roles in the pathogenesis of cancer cachexia and should be
further investigated.
It should also be emphasized that while certain variant
combinations can predispose to a condition, others may be
protective against the same condition. For example, polymor¬
phisms resulting in an increase in systemic inflammation, a
decrease in lean or fat mass and decreased survival in cancer
are likely to be cachexia prone variants. On the other hand,
polymorphisms that result in a decrease in systemic inflam¬
mation, an increase in body mass and improved survival in
cancer are likely to be cachexia resistant variants.
In multigene studies, judicious selection of candidate
genes and polymorphisms within them is a key element
of study design. It is always important to choose genes,
products of which interact within regulatory or metabolic
pathways. In most cases, it is not realistic to analyse all pos¬
sible gene variants and combinations, hence existing poly¬
morphisms should be initially prioritized on the basis of their
likelihood to affect function of the encoded product (Tabor
et al. 2002).
The present study has provided an initial framework to
select and study the possible genetic variance in develop¬
ing cancer cachexia by identifying polymorphisms with puta¬
tive functional and/or clinical significance in relation to the
development of cachexia. The identification of genetic vari¬
ants that have undergone repeat studies allows the selection
of robust and reliable candidates. Furthermore, prioritization
of the most likely genetic variants that are likely to influence
the development of cachexia have been derived by select¬
ing polymorphisms that influence two or more hallmarks of
cachexia (i.e. systemic inflammation, loss of fat mass, loss of
lean mass and reduced survival).
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The variable predisposition to cachexia may, in part, be due to the interaction of
host genotype. We analyzed 129 single nucleotide polymorphisms (SNPs) in 80
genes for association with cachexia based on degree of weight loss (>5, >10,
>15%) as well as weight loss in the presence of systemic inflammation (C-reactive
protein, >10 mg/l). 775 cancer patients were studied with a validation association
study performed on an independently recruited cohort (n = 101) of cancer
patients. The C allele (minor allele frequency 10.7%) of the rs6136 (SELP)
SNP was found to be associated with weight loss >10% both in the discovery
study (odds ratio (OR) 0.52; 95% confidence intervals (CI), 0.29-0.93; p = 0.026)
and the validation study (OR 0.09, 95% CI 0.01-0.98, p = 0.035). In separate
studies, induction of muscle atrophy gene expression was investigated using
qPCR following either tumour-induced cachexia in rats or intra-peritoneal
injection of lipopolysaccharide in mice. P-selectin was found to be significantly
upregulated in muscle in both models. Identification of P-selectin as relevant in
both animal models and in cachectic cancer patients supports this as a risk
factor/potential mediator in cachexia.
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INTRODUCTION
Cachexia is a wasting condition that manifests itself in several
life-threatening diseases, including cancer, AIDS, congestive
heart failure and sepsis (Argiles et al, 2003; Tisdale, 2004).
Patients exhibit a loss of both adipose tissue and lean body mass
(Fearon & Preston, 1990), which is resistant to conventional
nutritional support (Tisdale et al, 1987). Cachexia is typically
characterized by severe weight loss, anorexia, early satiety,
weakness, anaemia and oedema (Fearon & Preston, 1990). The
cachectic state is particularly problematic in cancer, typified by
poor prognosis and often associated with a lower response
to chemotherapy and radiotherapy than might be expected
(Tisdale, 2002). Patients are also more likely to report decreased
quality of life (QoL) scores (Fearon et al, 2006). More than half
of cancer patients suffer from cachexia, and it is responsible for
death in up to 20% of cases (Tisdale, 2002). Cachexia is
therefore a significant cause of morbidity and mortality in cancer
patients.
Based on our current knowledge of demographic and clinical
factors, we are unable to predict, for any given cohort of
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patients, who will develop cancer cachexia and who will not.
Such variation may, in part, be due to the patient's genotype.
Knowledge of genotypic variation associated with cachexia
would contribute to early identification of patients at risk
and allow institution of prophylactic measures. The wealth
of known genetic polymorphisms in genes controlling pro/anti-
inflammatory pathways, neuronal melanocortin signalling
pathways and muscle and adipose tissue catabolic pathways
suggest their exploitable potential as biomarkers of inter-
individual predictability of developing cachexia.
We utilized a candidate gene approach to evaluate the
association between genetic polymorphisms and the risks of
developing cachexia in patients recruited across three centres.
Patients recruited from a fourth centre were used as a validation
cohort. To further corroborate the most significantly related
single nucleotide polymorphism (SNP) to cancer cachexia in the
gene association study, we tested the same gene for participation
in the induction of the skeletal muscle atrophy gene program,
either by intra-peritoneal administration of lipopolysaccharide
(LPS) in mice or in a rat model of cancer cachexia
(methylcholanthrene (MCA)-induced sarcoma). LPS is known
to induce acutely a number of catabolic factors in sepsis,
suppress anabolic factors and result in muscle atrophy (Dehoux
et al, 2003; Vary et al, 1998). The MCA model is a preclinical
cancer cachexia model, and is known to reliably induce loss of
lean body mass (Sato et al, 2001).
RESULTS
Following the relevant quality control checks, 129 SNPs in
80 genes (Supporting Information Table SI) were available
for analysis in 775 patients. The overall completion rate of
genotyping was 95.6%.
The general characteristics of the study population are
presented in Table 1. Average age of the patient cohort at
diagnosis was 65.5± 11.8 years (mean±SD). The majority of
patients were diagnosed with stage III or IV cancers. Average
weight loss was 6.9 ± 9.8% with a mean body mass index (BMI)
of 24.9 ±4.9 at diagnosis. Of the patients in whom C-reactive
protein (CRP) levels were assessed (rz = 569), 58.7% had a CRP
concentration of >10mg/l. There were no significant differ¬
ences in age, stage of disease, pre-diagnosis BMI and percentage
weight loss between patients with CRP measured and the entire
cohort.
Table 2a lists the detailed results for SNPs significantly
associated with cancer cachexia in patients classified according
to weight loss alone. Table 2b lists the detailed results for SNPs
significantly associated with cancer cachexia in patients
classified according to weight loss with systemic inflammation
(CRP >10mg/l). In total, eight SNPs have associations of
p<0.02 with various cachexia phenotypes. Three of these
SNPs are found within chromosome 1 in the genes selectin P
[SELF], leptin receptor (LfiPR) and deiodinase, iodothyronine,
type I (D/Ol); three within chromosome 3 in the genes
N-acylaminoacyl-peptide hydrolase (APEH] and ghrelin
(GHRL), one within chromosome 12 in the TNFRSF1A gene
Table 1. Patient demographics (main cohort). Patients were recruited from
(2004 to 2008) from the NHS Lothian, UK, Cross Cancer Institute, Edmonton,
Canada, and McGill University Health Centre, Montreal, Canada
No. of patients (n = 775)






Oesophageal or gastric 389 (50.2)
Pancreatic 114 (14.7)








Body mass index (kg/m2) ' 24.9 ±4.9
Range 12.9-46.7
Percentage weight loss ' 7.95 ±8.16
Range 0-43.8
C-reactive protein (mg/l)' (n = 569) 23.0 ±35.9
CRP > 10 mg/l 235 (41.3)
CRP < 10 mg/l 334 (58.7)
Values are number of patients with percentages in parentheses unless
indicated otherwise.
'values are mean ± SO. Characteristics were measured at first presentation to
a surgical or oncology clinic.
and one within chromosome 19 in the ICAM1 gene. SNPs found
on the same chromosomal region (within lOOOOkb) were
grouped together to form haplotypes. The haplotypes formed by
the rs4855881 and rs2960548 SNPs in the APEH gene failed to
show any significant association with weight loss.
Analyses of candidate gene groups based on functional
similarity revealed three groups that were associated with at
least one cachexia phenotype at the p<0.05 level (Table 3).
Validation study
Patient demographics of the validation cohort (rc = 101) are
presented in Table 4. Although, patients in the validation cohort
did not have an identical distribution of cancer types as the main
cohort, the distribution of BMI and weight loss remain quite
similar between the two cohorts. Approximately 60% of the
patients in the validation cohort had other cancer types which
also had tendency to develop cachexia like prostate cancer and
colorectal cancer (it is estimated that 30% of patients suffering
from these cancers have a weight loss of 5 % or more (Dewys
et al, 1980)).
Study subjects were genotyped for SNPs with p<0.05 in
the main study. One replication of the main study was found.
The C allele of the rs6136 SNP was inversely associated with
weight loss >10% in the main study (odds ratio, OR 0.52; 95%
confidence intervals, 95% CI 0.29-0.93; p = 0.026) as well as in
the validation study (OR 0.09, 95% CI 0.01-0.98, p = 0.035).
© 2012 EMBO Molecular Medicine EMBO Mol Med 4, 1-10 www.embomolmed.org
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Table 2a. Genes with variants significantly associated with cancer cachexia in patients classified according to weight loss alone
Weight loss >15%. Number affected: 145/775 (18.7%)
Gene SNP Risk allele OR (95% CI) p-Value Permutated p
SELP rs6136 C 0.31 (0.14-0.72) 0.006615 0.008062
ICAM1 rs281432 G 1.53 (1.06-2.20) 0.02163 0.01652
DIOl rsll206244 T 1.54 (1.06-2.24) 0.0226 0.02164
ADIPOR2 rsl6928751 A 0.53 (0.29-0.96) 0.03521 0.03053
APEH rs2960548 G 1.48 (1.03-2.11) 0.03384 0.03768
Weight loss >10%. Number affected: 266/775 (34.3%)
Gene SNP Risk allele OR (95% CI) p-Value Permutated p
LEPR rsll37100 G 0.66 (0.47-0.92) 0.01494 0.013
DIOl rsll206244 T 1.52 (1.09-2.11) 0.0129 0.01512
SELP rs6136 C 0.52 (0.29-0.93) 0.02746 0.02581
HYLS1 rs3088241 C 0.72 (0.53-0.97) 0.02829 0.02709
CAMK2B rsl0441113 A 0.73 (0.54-0.99) 0.04096 0.03419
Weight loss >5%. Number affected: 415/775 (53.5%)
Gene SNP Risk allele OR (95% CI) p-Value Permutated p
TNFRSF1A rs4149570 T 1.42 (1.08-1.87) 0.01134 0.01759
TNFRSF1A rs767455 C 0.71 (0.53-0.95) 0.02034 0.02275
TNFRSF1B rs976881 A 0.76 (0.57-1.00) 0.04804 0.04324
IL18 rsl946519 A 1.35 (1.02-1.79) 0.03895 0.04969
Table 2b. Genes with variants significantly associated with cancer cachexia in patients classified according to weight loss with systemic inflammation
(CRP >10 mg/l)
Weight loss >15% & CRP >10 mg/l. Number affected: 76/569 (13.4%)
Gene SNP Risk allele OR (95% CI) p-Value Permutated p
APEH rs2960548 C 2.17 (1.36-3.47) 0.001125 0.000997
GHRL rs42451 T 2.04 (1.25-3.31) 0.004031 0.004058
TNFRSF1A rs4149570 T 1.84 (1.16-2.92) 0.009322 0.01031
SELP rs6136 C 0.26 (0.08-0.79) 0.01765 0.01103
CNR1 rsl049353 A 1.82 (1.08-3.06) 0.02366 0.02254
IRS1 rsl025333 A 2.24 (1.07-4.69) 0.03257 0.03183
APEH rs48S5881 C 1.64 (1.04-2.59) 0.03431 0.03191
FOXOl rsl7446593 G 0.49 (0.26-0.92) 0.02704 0.03239
ICAM1 rs281432 G 1.63 (1.04-2.54) 0.03276 0.03941
Weight loss >10% & CRP >10 mg/l. Number affected: 123/569 (21.6%)
Gene SNP Risk allele OR (95% CI) p-Value Permutated p
APEH rs2960548 C 1.80 (1.21-2.68) 0.003528 0.003499
GHRL rs42451 T 1.79 (1.18-2.72) 0.006219 0.00467
TNFRSF1A rs4149570 T 1.51 (1.04-2.18) 0.02958 0.01998
HYLS1 rs3088241 C 0.66 (0.46-0.95) 0.02374 0.02074
APEH rs4855881 C 1.57 (1.06-2.32) 0.02334 0.02847
TSC2 rs7187438 C 0.64 (0.43-0.95) 0.0265 0.03438
TNFRSF1B rs3397 C 0.67 (0.46-0.97) 0.03527 0.04286
Weight loss >5% & CRP >10 mg/l. Number affected: 166/569 (29.2%)
Gene SNP Risk allele OR (95% CI) p-Value Permutated p
APEH rs2960548 C 1.67 (1.17-2.38) 0.004924 0.004533
APEH rs4855881 C 1.56 (1.10-2.21) 0.01321 0.01212
TNFRSF1A rs4149570 T 1.51 (1.08-2.10) 0.01559 0.02074
ADIP0R2 rsl6928751 A 0.56 (0.33-0.95) 0.03308 0.02096
ADIP0R2 rs35854772 T 0.57 (0.33-0.97) 0.03733 0.02667
TNFRSF1B rs3397 C 0.70 (0.50-0.98) 0.03944 0.02923
LTBP1 rs817529 G 0.70 (0.49-0.98) 0.03719 0.03791
TNFRSF1A rs767455 C 0.68 (0.48-0.96) 0.02682 0.03846
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Table 3. Candidate gene groups associated with cancer cachexia phenotypes
Phenotype Candidate gene group Number Number p-Values
function of genes' of SNPs
Weight loss >10% &. CRP >10 mg/l Appetite regulation 2 3 0.0155
Glucocorticoid signalling 4 9 0.0351
MAPK activity regulation 7 14 0.0481
Weight loss >15% &. CRP >10 mg/l Appetite regulation 2 3 0.008499
Glucocorticoid signalling 4 9 0.0181
MAPK activity regulation 7 14 0.0264
'The genes in each candidate gene group are listed in Supporting Information Table S2.
Changes in skeletal muscle gene expression following either
intra-peritoneal injection of LPS in mice or in rats bearing the
MCA sarcoma
qPCR analysis of mouse skeletal muscle RNA performed after
intra-peritoneal LPS injection revealed that the SELP (P-selectin)
transcript was significantly differentially expressed compared
with control (Fig la). In a separate study, rats with net loss of
lean body mass and gastrocnemius mass due to growth of the
MCA tumour (Fig lc), showed similar upregulation of the SELP
transcript. The latter was associated with significant upregula¬
tion of the 'atrogen' E3 ligases muscle atrophy F-box (MAFBx)
and muscle ring finger 1 (MuRFl) along with forkhead box 01
(F0X01), a transcription factor associated with muscle atrophy
(Fig lb).
DISCUSSION
This study has identified that individuals who carry the C-allele
of the rs6136 polymorphism in SELP gene which encodes
P-selectin, are at reduced risk of developing cachexia as defined
by weight loss >10%. The C allele of the non-synonymous
intronic variant, rs6136 has been previously associated with
decreased serum P-selectin levels (Miller et al, 2004; Volcik et al,
2006). Information on P-selectin genotypes may eventually
prove useful in the risk stratification of pre-cachectic cancer
patients. Further evidence for the role of P-selectin in the
development of cachexia is highlighted in the studies involving
the induction of muscle atrophy in mice/rats. Strikingly,
P-selectin was highly upregulated following either intra-
Table 4. Patient demographics (validation cohort). Patients recruited from
(2007 to 2008) from the Oncology & Palliative Medicine, Cantonal














Body mass index (kg/m2) '
Range
Percentage weight loss '
Range
C-reactive protein (mg/l)' (n = 95)
CRP > 10 mg/l
CRP < 10 mg/l




















Values are number of patients with percentages in parentheses unless
indicated otherwise.
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Figure 1. >Changes in skeletal muscle gene expression following either
intra-peritoneal injection of LPS in mice or in rats bearing the MCA
sarcoma. Wild type mice received either intra-peritoneal injections of LPS or
vehicle alone. Food was removed from the cages at the time of injection, and
animals were sacrificed at 8 h after the injection (n = 6-7/group).
Veh = vehicule. 'Student's t-test p < 0.05, "p < 0.01, "*p < 0.001.
A. Intra-peritoneal LPS treatment in mice or solid tumour growth in rats
induces dynamic changes in P-selectin mRNA levels.
B. In tumour-bearing rats the changes in P-selectin expression are accom¬
panied by concomitant upregulation of the E3-ligases (MAFBx and MuRFl)
and transcription factor FOXOl.
C. The growth of the MCA sarcoma in rats is associated with net loss of lean
body mass and muscle mass.
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peritoneal injection of LPS or in tumour-bearing (TB) animals.
Furthermore, preliminary studies also indicate that P-selectin
show a similar striking upregulation (10-fold) 2h after
intra-cerebroventricular (ICV) injection of interleukin-1 beta
(IL-ip) in mice (Braun et al, 2011). Acute and chronic infusion
of IL-ip into the brain leads to muscle breakdown, anorexia,
weight loss and negative nitrogen balance (Hill et al, 1996) and
is a potential central mediator of LPS effects. Therefore, we have
confirmed this gene target in three separate murine models of
cachexia representing both acute and chronic inflammatory
insults.
It could be argued that P-selectin expression in skeletal
muscle is simply an endothelial event reflecting the presence
of systemic inflammation. However, both identification of
P-selectin as a top early induced gene of the mouse/rat muscle
atrophy program and the significant association of the rs6136
SNP in the P-selectin gene with wasting in cancer patients
provide supportive evidence for the likely involvement of
P-selectin in muscle wasting. The role of P-selectin in the genesis
of cachexia remains to be determined. The human P-selectin
gene spans over 50 kbp on chromosome 1, containing 17 exons,
almost all of which encode distinctive domain structures
(Johnston et al, 1990; Watson et al, 1990). It has both
membrane and soluble forms in platelets and endothelial cells
(Johnston et al, 1990). Both the membrane and soluble forms of
P-selectin bind to leukocytes. In certain inflammatory condi¬
tions, the plasma concentrations of soluble P-selectin is highly
elevated (Dunlop et al, 1992). It is suggested, that the membrane
and soluble forms of P-selectin may work co-ordinately in vivo
for the regulation of their cell adhesion and, perhaps, signalling
functionality. P-selectin has been characterized previously by
approaches such as gene knockout or the use of specific
inhibitors to be involved in the recruitment of neutrophils
and macrophages in inflammatory responses (Borges et al,
1997; Chen & Geng, 2006). P-selectin may also participate
in intra-tumoural regulation of the genesis of systemic
inflammation via the innate immune system and/or regulation
of the complex interaction within muscle between the
endothelium and signalling pathways in muscle fibres
(Wagenmakers et al, 2006).
CRP is a marker of systemic inflammation that has been
studied in a wide variety of tumour types and has been linked to
poorer survival (Mahmoud & Rivera, 2002; McMillan et al,
2003). To reflect that cachexia represents a spectrum and that
the presence of systemic inflammation with weight loss may
represent a unique sub-phenotype of cachexia which confers an
increased mortality risk, we have chosen to study cachexia
across three different percentage weight loss categories alone
and with the presence of an increased CRP concentration in
comparison with a weight-stable phenotype (i.e. <5% weight
loss). Clearly, much work is required before fully validated
definitions of cachexia are available. Until then, it appears
reasonable to investigate cachexia based on the present
definitions.
One limitation of the study is that patients were recruited at
various stages of the disease process therefore there may be
significant variation in time frame for weight loss. We have
attempted to address this issue by adjusting the analyses for
tumour stage at the time of recruitment assuming that patients
who are diagnosed with more advanced disease would present
with greater amount of weight loss. The amount of weight lost
during the cancer journey may be affected by patients' pre-
diagnosis BMI. The initially overweight/obese cancer patient
may be more likely to lose a greater amount weight compared
with a patient with the same cancer type in the normal BMI
range over the same period of time. To account for this variation
we have also adjusted the analyses for pre-diagnosis BMI.
Another limitation of the study is that patients with upper GI
malignancy often report dysphagia which may contribute to
secondary malnutrition and influence the degree of weight loss.
However, a previous study suggest that dysphagia may not be
the sole contributing factor to weight loss in gastro-oesophageal
malignancy as patients without dysphagia still report a median
4.4% weight loss at diagnosis. Moreover, in a multivariate
model of the same cohort, dietary intake accounted for only 38%
of variation in weight loss (Deans et al, 2009b).
The present study represents the first large scale candidate
gene association study of cancer cachexia spanning a wide
variety of genes such as genes that regulate inflammation,
muscle and adipose tissue metabolism and appetite. SNPs
chosen for the study were based on a literature review of
SNPs with known functional effects and/or clinical relevance
with regard to the development of cachexia (Tan et al, 2011). We
also chose to analyze SNPs based on 18 genes identified
in a gene expression study on muscle wasting in patients
with cancer cachexia (Stephens et al, 2010). Instead of utilizing a
tag SNP approach, as it was not realistic to analyze all possible
gene variants and combinations, we selected SNPs that were
most likely to be functional (i.e. within exons, non-synonymous
and with a minor allele frequency (MAF) of >0.1) and
hence more likely to be associated with the development of
cachexia.
To further add strength to the study, we also attempted to
validate the results by replicating the association study in an
independently recruited group of patients. In the initial
exploratory cohort we identified 21 SNPs in 17 genes with
significant associations with cachexia phenotypes. However,
when both the exploratory and validation cohorts were
considered, only cancer patients carrying the minor allele (C)
of rs6136 were found to be at reduced risk of developing
cachexia as defined by weight loss >10% (main study (OR 0.52,
95% CI 0.29-0.93,p = 0.026); validation study (OR 0.09,95% CI
0.01-0.98, p = 0.035)). We were unable to confirm other
significant associations from the main cohort in the validation
study. This may be due to the small sample size of the validation
study which is a key limitation.
This study included a variety of cancer types, with significant
numbers of patients with cancers of the digestive tract, lung and
pancreas. Validation in larger independent cohorts is required to
fully establish the generalizability of our findings, however the
significant association with the rs6136 polymorphism and
cachexia across both the main group and an independent
validation cohort suggest that our results may apply across
numerous cancer types.
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Due to the small sample size of the validation cohort, we
chose only to perform gene group analysis on the main cohort.
The gene group analysis performed provides one way of
summarizing the evidence between cachexia traits and multiple
genetic variants across groups of genes that share functional
similarity. Appetite regulation was found to be most signifi¬
cantly associated with the cachexia trait weight loss >15% and
CRP >10mg/l (p = 0.008). There has been some evidence to
date that negative regulators of appetite are elevated in cachexia
(Doehner et al, 2001; le Roux et al, 2005). A number of animal
studies have also shown prevention or reversal of cachexia by
deletion or blockade of specific appetite pathways (Marks et al,
2001; Nicholson et al, 2006; Wisse et al, 2001).
In addition to the above link, the glucocorticoid signalling
pathway was also found to be associated with cachexia
(weight loss >15% and CRP >10mg/l) (p = 0.0181). There
has been evidence that glucocorticoids and its associated
signalling pathway are involved in accelerating protein
degradation in muscle, which results in loss of lean body mass
in cachexia (Tisdale, 2009). Glucocorticoids work through a
permissive effect on the upregulation of messenger RNA and
the subsequent synthesis of components of the ubiquitin-
proteasome system in muscle. Glucocorticoids inhibit
protein synthesis and promote gluconeogenesis, and suppress
glucose and amino acid muscle uptake by inhibiting cellular
transporters (Lecker et al, 2006). Mitogen activated protein
kinases (MAPK) activity regulation was also found to be
associated with cachexia (weight loss >15% and CRP >10mg/l)
(p = 0.0264). MAPKs are known to mediate lipolysis in
cancer cachexia (Ryden & Arner, 2007), and are also
potential regulators of muscle catabolism in cachexia (Keren
et al, 2006).
Previous genetic studies on cancer cachexia have identified
associations with cachexia and polymorphisms in cytokine
genes such as the IL1B 3954C/T polymorphism (rsl 143634)
in patients with gastric cancer (Zhang et al, 2007), and the
IL10-1082A/G polymorphism (rsl800896) in patients with
gastro-oesophageal cancer (Deans et al, 2009a). Cancer related
anorexia has been associated with the TNF-308G/A polymorph¬
ism (rsl800629) in patients with non-small cell lung cancer
(Jatoi et al, 2009). Despite some significant associations with
other polymorphisms in pro-inflammatory cytokines genes
(Table 2), we were unable to confirm the previous specific
associations in the present study. However, all these studies
have focused only on one particular type of cancer and on a
small number of genetic variants. More widely applicable
biomarkers may prove more useful. One of the strengths of the
present study is the analysis of a wide variety of candidate genes
that may influence the development of cachexia in patients with
various cancer types.
The nature of cancer cachexia dictates that there are fewer
individuals who develop the most severe aspects of the
syndrome. At the severe end of the cachexia spectrum, the
power in the present study to detect weak associations with
uncommon variants was low. It may be that a larger sample size
may be required to fully elucidate the effects of such variants in
individuals with severe or refractory cachexia.
The diverse cachexia phenotypes we investigated represent
various stages in the cachexia journey with potential genetic
influences at each stage. The present study suggests that
multiple pathways are likely to be involved in the pathogenesis
of cancer cachexia and, in particular, P-selectin, appetite
regulation, glucocorticoid signalling and MAPK activity regula¬
tion may have central roles in this process and should be further
investigated. The animal data presented herein suggests that
upregulation of P-selectin in skeletal muscle accompanies
muscle atrophy in different circumstances. It remains to be
determined if modulation of P-selectin might alter the devel¬
opment of cachexia in such models and therefore be a candidate
therapeutic target in human cancer cachexia.
MATERIALS AND METHODS
Main study population
Study subjects were recruited from three centres from 2004 to 2008:
NHS Lothian, UK; Cross Cancer Institute, Edmonton, Canada; and
McCill University Health Centre, Montreal, Canada.
All subjects recruited had participated in clinical or research studies at
the host institutions under ethically approved protocols. Recruitment
was conducted at first presentation to surgical or oncology clinics at
each institution. Recruitment was performed sequentially with the
following exclusion criteria: (i) under 18 years of age; (ii) learning
disability, and mental health problems; (iii) inability to give written,
informed consent; (iv) presence of underlying infection; (v) on
corticosteroids.
Patients recruited generally had cancer types with propensity to
develop cachexia (e.g. gastric/oesophageal, pancreatic, lung). Overall,
855 patients were recruited. More than 98% of the study subjects
were of European descent. Information collected on each patient
included date of birth, date of diagnosis, type and stage of cancer. All
patients underwent measurements of height and weight at the time
of recruitment to the study. Pre-morbid weight was recalled by the
patient and verified where possible from the medical notes. Although
there may be recall bias, evidence to support the reliability of self-
reported weight and weight history (Perry et al, 1995; Stunkard &.
Albaum, 1981) is well documented. Individual weight loss was
calculated and expressed as percentage of pre-morbid body weight
lost. Height and weight data were subsequently used to compute a
common anthropometric descriptor, BMI (kg/m2).
Serum CRP concentration was measured with an automated
immunoturbidimetric assay by each institution's clinical chemistry
department using blood collected from patients at the time of
recruitment and before any therapeutic intervention. CRP measure¬
ment was not available from patients recruited from the Cross Cancer
Institute, Edmonton, Canada.
Stage of disease was based on the American Joint Committee on
Cancer stage groupings I, II, III and IV.
All patients provided written informed consent to allow analysis of
their DNA.
Phenotype definitions
There is currently no consensus diagnostic criteria for cancer cachexia,
however two recent international consensus groups (Evans et al,
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2008; Fearon et al, 2011) provide a conceptual framework for the
classification of this condition. Cachexia is defined by the presence of
involuntary weight loss. Varying thresholds of weight loss have been
used, the most common being >5% (Fox et al, 2009; Knoll et al, 2008;
Maltoni et al, 2001) and >10% (Gordon et al, 2005; Skipworth et al,
in press; Zhang et al, 2007). A weight loss of >15% has been linked to
major complications in cancer patients undergoing surgery (Antoun et
al, 2009). Evans et al (2008) suggested classifying cachexia as mild or
greater, moderate or greater or severe depending on whether the
observed weight loss is >5, >10 or >15%, respectively.
The presence of underlying disease and pro-inflammatory catabolic
signals discriminate cachexia from malnutrition (Evans et al, 2008;
Fearon et al, 2011). The presence of systemic inflammation (serum
CRP >10mg/l) has also been linked to decreased survival (Mahmoud
& Rivera, 2002; McMillan et al, 2003), and has also been correlated
positively with weight loss in human cancer patients (Deans et al,
2009b; O'Gorman et al, 1999). CRP was incorporated into a three-
factor model of cachexia for patients with pancreatic cancer (Fearon
et al, 2006). The latter multi-profile definition was found to have more
prognostic value compared with weight loss alone.
To take into account the above, we classified cachexia as a spectrum,
represented by cut-offs of >5, >10 and >15% weight loss and we
also examined weight loss in the presence of systemic inflammation.
Candidate gene and SNP selection
Initial candidate gene and SNP selection was based on a systematic
literature review of SNPs with either putative functional or clinical
relevance in the development of cancer cachexia (Tan et al, 2011). A
further 18 candidate genes were selected based on the results of a
gene expression analysis array study on muscle samples of cancer
patients with cachexia (Stephens et al, 2010). From these genes were
selected non-synonymous coding SNPs with MAF of >0.05. Overall
191 SNPs in 99 genes were considered for the association study.
Cenotyping
The Applied Biosystems SNPlex™ Genotyping System (Applied Biosys-
tems, California, USA) was employed for SNP genotyping. All DNA
samples were processed and assayed without regard to phenotype. DNA
samples were separated electrophoretically on a 3730 DNA Genetic
Analyzer (Applied Biosystems, California, USA), and automated allele
calls and genotype clustering of each individual sample was performed
by Applied Biosystems' GeneMapper® Software (version 4.0). All
automatic calls by the software were evaluated by one researcher.
Any SNPs with less than 90% of the sample auto-called by the software
were either rescored manually or discarded if clustering confidence was
low. Reproducibility was determined by rerunning entire plates of DNA
samples and a reproducibility rate of 99.7% was achieved.
Individual samples were removed if more than 10% of SNPs failed
genotyping, and individual SNPs were removed if more than 10% of
samples failed. As an additional genotyping quality-control check,
SNPs with significant deviation from Hardy-Weinberg equilibrium
(HWE) (p <0.01) were removed from the final analysis. SNPs with a
MAF <0.03 were also removed from the final analysis.
Power calculations
Power calculations were performed using Quanto. For the most
prevalent cachexia phenotype (i.e. >5% weight loss, 54% affected), the
present study has between 43 and 97% power to detect an OR of 1.5
for SNPs with a MAF of 0.05-0.35.
For the least prevalent cachexia phenotype (i.e. >15% weight loss &.
CRP >10 mg/l, 14% affected), the present study has between 12 and
40% power to detect an OR of 1.5 for SNPs with a MAF of 0.05-0.35.
Statistical analysis
Statistical analyses were performed using PUNK (version 1.06) (Purcell
et al, 2007). Patients who met the criteria for each of the proposed
cachexia phenotypes were compared with patients who have lost
<5% body weight as control. Unconditional logistic regression was
employed to calculate ORs and their 95% CI for the minor allele of
individual SNPs and its association with each proposed cachexia
phenotype. All analyses were adjusted for covariates that may affect
weight loss, i.e. age at diagnosis, sex, pre-diagnosis BMI, tumour type
and stage.
To account for multiple testing, permutation testing was performed by
running the adaptive permutation test in PUNK within each proposed
phenotype. Permutation tests are often employed to adjust groups of
correlated tests for multiple testing, since conventional methods such
as Bonferroni correction are overly conservative when tests are
correlated (Conneely & Boehnke, 2007).The adaptive permutation test
in PUNK gives up permuting SNPs that are clearly going to be non¬
significant. This greatly speeds up the permutation procedure, as SNPs
that are not significant will drop out quite quickly, making it possible
to properly evaluate significance for the handful of SNPs that require
millions of permutations.
SNPs with a permuted p-value of <0.02 within the same
chromosomal region (within lOOOOkb) were then analyzed for any
possible haplotype associations. Only haplotypes that had a frequency
greater than 5% were considered for further analysis. Each identified
haplotype and significant SNPs were then tested for association with
percentage weight loss as a continuous variable.
Finally, candidate genes (and the SNPs in the corresponding gene
regions) were grouped based on known functional similarity according
to gene ontology using AmiGO (Supporting Information Table S2).The
set-based test in PUNK was used to analyze association between
grouped SNPs and cachexia phenotypes.The set-based test selects the
best set of SNPs whose mean of these single SNP statistics is
significant after permutation, which is particularly suited to large-
scale candidate gene studies (Ott & Hoh, 2003).The empirical p-values
of the set-based test were obtained by a permutation of 10 000 times
of phenotype labels.
Validation study
Subjects from the validation study were recruited from an indepen¬
dent centre, Oncology &. Palliative Medicine, Cantonal Hospital, St.
Gallen, Switzerland from 2007 to 2008. All patients with proven
cancer diagnosis were considered. Patients were recruited sequentially
at first presentation to the oncology clinic. Exclusion criteria were
identical to the main study.
In total, 101 cancer patients were recruited, all of whom were of
European descent. Like the main study, all patients underwent
measurements of height and weight at the time of recruitment. Pre¬
morbid weight was recalled by the patient and verified where possible
from the medical notes. Individual weight loss was calculated and
expressed as percentage of pre-illness body weight lost. Height and





More than half of cancer patients suffer from cachexia, and it is
responsible for death in up to 20% of cases. Cachexia is also a
significant cause of morbidity in cancer patients. Based on our
current knowledge of demographic and clinical factors, we are
unable to predict, for any given cohort of patients, who will
develop cancer cachexia and who will not Such variation may, in
part, be due to the patient's genotype. Knowledge of genotypic
variation associated with cachexia would contribute to early
identification of patients at risk and allow institution of
prophylactic measures.
RESULTS:
In a large scale genetic association study, the C allele of the
rs6136 (P-selectin) SNP was found to be associated with weight
loss >10% both in the discovery study and the validation study.
To further corroborate the P-selectin SNP to cancer cachexia in
the gene association study, we tested the same gene for
participation in the induction of the skeletal muscle atrophy gene
program in animal models of cachexia. P-selectin was found to be
significantly upregulated in muscle following both tumour-
induced cachexia in rats and intra-peritoneal injection of LPS in
mice.
IMPACT:
The C-allele of the rs6136 polymorphism is associated with
reduced risk of developing cachexia. Identification of P-selectin
as relevant in both animal models and in cachectic cancer
patients supports this as a risk factor/potential mediator in
cachexia.
weight data were subsequently used to compute a common anthropo¬
metric descriptor, BMI (kg/m2). Serum CRP concentration was measured
with an automated immunoturbidimetric assay at the institution's
clinical chemistry department using blood collected from patients at the
time of recruitment and before any therapeutic intervention.
Patients were genotyped for SNPs found to have permuted p < 0.05 in
the main study and quality control checks were carried out as
described previously. As with the main study, patients in each of the
proposed cachexia phenotypes were compared with patients with
<5% weight loss as control, and association analyses were adjusted
for age at diagnosis, sex, pre-diagnosis BMI, tumour type and stage.
Animal studies
Wild type C57BL/6J mice (20-25 g) (Jackson Laboratories) and male
F344/NTacfBR rats were maintained on a normal 12:12 h light/dark
cycle and provided ad libitum access to water and food. Animals were
anaesthetized at the time of tumour implantation or sacrifice using a
ketamine cocktail. Experiments were conducted in accordance with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and approved by the Animal Care and Use
Committees of Oregon Health & Science University.
Intra-peritoneal injection of LPS
Lipopolysaccharide was dissolved in 0.5% bovine serum albumin
(BSA)/0.9% saline and injected intra-peritoneally at 250 |xg/kg. Food
was removed from cages at the time of injection, and animals were
sacrificed 8 h after injection.
Cancer cachexia model
The MCA sarcoma does not metastasize and has a curvilinear growth
pattern (Sato et al, 2001). On day 0, TB rats (n = 8) had 0.2-0.3 g
tumour tissue implanted subcutaneously into the flank (Ramos et al,
2004) whilst controls (n = 7) underwent sham operation (SH). On day
13, tumour growth was within the pre-determined end-points of the
study, according to OHSU IACUC Policy on tumour burden and the
animals were sacrificed. Body composition was determined by
magnetic resonance (EchoMRl, Echo Medical Systems, Houston, TX)
at the time of tumour implantation and again at the time of sacrifice.
The gastrocnemius muscles were immediately removed, weighed,
preserved in RNAlater solution (Ambion, Inc.) and stored at -80°C
until RNA extraction and qPCR analysis.
qPCR analysis
Total gastrocnemius muscle RNA was extracted using the RNeasy
fibrous tissue mini kit (Qiagen, Valencia, CA). The total RNA was
quantified and checked for integrity using standard protocols.
Complementary DNA (cDNA) was transcribed using Taqman reverse
transcription reagents according to the manufacturer's instructions.
PCR reactions were run on an ABI 7300, using Taqman universal PCR
master mix, using Taqman gene expression assays. Relative expression
was calculated by the AACt method using GAPDH as an endogenous
control.
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